Pyrazole substituted cyclopentyl ester derivative and application thereof
Patent Information
- Application Number
- CN202380036025.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-17
- Filing Date
- 2023-04-27
- Publication Date
- 2024-12-03
AI Technical Summary
Existing technologies are difficult to effectively inhibit the activity of cyclin-dependent kinase CDK2/Cyclin A, leading to uncontrolled cell proliferation and tumorigenesis.
Provide a pyrazole-substituted cyclopentyl ester derivative that binds to CDK2/Cyclin A through a specific structure to selectively inhibit its activity, thereby affecting the activity of E2F and achieving the purpose of inhibiting the cell cycle.
Effectively inhibits the activity of CDK2/Cyclin A, leading to cell cycle arrest or apoptosis, and has potential tumor therapeutic effects.
Smart Images

Figure CN119072471A_ABST
Abstract
Description
A pyrazole-substituted cyclopentyl ester derivative and its use
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the priority and benefits of Chinese Patent Application No. 202210469621.9 filed with the State Intellectual Property Office of China on April 28, 2022, the priority and benefits of Chinese Patent Application No. 202210836180.1 filed with the State Intellectual Property Office of China on July 15, 2022, the priority and benefits of Chinese Patent Application No. 202210999975.4 filed with the State Intellectual Property Office of China on August 19, 2022, and the priority and benefits of Chinese Patent Application No. The invention claims the priority and benefits of Chinese patent application No. 202211603669.0 filed with the State Intellectual Property Office of China on March 13, 2023, the priority and benefits of Chinese patent application No. 202310250462.8 filed with the State Intellectual Property Office of China on March 15, 2023, and the priority and benefits of Chinese patent application No. 202310411874.5 filed with the State Intellectual Property Office of China on April 17, 2023, the contents disclosed in which are incorporated herein by reference in their entirety. Technical Field
[0003] The present application relates to a pyrazole-substituted cyclopentyl ester derivative and its use, and specifically to a compound represented by formula (I), its isomers or pharmaceutically acceptable salts thereof. Background Art
[0004] Cyclin-dependent kinases (CDKs) belong to the serine / threonine protein kinase family and are directly involved in regulating the cell cycle, promoting orderly cell growth, proliferation, and apoptosis. The cell division cycle is divided into four phases: G1, S, G2, and M. The G1-S phase is the most important, and its regulation is closely linked to CDKs. CDKs bind to cyclins to form protein kinase complexes, which catalyze substrate phosphorylation and control cell cycle progression, sequentially completing DNA replication and mitosis, leading to cell division and proliferation. The cell division cycle is regulated by two factors: inhibition and promotion, which are normally in a dynamic equilibrium. However, when signals promoting cell proliferation are enhanced or signals inhibiting cell proliferation are weakened, this balance is disrupted, leading to uncontrolled cell proliferation and tumorigenesis. Studies have shown that overexpression of CDKs is found in many malignant tumors.
[0005] Research has shown that CDKs directly involved in cell cycle regulation primarily include CDK1, CDK2, CDK4, and CDK6, playing a key role in cell cycle regulation. CDK2, a member of the CDK family, is a cell cycle-dependent kinase crucial for the completion of G1 phase of mitosis and for the transition from G1 to S phase. In late G1, CDK2 binds to and activates Cyclin E, promoting sustained phosphorylation of pRb, ensuring smooth progression through G1 and into S phase. Inactivation of E2F is essential for S phase completion. Early in S phase, CDK2 binds to Cyclin A, inactivating the E2F transcription factor and enabling successful S phase completion. However, sustained E2F activity can lead to apoptosis. Therefore, selective inhibition of CDK2 / Cylin A activity can increase E2F concentrations, leading to cell cycle arrest in S phase or apoptosis, thereby achieving the therapeutic goal of tumor cells.
[0006] Summary of the Invention
[0007] The present application provides a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof,
[0008] in,
[0009] Ring A is selected from C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 alkyl ring or 5-6 membered heteroaryl ring and 5-6 membered heteroalkyl ring are optionally independently substituted by one or more R a replace;
[0010] L 1 and L 2 Each independently selected from a single bond, -N(R b )-, -N=, -O-, -S-, -(CH2) m -、-(CD2) m -、-(CHD) m -, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=N(R b ))-、-S(=O)(R c )-、-P(=O)(R c )-or-P(=O)(NRb R b )-;
[0011] R 1 Selected from H, deuterium, C 1-3 Alkyl, C 1-3 Alkoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R d Substitute, the C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl are optionally independently substituted by one or more R e replace;
[0012] R 2 、R 3 and R 4 Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with one or more R z replace;
[0013] or R 2 and R 3 and the carbon atoms that are connected together to form C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, R 4 Selected from H, deuterium, halogen, OH, CN, NH2, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl optionally independently substituted by one or more R z replace;
[0014] Each R a Each independently selected from deuterium, halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with one or more R x replace;
[0015] Each R b Each independently selected from H, C1-3 Alkyl, C 1-3 Alkoxy, -C(=O)H, -S(=O)2C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution; said C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl optionally independently substituted by one or more R y replace;
[0016] R c Selected from halogen, OH, CN or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with one or more R x replace;
[0017] Each R d are each independently selected from deuterium, halogen, OH, CN or NH2;
[0018] Each R e Each independently selected from deuterium, halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with one or more R x replace;
[0019] Each R x are each independently selected from deuterium, halogen, OH, CN or NH2;
[0020] Each R y Each independently selected from deuterium, halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally substituted independently with one or more substituents selected from deuterium, halogen, OH, CN or NH2;
[0021] Each R z are each independently selected from deuterium, halogen, OH, CN or NH2;
[0022] m is selected from 1, 2 or 3;
[0023] The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer;
[0024] Or, each L1 , L 2 、R 1 、R 2 、R 3 、R 4 、R a 、R b 、R c 、R d 、R e 、R x 、R y or R z Each is independently optionally substituted with one or more substituents.
[0025] In some embodiments of the present application, each R a 、R b 、R c 、R d 、R e 、R x 、R y or R z Each is independently optionally substituted with one or more substituents.
[0026] In some embodiments of the present application, each R d 、R x 、R y or R z Each is independently optionally substituted with one or more substituents.
[0027] In other embodiments of the present application, the R 1 、R 2 、R 3 、R 4 、R a 、R d 、R e 、R x 、R y or R z Each is independently optionally substituted with one or more deuterium.
[0028] In other embodiments of the present application, the R 1 、R 2 、R 3 、R 4 、R a 、R d 、R e 、R x 、R y or R z each independently optionally substituted with 1, 2, 3, 4 or 5 deuteriums; or each independently optionally substituted with 3 or 5 deuteriums.
[0029] In some embodiments of the present application, the R 1 、R 2 、R 3 、R 4 、R a 、R d 、R e 、R x 、R y and R z At least one of the groups is a deuterium-containing group.
[0030] In some embodiments of the present application, the "substituted by 1 or more" are each independently selected from substituted by 1, 2, 3, 4, 5 or 6.
[0031] In some embodiments of the present application, the "substituted by 1 or more" are each independently selected from substituted by 1, 2, 3, 4 or 5.
[0032] In some embodiments of the present application, the "substituted by 1 or more" are each independently selected from substituted by 1, 2, 3 or 4.
[0033] In some embodiments of the present application, the "substituted by 1 or more" are each independently selected from substituted by 1, 2 or 3.
[0034] In some embodiments of the present application, the "hetero" mentioned in the ring A is independently selected from oxygen, sulfur and nitrogen heteroatoms, wherein the nitrogen atom is optionally quaternized or oxidized to N(O), and the sulfur atom is optionally oxidized to S(O) or S(O)2, and other variables are as defined in the present application.
[0035] In some embodiments of the present application, the "hetero" mentioned in the ring A is independently selected from oxygen, sulfur and nitrogen heteroatoms, wherein the sulfur heteroatom is optionally oxidized to S(O) or S(O)2, and other variables are as defined in the present application.
[0036] In some embodiments of the present application, the ring A is selected from C 3-6 Alkane ring, 5-6 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-6 Alkane ring, 5-6 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 The alkyl ring or 5-6 membered heteroaryl ring and the 5-6 membered heteroalkyl ring are optionally independently substituted by 1, 2, 3 or 4 R a Substitution, other variables are as defined in this application.
[0037] In some embodiments of the present application, the ring A is selected from C 3-6 Alkane ring, 5-6 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-6 Alkane ring, 5-6 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 The alkyl ring or 5-6 membered heteroaryl ring and the 5-6 membered heteroalkyl ring are optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0038] In some embodiments of the present application, the ring A is selected from a 5-6 membered heteroalkane ring, a benzene ring, a benzene ring and a 5-6 membered heteroalkane ring, a 5-6 membered heteroaromatic ring or a 5-6 membered heteroaromatic ring and a 5-6 membered heteroalkane ring, wherein the 5-6 membered heteroalkane ring, the benzene ring, the benzene ring and a 5-6 membered heteroalkane ring, a 5-6 membered heteroaromatic ring or a 5-6 membered heteroaromatic ring and a 5-6 membered heteroalkane ring is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0039] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring, a benzene ring, a 5-membered heteroalkane ring, a 5-6-membered heteroaromatic ring, or a 6-membered heteroaromatic ring and a 5-6-membered heteroalkane ring, and the 6-membered heteroalkane ring, the benzene ring, the 5-membered heteroalkane ring, the 5-6-membered heteroaromatic ring, or the 6-membered heteroaromatic ring and a 5-6-membered heteroalkane ring are optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0040] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring, a benzene ring, a 5-membered heteroalkane ring, a 5-9-membered heteroaromatic ring, or a 6-membered heteroaromatic ring and a 5-6-membered heteroalkane ring, and the 6-membered heteroalkane ring, the benzene ring, the 5-membered heteroalkane ring, the 5-9-membered heteroaromatic ring, or the 6-membered heteroaromatic ring and the 5-6-membered heteroalkane ring are optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0041] In some other embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring, a benzene ring, a 5-membered heteroalkane ring or a 6-membered heteroaromatic ring and a 5-6-membered heteroalkane ring, and the 6-membered heteroalkane ring, the benzene ring, the 5-membered heteroalkane ring or the 6-membered heteroaromatic ring and the 5-6-membered heteroalkane ring are optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0042] In some embodiments of the present application, the ring atoms of the 5-10 membered heteroaromatic ring or the 5-9 membered heteroaromatic ring defined in Ring A contain only 1 or 2 N atoms, and other variables are as defined in the present application.
[0043] In other embodiments of the present application, the 5-10 membered heteroaromatic ring or 5-9 membered heteroaromatic ring in the definition of Ring A contains only one N atom in the ring atoms, and other variables are as defined in the present application.
[0044] In some embodiments of the present application, the 5-10 membered heteroaromatic ring or 5-9 membered heteroaromatic ring in the definition of Ring A is selected from a 5-membered heteroaromatic ring or a 6-membered heteroaromatic ring, and other variables are as defined herein.
[0045] In other embodiments of the present application, the ring atoms of the 5-membered heteroaromatic ring or the 6-membered heteroaromatic ring in the definition of Ring A contain only 1 N atom, and other variables are as defined in the present application.
[0046] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring, a benzene ring, a 5-membered heteroalkane ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 9-membered heteroaromatic ring, a 6-membered heteroaromatic ring and a 5-membered heteroalkane ring or a 6-membered heteroaromatic ring and a 6-membered heteroalkane ring, and the 6-membered heteroalkane ring, the benzene ring, the 5-membered heteroalkane ring, the 5-membered heteroaromatic ring, the 6-membered heteroaromatic ring, the 9-membered heteroaromatic ring, the 6-membered heteroalkane ring and the 5-membered heteroalkane ring or the 6-membered heteroaromatic ring and the 6-membered heteroalkane ring are optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0047] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring, a benzene ring, a 5-membered heteroalkane ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 6-membered heteroaromatic ring and a 5-membered heteroalkane ring or a 6-membered heteroaromatic ring and a 6-membered heteroalkane ring, and the 6-membered heteroalkane ring, the benzene ring, the 5-membered heteroalkane ring, the 5-membered heteroaromatic ring, the 6-membered heteroaromatic ring, the 6-membered heteroalkane ring, the 6-membered heteroalkane ring, the 5-membered heteroaromatic ring, the 6-membered heteroaromatic ring, the 6-membered heteroaromatic ring and the 5-membered heteroalkane ring or the 6-membered heteroaromatic ring and the 6-membered heteroalkane ring are optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0048] In some other embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring, a benzene ring, a 5-membered heteroalkane ring, a 6-membered heteroaromatic ring and a 5-membered heteroalkane ring, or a 6-membered heteroaromatic ring and a 6-membered heteroalkane ring, and the 6-membered heteroalkane ring, the benzene ring, the 5-membered heteroalkane ring, the 6-membered heteroaromatic ring and a 5-membered heteroalkane ring, or the 6-membered heteroaromatic ring and a 6-membered heteroalkane ring are optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0049] In other embodiments of the present application, the ring A is selected from a benzene ring and a 5-membered heteroalkane ring, a 6-membered heteroaromatic ring and a 5-membered heteroalkane ring, or a 6-membered heteroaromatic ring and a 6-membered heteroalkane ring, and the benzene ring and a 5-membered heteroalkane ring, a 6-membered heteroaromatic ring and a 5-membered heteroalkane ring, or a 6-membered heteroaromatic ring and a 6-membered heteroalkane ring are optionally independently substituted with 1, 2 or 3 R a The "hetero" mentioned in the 5-membered heteroalkane ring or the 6-membered heteroalkane ring is independently selected from oxygen, sulfur and nitrogen heteroatoms, wherein the nitrogen atom is optionally quaternized or oxidized to N(O), and the sulfur atom is optionally oxidized to S(O) or S(O)2, and other variables are as defined in the present application.
[0050] In other embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring containing 1-3 N atoms, a benzene ring, a 5-membered heteroalkane ring containing a benzene ring and 1-3 N atoms, a 5-membered heteroaromatic ring containing 1-3 N atoms, a 6-membered heteroaromatic ring with only 1 N atom, a 6-membered heteroaromatic ring containing 1-3 N atoms and a 5-membered heteroalkane ring containing 1-3 N atoms, or a 6-membered heteroaromatic ring containing 1-3 N atoms and a 6-membered heteroaromatic ring containing 1-3 N atoms. The 6-membered heteroalkyl ring containing 1-3 N atoms, benzene ring, 5-membered heteroalkyl ring containing 1-3 N atoms, 5-membered heteroaromatic ring containing 1-3 N atoms, 6-membered heteroaromatic ring containing only 1 N atom, 5-membered heteroalkyl ring containing 1-3 N atoms, or 6-membered heteroaromatic ring containing 1-3 N atoms and 1-3 N atoms, is optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0051] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring containing 1-3 N atoms, a benzene ring, a 5-membered heteroalkane ring containing 1-3 N atoms, a 5-membered heteroaromatic ring containing 1-3 N atoms, a 6-membered heteroaromatic ring containing 1-3 N atoms, a 9-membered heteroaromatic ring containing 1-3 N atoms, a 6-membered heteroaromatic ring containing 1-3 N atoms and a 5-membered heteroalkane ring containing 1-3 N atoms, or a 6-membered heteroaromatic ring containing 1-3 N atoms and a 6-membered heteroaromatic ring containing 1-3 N atoms. alkyl ring, the 6-membered heteroalkyl ring containing 1-3 N atoms, benzene ring, benzene ring and 5-membered heteroalkyl ring containing 1-3 N atoms, 5-membered heteroaromatic ring containing 1-3 N atoms, 6-membered heteroaromatic ring containing 1-3 N atoms, 9-membered heteroaromatic ring containing 1-3 N atoms, 6-membered heteroaromatic ring containing 1-3 N atoms and 5-membered heteroalkyl ring containing 1-3 N atoms or 6-membered heteroaromatic ring containing 1-3 N atoms and 6-membered heteroalkyl ring containing 1-3 N atoms are optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0052] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring containing 1 or 2 N atoms, a benzene ring, a 5-membered heteroalkane ring containing 1 or 2 N atoms, a 5-membered heteroaromatic ring containing 1 or 2 N atoms, a 6-membered heteroaromatic ring containing 1 or 2 N atoms, a 5-membered heteroalkane ring containing 1 or 2 N atoms, or a 6-membered heteroaromatic ring containing 1 or 2 N atoms and a 6-membered heteroalkane ring containing 1 or 2 N atoms. alkyl ring, the 6-membered heteroalkyl ring containing 1 or 2 N atoms, benzene ring, 5-membered heteroalkyl ring containing 1 or 2 N atoms, 5-membered heteroaromatic ring containing 1 or 2 N atoms, 6-membered heteroaromatic ring containing 1 or 2 N atoms, 5-membered heteroalkyl ring containing 1 or 2 N atoms, or 6-membered heteroaromatic ring containing 1 or 2 N atoms and 1 or 2 N atoms, 6-membered heteroalkyl ring containing 1 or 2 N atoms and 1 or 2 N atoms, are optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0053] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring containing 1 N atom, a benzene ring, a 5-membered heteroalkane ring containing a benzene ring and 1 N atom, a 5-membered heteroaromatic ring containing 1 or 2 N atoms, a 6-membered heteroaromatic ring containing 1 N atom, a 5-membered heteroalkane ring containing 1 N atom, or a 6-membered heteroalkane ring containing 1 N atom and 1 N atom, wherein the 6-membered heteroalkane ring containing 1 N atom, the benzene ring, the 5-membered heteroalkane ring containing a benzene ring and 1 N atom, a 5-membered heteroaromatic ring containing 1 or 2 N atoms, a 6-membered heteroaromatic ring containing 1 or 2 N atoms, a 5-membered heteroalkane ring containing 1 N atom, or a 6-membered heteroalkane ring containing 1 N atom and 1 N atom is optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0054] In other embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring containing 1 N atom, a benzene ring, a 5-membered heteroalkane ring containing 1 N atom, a 5-membered heteroaromatic ring containing 1 or 2 N atoms, a 6-membered heteroaromatic ring with only 1 N atom, a 6-membered heteroaromatic ring containing 1 N atom and a 5-membered heteroalkane ring containing 1 N atom, or a 6-membered heteroaromatic ring containing 1 N atom and a 6-membered heteroalkane ring containing 1 N atom, wherein the 6-membered heteroalkane ring containing 1 N atom, the benzene ring, the 5-membered heteroalkane ring containing 1 or 2 N atoms, the 6-membered heteroaromatic ring with only 1 N atom, the 5-membered heteroalkane ring containing 1 N atom and a 6-membered heteroaromatic ring containing 1 N atom, or the 6-membered heteroalkane ring containing 1 N atom and a 6-membered heteroalkane ring containing 1 N atom are optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0055] In some embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring containing 1 N atom, a benzene ring, a 5-membered heteroalkane ring containing a benzene ring and 1 N atom, a 5-membered heteroaromatic ring containing 1 or 2 N atoms, a 6-membered heteroaromatic ring containing 1 N atom, a 5-membered heteroalkane ring containing 1 N atom, or a 6-membered heteroalkane ring containing 1 N atom and 1 N atom, wherein the 6-membered heteroalkane ring containing 1 N atom, the benzene ring, the 5-membered heteroalkane ring containing a benzene ring and 1 N atom, a 5-membered heteroaromatic ring containing 1 or 2 N atoms, a 6-membered heteroaromatic ring containing 1 or 2 N atoms, a 5-membered heteroalkane ring containing 1 N atom, or a 6-membered heteroalkane ring containing 1 N atom and 1 N atom is optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0056] In some other embodiments of the present application, the ring A is selected from a 6-membered heteroalkane ring containing 1 N atom, a benzene ring, a 5-membered heteroalkane ring containing a benzene ring and 1 N atom, a 6-membered heteroaromatic ring containing 1 N atom and a 5-membered heteroalkane ring containing 1 N atom, or a 6-membered heteroaromatic ring containing 1 N atom and a 6-membered heteroalkane ring containing 1 N atom, and the 6-membered heteroalkane ring containing 1 N atom, the benzene ring, the 5-membered heteroalkane ring containing a benzene ring and 1 N atom, the 6-membered heteroalkane ring containing 1 N atom, the 5-membered heteroalkane ring containing a 6-membered heteroaromatic ring containing 1 N atom and 1 N atom, or the 6-membered heteroalkane ring containing 1 N atom and 1 N atom are optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0057] In some embodiments of the present application, the ring A is selected from the group consisting of a pyrrolidine ring, a pyrazolidine ring, an imidazolidine ring, a tetrahydrothiophene ring, a tetrahydrofuran ring, a tetrahydropyran ring, a thiazolidine ring, an isothiazolidine ring, an oxazolidine ring, an isoxazolidine ring, a piperidine ring, a piperazine ring, a morpholine ring, a thiazinane ring, a benzene ring, a phenyldioxolane ring, a phenylpyrrolidine ring, a phenylpyrazolidine ring, a benzimidazolidine ring, a phenyltetrahydrothiophene ring, a phenyltetrahydrofuran ring, a phenyltetrahydropyran ring, a phenylthiazolidine ring, a phenylisothiazolidine ring, a phenyloxazolidine ring, a phenylisoxazolidine ring, a phenylpiperidine ring, a phenylpiperazine ring, a phenylmorpholine ring, a phenylthiazinane ring, a pyrrole ring, a pyrazole ring, an imidazole ring, an oxazole ring, an isoxazolidine ring, azole ring, thiazole ring, isothiazole ring, triazole ring, furan ring, thiophene ring, pyridine ring, pyrazine ring, pyrimidine ring, pyridazine ring, pyridine ring and pyrrolidine ring, pyridine ring and pyrazolidine ring, pyridine ring and imidazolidine ring, pyridine ring and tetrahydrothiophene ring, pyridine ring and tetrahydrofuran ring, pyridine ring and tetrahydropyran ring, pyridine ring and thiazolidine ring, pyridine ring and isothiazolidine ring, pyridine ring and oxazolidine ring, pyridine ring and isoxazolidine ring, pyridine ring and piperidine ring, pyridine ring and piperazine ring, pyridine ring and morpholine ring, pyridine ring and thiazinane ring, pyrazine ring and pyrrolidine ring, pyrazine ring and pyrazolidine ring, pyrazine ring and imidazolidine ring, pyrazine ring and tetrahydrothiophene ring, pyrazine ring and tetrahydrofuran ring, pyrazine ring and tetrahydropyran ring, pyrazine ring and thiazolidine ring, pyrazine Cyclic and isothiazolidine ring, pyrazine cyclooxazolidine ring, pyrazine cycloisoxazolidine ring, pyrazine cyclopiperidine ring, pyrazine cyclopiperazine ring, pyrazine cyclomorpholine ring, pyrazine cyclothiazine ring, pyrimidine cyclopyrrolidine ring, pyrimidine cyclopyrazolidine ring, pyrimidine cycloimidazolidine ring, pyrimidine cyclotetrahydrothiophene ring, pyrimidine cyclotetrahydrofuran ring, pyrimidine cyclotetrahydropyran ring, pyrimidine cyclothiazolidine ring, pyrimidine cycloisothiazolidine ring, pyrimidine cyclooxazolidine ring, pyrimidine cycloisoxazolidine ring, pyrimidine cyclopiperidine ring, pyrimidine cyclopiperazine ring, pyrimidine cyclomorpholine ring, pyrimidine cyclothiazine ring, benzofuran ring, benzothiophene ring, indole ring, isoindole ring, benzimidazole ring, indazole ring, pyrrolo[2,3-b]pyridine ring, pyrrolo[2,3-b]pyridine ring, a pyrrolo[2,3-c]pyridine ring, a pyrrolo[3,2-c]pyridine ring, a pyrrolo[3,2-b]pyridine ring, an imidazo[4,5-b]pyridine ring, an imidazo[4,5-c]pyridine ring, an imidazo[1,2-a]pyridine ring, an imidazo[1,5-a]pyridine ring, a pyrazolo[4,3-d]pyridine ring, a pyrazolo[4,3-c]pyridine ring, a pyrazolo[3,4-c]pyridine ring, a pyrazolo[1,5-a]pyridine ring, a purine ring, an indolizine ring, a pyrrolo[1,2-a]pyridazine ring, an imidazo[1,2-c]pyrimidine ring, a pyrazolo[1,5-a]pyrazine ring or a pyrrolo[1,2-a]pyrazine ring, wherein the ring A is optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0058] In some embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene ring and a dioxolane ring, a benzene ring and a pyrrolidine ring, a benzene ring and a tetrahydrothiophene ring, a benzene ring and an isothiazolidine ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring, a pyridine ring and a tetrahydrofuran ring, a pyridine ring and an isothiazolidine ring or a pyridine ring and a thiazinane ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0059] In some embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene ring and an isothiazolidine ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring, a pyrazine ring, a pyrimidine ring, a pyridazine ring, a pyridine ring and an isothiazolidine ring, a pyridine ring and a thiazinane ring, a pyrrolo[3,2-c]pyridine ring, a pyrazolo[4,3-c]pyridine ring, a pyrazolo[1,5-a]pyrazine ring or a pyrrolo[1,2-a]pyrazine ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0060] In some other embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene ring and an isothiazolidine ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring and an isothiazolidine ring or a pyridine ring and a thiazinane ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0061] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0062] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0063] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0064] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0065] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0066] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2, 3 or 4 R a Substitution, other variables are as defined in this application.
[0067] In some further embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2, 3 or 4 R a Substitution, other variables are as defined in this application.
[0068] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2, 3 or 4 R a Substitution, other variables are as defined in this application.
[0069] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0070] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0071] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0072] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0073] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0074] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0075] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0076] In some embodiments of the present application, the sulfur heteroatom in Ring A is oxidized to S(O) or S(O)2, and other variables are as defined herein.
[0077] In some embodiments of the present application, the sulfur heteroatom in Ring A is oxidized to S(O)2, and other variables are as defined herein.
[0078] In some embodiments of the present application, each R a Each independently selected from deuterium, F, Cl, Br, I, CN, ═O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0079] In other embodiments of the present application, each R a Each independently selected from F, Cl, CN, ═O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0080] In some embodiments of the present application, each R aEach independently selected from F, Cl, Br, I, ═O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0081] In some embodiments of the present application, each R a Each independently selected from F, Cl, Br, I, ═O or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0082] In some embodiments of the present application, each R a Each is independently selected from F, Cl, CN, =0, methyl or methoxy, said methyl or methoxy being optionally substituted independently with 1, 2 or 3 halogens, and other variables are as defined herein.
[0083] In some embodiments of the present application, each R a Each is independently selected from F, =0 or methyl, said methyl being optionally independently substituted with 1, 2 or 3 halogens, and other variables are as defined herein.
[0084] In some embodiments of the present application, each R a Each is independently selected from F, =0, methyl or methoxy, said methyl or methoxy being optionally substituted independently with 1, 2 or 3 halogens, and other variables are as defined herein.
[0085] In some embodiments of the present application, each R a Each is independently selected from F, Cl, CN, =O, methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, methoxy, monofluoromethoxy, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0086] In some embodiments of the present application, each R a Each is independently selected from F, =0, methyl, monofluoromethyl, difluoromethyl or trifluoromethyl, and other variables are as defined herein.
[0087] In other embodiments of the present application, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0088] In some embodiments of the present application, each Ra Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0089] In some embodiments of the present application, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0090] In some embodiments of the present application, each R a Each is independently selected from F, =0, methyl, methoxy or trifluoromethyl, and other variables are as defined herein.
[0091] In other embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene dioxolane ring, a benzene pyrrolidine ring, a benzene tetrahydrothiophene ring, a benzene isothiazolidine ring, a benzene thiazinane ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring, a pyridine tetrahydrofuran ring, a pyridine isothiazolidine ring or a pyridine thiazinane ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0092] In some other embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene dioxolane ring, a benzene pyrrolidine ring, a benzene tetrahydrothiophene ring, a benzene isothiazolidine ring, a benzene thiazinane ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine tetrahydrofuran ring, a pyridine isothiazolidine ring or a pyridine thiazinane ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0093] In some embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene ring and a dioxolane ring, a benzene ring and a pyrrolidine ring, a benzene ring and a tetrahydrothiophene ring, a benzene ring and an isothiazolidine ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring, a pyrazine ring, a pyrimidine ring, a pyridazine ring, a pyridine ring and a tetrahydrofuran ring, a pyridine ring and an isothiazolidine ring, a pyridine ring and a thiazinane ring, a pyrrolo[3,2-c]pyridine ring, a pyrazolo[4,3-c]pyridine ring, a pyrazolo[1,5-a]pyrazine ring or a pyrrolo[1,2-a]pyrazine ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Replace, each R aEach is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0094] In some embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene ring and a dioxolane ring, a benzene ring and a pyrrolidine ring, a benzene ring and a tetrahydrothiophene ring, a benzene ring and an isothiazolidine ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring, a pyridine ring and a tetrahydrofuran ring, a pyridine ring and an isothiazolidine ring or a pyridine ring and a thiazinane ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0095] In some embodiments of the present application, the ring A is selected from a piperidine ring, a benzene ring, a benzene ring and an isothiazolidine ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring, a pyridine ring and an isothiazolidine ring or a pyridine ring and a thiazinane ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a Replace, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0096] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0097] In some further embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0098] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R aEach is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0099] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0100] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0101] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0102] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0103] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0104] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0105] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0106] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0107] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0108] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Substitution, other variables are as defined in this application.
[0109] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0110] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0111] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a are each independently selected from F or trifluoromethyl, and other variables are as defined herein.
[0112] In other embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a are each independently selected from F or trifluoromethyl, and other variables are as defined herein.
[0113] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0114] In some embodiments of the present application, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a Replace, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0115] In other embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0116] In some further embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0117] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0118] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0119] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0120] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0121] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0122] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0123] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0124] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0125] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0126] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0127] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0128] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0129] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0130] In other embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0131] In other embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0132] In other embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0133] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0134] In some embodiments of the present application, the ring A is selected from Other variables are as defined in this application.
[0135] In other embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0136] In some further embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0137] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0138] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, =O, methyl, methoxy, trifluoromethyl or trifluoromethoxy, and other variables are as defined herein.
[0139] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0140] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0141] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R aEach is independently selected from F, Cl, =O, methyl, trifluoromethyl or trifluoromethoxy, and other variables are as defined in the application.
[0142] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, =O, methyl, trifluoromethyl or trifluoromethoxy, and other variables are as defined in the application.
[0143] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined in the application. In some embodiments of the present application, each R a Each is independently selected from F, Cl, =O, methyl, trifluoromethyl or trifluoromethoxy, and other variables are as defined in the application.
[0144] In other embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0145] In other embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0146] In other embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, Cl, CN, =O, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy, and other variables are as defined herein.
[0147] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0148] In some embodiments of the present application, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a In some embodiments of the present invention, each R a Each is independently selected from F, =0, methyl or trifluoromethyl, and other variables are as defined herein.
[0149] In other embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0150] In some further embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0151] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0152] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0153] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0154] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0155] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0156] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0157] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0158] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0159] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0160] In some embodiments of the present application, the structural unit Selected from
[0161] Other variables are as defined in this application.
[0162] In other embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0163] In other embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0164] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0165] In some embodiments of the present application, the structural unit Selected from Other variables are as defined in this application.
[0166] In some embodiments of the present application, L 1 Selected from single bond, -N(R b )-, -N=, -O-, -S(=O)2-, -S-, -(CH2) m - or -C(=O)-, and other variables are as defined in this application.
[0167] In some embodiments of the present application, L 1 Selected from single bond, -N(R b )-, -O-, -S(=O)2-, -S-, -(CH2) m - or -C(=O)-, and other variables are as defined in this application.
[0168] In some embodiments of the present application, L 1 Selected from single bond, -NH-, -N=, -N(C(=O)H)-, -N(C 1-3 alkyl)-、-S(=O)2-、-CH2-、-CH2-CH2-、-CH2-CH2-CH2-、-N(S(=O)2C 1-3 alkyl)- or -C(=O)-, and the other variables are as defined herein.
[0169] In some embodiments of the present application, L 1 Selected from single bond, -NH-, -N(C(=O)H)-, -N(C 1-3 alkyl)-, -S(=O)2-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, or -C(=O)-, and the other variables are as defined herein.
[0170] In some embodiments of the present application, L 1 is selected from a single bond, -NH-, -N=, -N(C(=O)H)-, -N(CH3)-, -S(=O)2-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -C(=O)- or -N(S(=O)2CH3)-, and the other variables are as defined herein.
[0171] In other embodiments of the present application, L 1 is selected from a single bond, -NH-, -N=, -N(C(=O)H)-, -N(CH3)-, -S(=O)2-, -CH2-, -C(=O)- or -N(S(=O)2CH3)-, and the other variables are as defined herein.
[0172] In some embodiments of the present application, L 1 is selected from a single bond, -NH-, -N(C(=O)H)-, -N(CH3)-, -S(=O)2-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2- or -C(=O)-, and the other variables are as defined herein.
[0173] In some embodiments of the present application, L 1 is selected from a single bond, -NH-, -N(CH3)-, -S(=O)2-, -CH2- or -C(=O)-, and the other variables are as defined herein.
[0174] In some embodiments of the present application, L 1 is selected from a single bond, -NH- or -S(=O)2-, and the other variables are as defined herein.
[0175] In some embodiments of the present application, L 1 Selected from single bond, -N(R b )-、-O-、-S-、-(CH2) m - or -C(=O)-, and other variables are as defined in this application.
[0176] In some embodiments of the present application, L 1 Selected from single bond, -NH-, -N(C(=O)H)-, -N(C 1-3 alkyl)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, or -C(=O)-, and the other variables are as defined herein.
[0177] In some embodiments of the present application, L 1 Selected from single bond, -NH-, -N(C 1-3alkyl)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, or -C(=O)-, and the other variables are as defined herein.
[0178] In some embodiments of the present application, L 1 is selected from a single bond, -NH-, -N(C(=O)H)-, -N(CH3)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2- or -C(=O)-, and the other variables are as defined herein.
[0179] In some embodiments of the present application, L 1 is selected from a single bond, -NH-, -N(CH3)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2- or -C(=O)-, and the other variables are as defined herein.
[0180] In some embodiments of the present application, L 1 is selected from a single bond, -NH-, -N(CH3)-, -CH2- or -C(=O)-, and the other variables are as defined herein.
[0181] In some embodiments of the present application, L 1 is selected from a single bond or -NH-, and the other variables are as defined in this application.
[0182] In some embodiments of the present application, L 1 is selected from -NH-, and the other variables are as defined herein.
[0183] In some embodiments of the present application, L 2 Selected from single bond, -NH-, -N(C 1-3 alkyl)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=NH)-, -S(=O)(C 1-3 alkyl)-, -P(=O)(C 1-3 alkyl)-, -P(=O)(NH2)- or -P(=O)(NH(C 1-3 Other variables are as defined herein.
[0184] In some embodiments of the present application, L 2is selected from a single bond, -NH-, -N(CH3)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=NH)-, -S(=O)(CH3)-, -P(=O)(CH3)-, -P(=O)(NH2)- or -P(=O)(NHCH3)-, and the other variables are as defined herein.
[0185] In some embodiments of the present application, L 2 is selected from a single bond, -NH-, -N(CH3)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=NH)-, -P(=O)(CH3)-, -P(=O)(NH2)- or -P(=O)(NHCH3)-, and the other variables are as defined herein.
[0186] In other embodiments of the present application, L 2 is selected from a single bond, -NH-, -N(CH3)-, -CH2-CH2-, -C(=O)-, -S(=O)2-, -S(=O)(=NH)-, -S(=O)(CH3)-, -P(=O)(CH3) or -P(=O)(NHCH3)-, and the other variables are as defined herein.
[0187] In some embodiments of the present application, L 2 is selected from a single bond, -NH-, -N(CH3)-, -CH2-CH2-, -C(=O)-, -S(=O)2-, -S(=O)(=NH)-, -P(=O)(CH3) or -P(=O)(NHCH3)-, and the other variables are as defined herein.
[0188] In some embodiments of the present application, L 2 is selected from a single bond, -NH- or -S(=O)2-, and the other variables are as defined herein.
[0189] In some embodiments of the present application, L 2 is selected from a single bond or -S(=O)2-, and other variables are as defined in this application.
[0190] In some embodiments of the present application, L 2 is selected from -S(=O)2-, and other variables are as defined in this application.
[0191] In some embodiments of the present application, -L 2 -L 1- is selected from the group consisting of a single bond, -NH-, -N(CH3)-, -C(=O)-, -CH2-, -CH2-CH2-, -S(=O)2-, -CH2-NH-, -NH-CH2-, -CH2-N(CH3)-, -CH2-N(C(=O)H)-, -N(CH3)-CH2-, -N(C(=O)H)-CH2-, -C(=O)-CH2-, -CH2-C(=O)-, -C(=O)-NH-, -NH-C(=O)-, -NH-S(=O)2-, -S(=O)2-NH-, -N(CH3)-S(=O)2-, -N(S(=O)2CH3)-S(=O)2-, -S (=O)2-N(S(=O)2CH3)-, -S(=O)(CH3)=N-, -S(=O)2-N(CH3)-, -N(CH3)-C(=O)-, -C(=O)-N(CH3)-, -NH-S(=O)(=NH)-, -S(=O)(=NH)-NH-, -S(=O) (=NH)-, -P(=O)(CH3)-, -CH2-S(=O)(=NH)-, -S(=O)(=NH)-CH2-, -CH2-P(=O)(CH3)-, -P(=O)(CH3)-CH2-, -NH-P(=O)(CH3)-, -P(=O)(CH3)-NH-, -NH-P(=O)(NHCH3)-, -P(=O)(NHCH3)-NH-, -NH-P(=O)(NH2)-, -P(=O)(NH2)-NH-, -CH2-P(=O)(NHCH3)-, -P(=O)(NHCH3)-CH2-, -N(CH3)-CH2-CH2-, -N(C(=O)H)-CH2-CH2-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)-, -NH-CH2-CH2- or -CH2-CH2-NH-, and other variables are as defined herein.
[0192] In some embodiments of the present application, -L 2 -L 1-selected from a single bond, -NH-, -N(CH3)-, -C(=O)-, -CH2-, -CH2-CH2-, -S(=O)2-, -CH2-NH-, -NH-CH2-, -CH2-N(CH3)-, -CH2-N(C(=O)H)-, -N(CH3)-CH2-, -N(C(=O)H)-CH2-, -C(=O)-CH2-, -CH2-C(=O)-, -C(=O) -NH-, -NH-C(=O)-, -NH-S(=O)2-, -S(=O)2-NH-, -N(CH3)-S(=O)2-, -S(=O)2-N(CH3)-, -N(CH3) -C(=O)-, -C(=O)-N(CH3)-, -NH-S(=O)(=NH)-, -S(=O)(=NH)-NH-, -S(=O)(=NH)-, -P(=O)(CH3)- , -CH2-S(=O)(=NH)-, -S(=O)(=NH)-CH2-, -CH2-P(=O)(CH3)-, -P(=O)(CH3)-CH2-, -NH-P(=O)( CH3)-, -P(=O)(CH3)-NH-, -NH-P(=O)(NHCH3)-, -P(=O)(NHCH3)-NH-, -NH-P(=O)(NH2)-, -P(=O) (NH2)-NH-, -CH2-P(=O)(NHCH3)-, -P(=O)(NHCH3)-CH2-, -N(CH3)-CH2-CH2-, -N(C(=O)H)-CH2-CH2-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)-, -NH-CH2-CH2- or -CH2-CH2-NH-, and other variables are as defined herein.
[0193] In some embodiments of the present application, -L 2 -L 1- is selected from the group consisting of a single bond, -NH-, -N(CH3)-, -C(=O)-, -CH2-, -CH2-CH2-, -S(=O)2-, -CH2-NH-, -NH-CH2-, -CH2-N(CH3)-, -N(CH3)-CH2-, -C(=O)-CH2-, -CH2-C(=O)-, -C(=O)-NH-, -NH-C(=O)-, -NH-S(=O)2-, -S(=O)2-NH-, -N(CH3)-S(=O)2-, -S(=O)2-N(CH3)-, -N(CH3)-C(=O)-, -C(=O)-N(CH3)-, -NH-S(=O)(=NH)-, -S(=O)(=NH)-NH-, -S(= -P(=O)(CH3)-, -CH2-P(=O)(CH3)-, -P(=O)(CH3)-CH2-, -NH-P(=O)(CH3)-, -P(=O)(CH3)-NH-, -NH-P(=O)(NHCH3)-, -P(=O)(NHCH3)-NH-, -NH-P(=O)(NH2)-, -P(=O)(NH2)-NH-, -CH2-P(=O)(NHCH3)-, -P(=O)(NHCH3)-CH2-, -N(CH3)-CH2-CH2-, -CH2-CH2-N(CH3)-, -NH-CH2-CH2-, or -CH2-CH2-NH-, and other variables are as defined herein.
[0194] In other embodiments of the present application, -L 2 -L 1 - is selected from the group consisting of a single bond, -NH-, -CH2-, -S(=O)2-, -N(CH3)-CH2-, -NH-C(=O)-, -N(CH3)-C(=O)-, -S(=O)2-NH-, -NH-S(=O)2-, -S(=O)(CH3)=N-, -S(=O)2-N(CH3)-, -C(=O)-NH-, -C(=O)-N(CH3)-, -S(=O)(=NH)-NH-, -S(=O)(= NH)-, -P(=O)(CH3)-, -S(=O)(=NH)-CH2-, -P(=O)(CH3)-CH2-, -P(=O)(CH3)-NH-, -P(=O)(NHCH3)-NH-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)-, -CH2-CH2-NH- or -S(=O)2-N(S(=O)2CH3)-, and other variables are as defined herein.
[0195] In some embodiments of the present application, -L 2 -L1 - is selected from a single bond, -NH-, -CH2-, -S(=O)2-, -N(CH3)-CH2-, -NH-C(=O)-, -S(=O)2-NH-, -NH-S(=O)2-, -S(=O)(CH3)=N-, -S(=O)2-N(CH3)-, -C(=O)-NH-, -C(=O)-N(CH3)-, -S(=O)(=NH)-NH-, -S(=O)(=NH)-, -P (=O)(CH3)-, -CH2-S(=O)(=NH)-, -P(=O)(CH3)-CH2-, -P(=O)(CH3)-NH-, -P(=O)(NHCH3)-NH-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)-, -CH2-CH2-NH- or -S(=O)2-N(S(=O)2CH3)-, and other variables are as defined herein.
[0196] In some embodiments of the present application, -L 2 -L 1 - is selected from a single bond, -NH-, -CH2-, -S(=O)2-, -N(CH3)-CH2-, -NH-C(=O)-, -C(=O)-NH-, -S(=O)2-NH-, -S(=O)2-N(CH3)-, -C(=O)-NH-, -C(=O)-N(CH3)-, -S(=O)(=NH)-NH-, -S(=O)(=NH)-, -P(=O)(CH3)-, -CH2-S(=O)(=NH)-, -P(=O)(CH3)-CH2-, -P(=O)(CH3)-NH-, -P(=O)(NHCH3)-NH-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)- or -CH2-CH2-NH-, and the other variables are as defined herein.
[0197] In some embodiments of the present application, -L 2 -L 1- is selected from a single bond, -NH-, -CH2-, -S(=O)2-, -N(CH3)-CH2-, -NH-C(=O)-, -C(=O)-NH-, -S(=O)2-NH-, -S(=O)2-N(CH3)-, -C(=O)-NH-, -C(=O)-N(CH3)-, -S(=O)(=NH)-NH-, -S(=O)(=NH)-, -P(=O)(CH3)-, -P(=O)(CH3)-CH2-, -P(=O)(CH3)-NH-, -P(=O)(NHCH3)-NH-, -CH2-CH2-N(CH3)- or -CH2-CH2-NH-, and the other variables are as defined herein.
[0198] In some embodiments of the present application, -L 2 -L 1 - is selected from a single bond, -NH-, -CH2-, -NH-S(=O)2- or -S(=O)2-NH-, and the other variables are as defined herein.
[0199] In some embodiments of the present application, -L 2 -L 1 - is selected from a single bond, -NH-, -CH2- or -S(=O)2-NH-, and the other variables are as defined in this application.
[0200] In some embodiments of the present application, -L 2 -L 1 - is selected from a single bond or -S(=O)2-NH-, and the other variables are as defined in this application.
[0201] In some embodiments of the present application, -L 2 -L 1 - is selected from -S(=O)2-NH-, and the other variables are as defined in this application.
[0202] In some embodiments of the present application, -L 2 -L 1 - is selected from -NH-S(=O)2-, and the other variables are as defined in this application.
[0203] In some embodiments of the present application, -L 2 -L 1 - is selected from a single bond, and the other variables are as defined in this application.
[0204] In some embodiments of the present application, R 1 Selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -NH2, -NH(C 1-3alkyl), cyclopropyl, cyclobutyl, cyclopentyl, 4-6 membered heterocycloalkyl containing 1 or 2 atoms selected from N, O, S or 5-6 membered heteroaryl containing 1 or 2 N atoms, said C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R d Substituted; the 4-6 membered heterocycloalkyl or 5-6 membered heteroaryl is optionally independently substituted by 1, 2 or 3 R e Substitution, other variables are as defined in this application.
[0205] In some embodiments of the present application, R 1 is selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, cyclobutyl, cyclopentyl, a 4-6 membered heterocycloalkyl containing 1 or 2 N, O, S atoms, or a 5-6 membered heteroaryl containing 1 or 2 N atoms, wherein the methyl, ethyl or methoxy group is optionally independently replaced by 1, 2 or 3 R d substituted, the 4-6 membered heterocycloalkyl or 5-6 membered heteroaryl is optionally independently substituted by 1, 2 or 3 R e Substitution, other variables are as defined in this application.
[0206] In some embodiments of the present application, R 1 is selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, thietanyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, tetrahydropyranyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazole ring, isothiazolyl, triazolyl, furyl, thienyl, pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl, said methyl, ethyl or methoxy being optionally substituted independently by 1, 2 or 3 R d substituted; the cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, thietanyl, azetidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, tetrahydropyranyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazole ring, isothiazolyl, triazolyl, furanyl, thienyl, pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl are optionally independently substituted by 1, 2 or 3 R e Substitution, other variables are as defined in this application.
[0207] In some embodiments of the present application, R 1is selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, pyrazolyl, oxazolyl or pyrimidinyl, wherein the methyl, ethyl or methoxy group is optionally substituted independently by 1, 2 or 3 R d Substituted; the cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl are optionally independently substituted by 1, 2 or 3 R e Substitution, other variables are as defined in this application.
[0208] In some embodiments of the present application, R 1 is selected from H, methyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl, wherein the methyl, ethyl or methoxy is optionally substituted independently by 1, 2 or 3 R d Substituted; the cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl are optionally independently substituted by 1, 2 or 3 R e Substitution, other variables are as defined in this application.
[0209] In some embodiments of the present application, R 1 is selected from H or methyl, and the other variables are as defined herein.
[0210] In some embodiments of the present application, each R d are each independently selected from F, Cl, Br, I or OH, and other variables are as defined in this application.
[0211] In some embodiments of the present application, each R d are each independently selected from F or OH, and the other variables are as defined in this application.
[0212] In some embodiments of the present application, each R e Each independently selected from F, Cl, Br, I, ═O or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0213] In some embodiments of the present application, each R x are each independently selected from halogen, and the other variables are as defined herein.
[0214] In some embodiments of the present application, each R e Each independently selected from F, Cl, Br, I, ═O or C1-3 Alkyl, and other variables are as defined herein.
[0215] In other embodiments of the present application, each R e are each independently selected from =0 or methyl, and the other variables are as defined herein.
[0216] In other embodiments of the present application, each R y are each independently selected from halogen, and the other variables are as defined herein.
[0217] In some embodiments of the present application, R 1 is selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, pyrazolyl, imidazolyl, oxazolyl or pyrimidinyl, wherein the methyl, ethyl or methoxy is optionally substituted independently by 1, 2 or 3 R d Substituted, the cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl are optionally independently substituted by 1, 2 or 3 R e In some embodiments of the present invention, each R d Each independently selected from F, Cl, Br, I and OH, said R e Selected from F, Cl, Br, I, ═O or C 1-3 alkyl; other variables are as defined herein.
[0218] In some embodiments of the present application, R 1 is selected from H, methyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, pyrazolyl, oxazolyl or pyrimidinyl, wherein the methyl, ethyl or methoxy is optionally substituted independently by 1, 2 or 3 R d Substituted, the cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl are optionally independently substituted by 1, 2 or 3 R e In some embodiments of the present invention, each R d Each independently selected from F, Cl, Br, I and OH, said R e Selected from F, Cl, Br, I, ═O or C 1-3 alkyl; other variables are as defined herein.
[0219] In some embodiments of the present application, R 1is selected from H, methyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl, wherein the methyl, ethyl or methoxy is optionally substituted independently by 1, 2 or 3 R d Substituted, the cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl are optionally independently substituted by 1, 2 or 3 R e In some embodiments of the present invention, each R d Each independently selected from F or OH, the R e is selected from =0 or methyl; other variables are as defined herein.
[0220] In some embodiments of the present application, R 1 Selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), The methyl, ethyl or methoxy groups are optionally independently substituted with 1, 2 or 3 R d Replace, the Optionally independently 1, 2 or 3 R e Other variables are as defined herein. In some embodiments of the present application, each R d Each independently selected from F or OH, each R e are each independently selected from =0 or methyl, and the other variables are as defined herein.
[0221] In other embodiments of the present application, R 1 Selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), The methyl, ethyl or methoxy groups are optionally independently substituted with 1, 2 or 3 R d Replace, the Optionally independently 1, 2 or 3 R e Other variables are as defined herein. In some embodiments of the present application, each R d Each independently selected from F or OH, each R e are each independently selected from =0 or methyl, and the other variables are as defined herein.
[0222] In some embodiments of the present application, R 1Selected from H, methyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), The methyl or methoxy groups are optionally independently substituted with 1, 2 or 3 R d Replace, the Optionally independently 1, 2 or 3 R e Other variables are as defined herein. In some embodiments of the present application, each R d Each independently selected from F or OH, each R e are each independently selected from =0 or methyl, and the other variables are as defined herein.
[0223] In other embodiments of the present application, R 1 Selected from H, methyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), The methyl, ethyl or methoxy groups are optionally independently substituted with 1, 2 or 3 R d Replace, the Optionally independently 1, 2 or 3 R e Other variables are as defined herein. In some embodiments of the present application, each R d Each independently selected from F or OH, each R e are each independently selected from =0 or methyl, and the other variables are as defined herein.
[0224] In some embodiments of the present application, R 1 Selected from H, methyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), The methyl, ethyl or methoxy groups are optionally independently substituted with 1, 2 or 3 R d Replace, the Optionally independently 1, 2 or 3 R e Other variables are as defined herein. In some embodiments of the present application, each R d Each independently selected from F or OH, each R e are each independently selected from =0 or methyl, and the other variables are as defined herein.
[0225] In other embodiments of the present application, R 1Selected from H, methyl, -CH2CH2OH, methoxy, -OCF3, -CH2OH, -NH2, -NH(CH3), -NH(CH2CH2OH), Other variables are as defined in this application.
[0226] In some embodiments of the present application, R 1 Selected from H, methyl, -CH2CH2OH, methoxy, -OCF3, -CH2OH, -NH2, -NH(CH3), -NH(CH2CH2OH), Other variables are as defined in this application.
[0227] In some embodiments of the present application, R 1 Selected from H, methyl, methoxy, -OCF3, -CH2OH, -NH2, -NH(CH3), -NH(CH2CH2OH), Other variables are as defined in this application.
[0228] In some embodiments of the present application, R 1 is selected from H, methyl or methoxy, and the other variables are as defined in this application.
[0229] In some embodiments of the present application, R 1 is selected from methyl, and other variables are as defined herein.
[0230] In some embodiments of the present application, R 1 is selected from H, and other variables are as defined in this application.
[0231] In some embodiments of the present application, each R b Each independently selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution; said C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R y Substitution, other variables are as defined in this application.
[0232] In other embodiments of the present application, each R b Each is independently selected from H, -C(=O)H, -S(=O)2CH3 or methyl, said methyl optionally independently substituted by 1, 2 or 3 R xSubstitution, other variables are as defined in this application.
[0233] In some embodiments of the present application, each R b Each independently selected from H or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0234] In some embodiments of the present application, each R b are each independently selected from H or methyl, said methyl optionally independently replaced by 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0235] In other embodiments of the present application, each R b Each is independently selected from H, -C(=O)H, -S(=O)2CH3 or methyl, and the other variables are as defined in this application.
[0236] In some embodiments of the present application, each R b are each independently selected from H or methyl, and the other variables are as defined herein.
[0237] In some embodiments of the present application, R c Selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0238] In some embodiments of the present application, R c is selected from methyl, said methyl being optionally independently substituted by 1, 2 or 3 R x Substitution, other variables are as defined in this application.
[0239] In some embodiments of the present application, R c is selected from methyl, and other variables are as defined herein.
[0240] In some embodiments of the present application, m is selected from 1 or 2, and other variables are as defined herein.
[0241] In some embodiments of the present application, R 2 、R 3 and R 4 are each independently selected from H, deuterium or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R z Substitution, other variables are as defined in this application.
[0242] In some embodiments of the present application, R 2 、R 3 and R 4 Each independently selected from H or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R z Substitution, other variables are as defined in this application.
[0243] In some embodiments of the present application, R 2 、R 3 and R 4 Each is independently selected from H, deuterium, methyl, -CD3, difluoromethyl, trifluoromethyl or ethyl, and the other variables are as defined herein.
[0244] In other embodiments of the present application, R 2 、R 3 and R 4 Each is independently selected from H, deuterium, methyl, -CD3, or trifluoromethyl, and other variables are as defined herein.
[0245] In some embodiments of the present application, R 2 、R 3 and R 4 Each is independently selected from H, methyl or ethyl, and other variables are as defined in the application. In some embodiments of the present application, R 2 、R 3 and R 4 are each independently selected from H or methyl, and the other variables are as defined herein.
[0246] In some embodiments of the present application, R 2 、R 3 and R 4 At least one of the variables is selected from H, and the other variables are as defined in this application.
[0247] In other embodiments of the present application, R 2 Selected from H or deuterium, R 3 and R 4 Each is independently selected from H, methyl, -CD3 or trifluoromethyl, and other variables are as defined herein.
[0248] In some embodiments of the present application, R 2 Selected from H or deuterium, R 3 and R 4 are each independently selected from methyl, -CD3 or trifluoromethyl, and other variables are as defined herein.
[0249] In some embodiments of the present application, R 2 Selected from deuterium, R 3and R 4 are each independently selected from -CD3, and other variables are as defined herein.
[0250] In some embodiments of the present application, R 2 Selected from H, R 3 and R 4 are each independently selected from methyl, and other variables are as defined herein.
[0251] In other embodiments of the present application, R 2 Selected from H, R 3 and R 4 are each independently selected from methyl and CF3, and the other variables are as defined herein.
[0252] In some embodiments of the present application, R 2 Selected from methyl, R 3 and R 4 are each independently selected from H, and the other variables are as defined herein.
[0253] In some embodiments of the present application, R 2 、R 3 and R 4 All are H, and other variables are as defined in this application.
[0254] In some embodiments of the present application, R 2 and R 3 and the carbon atoms that are connected together to form C 3-4 Cycloalkyl or 3-4 membered heterocycloalkyl, R 4 Selected from H or C 1-3 Alkyl, the C 1-3 Alkyl, C 3-4 Cycloalkyl or 3-4 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R z Substitution, other variables are as defined in this application.
[0255] In some embodiments of the present application, R 2 and R 3 and the carbon atoms to which they are connected together form a cyclopropyl, oxirane or azirane group, R 4 is selected from H, methyl or ethyl, wherein the methyl, ethyl, cyclopropyl, oxirane or aziridine radicals are optionally independently replaced by 1, 2 or 3 R z Substitution, other variables are as defined in this application.
[0256] In some embodiments of the present application, R 2 and R 3 and the carbon atoms to which they are attached together form a cyclopropyl group, R 4is selected from H or methyl, said methyl or cyclopropyl optionally independently substituted by 1, 2 or 3 R z Substitution, other variables are as defined in this application.
[0257] In some embodiments of the present application, R 2 and R 3 and the carbon atoms to which they are attached together form a cyclopropyl group, R 4 is selected from methyl, and other variables are as defined herein.
[0258] In some embodiments of the present application, R 2 and R 3 and the carbon atoms to which they are attached together form a cyclopropyl group, R 4 is selected from H, and other variables are as defined in this application.
[0259] In some embodiments of the present application, each R z are each independently selected from deuterium, halogen or OH, and the other variables are as defined in this application.
[0260] In some embodiments of the present application, each R z are each independently selected from halogen or OH, and the other variables are as defined in this application.
[0261] In some embodiments of the present application, each R z are each independently selected from F, and the other variables are as defined in this application.
[0262] In some embodiments of the present application, the compound represented by formula (I), its isomer or pharmaceutically acceptable salt thereof, wherein,
[0263] Ring A is selected from C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 The alkyl ring or 5-6 membered heteroaryl ring and the 5-6 membered heteroalkyl ring are optionally independently substituted by 1, 2 or 3 R a replace;
[0264] L 1 and L 2 Each independently selected from a single bond, -N(R b )-, -N=, -O-, -S-, -(CH2) m-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=N(R b ))-、-S(=O)(R c )-、-P(=O)(R c )-or-P(=O)(NR b R b )-;
[0265] R 1 Selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R d Substitute, the C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl are optionally independently substituted by 1, 2 or 3 R e replace;
[0266] R 2 、R 3 and R 4 Each independently selected from H, halogen, OH, CN, NH2, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R z replace;
[0267] or R 2 and R 3 and the carbon atoms that are connected together to form C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, R 4 Selected from H, halogen, OH, CN, NH2, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R z replace;
[0268] Each R a Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x replace;
[0269] Each R b Each independently selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -C(=O)H, -S(=O)2C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution; said C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R y replace;
[0270] R c Selected from halogen, OH, CN or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x replace;
[0271] Each R d Each independently selected from halogen, OH, CN or NH2;
[0272] Each R e Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x replace;
[0273] Each R x Each independently selected from halogen, OH, CN or NH2;
[0274] Each R y Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally substituted independently with 1, 2 or 3 substituents selected from halogen, OH, CN or NH2;
[0275] Each R z Each independently selected from halogen, OH, CN or NH2;
[0276] m is selected from 1, 2 or 3;
[0277] The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.
[0278] The present application provides a compound represented by formula (II), an isomer thereof or a pharmaceutically acceptable salt thereof,
[0279] in,
[0280] Ring A is selected from C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-6 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 The alkyl ring or 5-6 membered heteroaryl ring and the 5-6 membered heteroalkyl ring are optionally independently substituted by 1, 2 or 3 R a replace;
[0281] L 1 and L 2 Each independently selected from a single bond, -N(R b )-、-O-、-S-、-(CH2) m -, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=N(R b ))-、-P(=O)(R c )-or-P(=O)(NR b R b )-;
[0282] R 1 Selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R d Substitute, the C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl are optionally independently substituted by 1, 2 or 3 R e replace;
[0283] Each R a Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x replace;
[0284] Each R b Each independently selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -C(=O)H, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution; said C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R y replace;
[0285] R c Selected from halogen, OH, CN or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x replace;
[0286] Each R d Each independently selected from halogen, OH, CN or NH2;
[0287] Each R e Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x replace;
[0288] Each R x Each independently selected from halogen, OH, CN or NH2;
[0289] Each R y Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally substituted independently with 1, 2 or 3 substituents selected from halogen, OH, CN or NH2;
[0290] m is selected from 1, 2 or 3;
[0291] The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.
[0292] In some embodiments of the present application, the compound represented by formula (II), its isomer or pharmaceutically acceptable salt thereof, wherein Ring A, R 1 , L 1 and L 2 It may also be defined as in the compound represented by formula (I) above.
[0293] In some embodiments of the present application, the compound represented by formula (II), its isomer or pharmaceutically acceptable salt thereof is selected from the compound represented by formula (II-1),
[0294] Among them, ring A, R 1 , L 1 and L 2 The compound is defined as shown in formula (II).
[0295] In some embodiments of the present application, the compound of formula (II), its isomer or pharmaceutically acceptable salt thereof is selected from the compound of formula (II-2)
[0296] in,
[0297] X is selected from CH or N;
[0298] R 1 、R a , L 1 and L 2 As defined by the compound represented by formula (II);
[0299] The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.
[0300] In some embodiments of the present application, X is selected from N, and other variables are as defined herein.
[0301] In some embodiments of the present application, the compound of formula (II), its isomer or pharmaceutically acceptable salt thereof is selected from the compound of formula (II-2a)
[0302] in,
[0303] X is selected from CH or N;
[0304] R 1 、R a , L1 and L 2 The compound is defined as shown in formula (II).
[0305] In some embodiments of the present application, X is selected from N, and other variables are as defined herein.
[0306] In some embodiments of the present application, the compound of formula (II), its isomer or pharmaceutically acceptable salt thereof is selected from the compound of formula (II-3)
[0307] in,
[0308] X is selected from CH or N;
[0309] R 1 and R a As defined by the compound represented by formula (II);
[0310] The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.
[0311] In some embodiments of the present application, X is selected from N, and other variables are as defined herein.
[0312] In some embodiments of the present application, the compound of formula (II), its isomer or pharmaceutically acceptable salt thereof is selected from the compound of formula (II-3a)
[0313] in,
[0314] X is selected from CH or N;
[0315] R 1 and R a The compound is defined as shown in formula (II).
[0316] In some embodiments of the present application, X is selected from N, and other variables are as defined herein.
[0317] In some embodiments of the present application, the compound represented by formula (I), its isomer or pharmaceutically acceptable salt thereof is selected from the compound represented by formula (I-4),
[0318] Among them, ring A, R 1 , L 1 and L 2 The compound is defined as shown in formula (I).
[0319] In some embodiments of the present application, the compound represented by formula (I), formula (II), formula (II-1), formula (II-2) or formula (II-2a) does not include the following structure:
[0320] Some other embodiments of the present application are formed by any combination of the above variables.
[0321] On the other hand, the present application also provides a compound of the following formula, an isomer thereof or a pharmaceutically acceptable salt thereof,
[0322] On the other hand, the present application also provides a compound of the following formula, an isomer thereof or a pharmaceutically acceptable salt thereof,
[0323] On the other hand, the present application also provides a pharmaceutical composition containing a therapeutically or prophylactically effective amount of the compound described herein, its isomers, or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical composition of the present application further comprises a pharmaceutically acceptable excipient.
[0324] On the other hand, the present application also provides the use of the compound described in the present application, its isomer or pharmaceutically acceptable salt or pharmaceutical composition thereof in the preparation of a drug for treating or preventing CDK2-mediated diseases.
[0325] On the other hand, the present application also provides a method for treating or preventing CDK2-mediated diseases, comprising administering a therapeutically or preventively effective amount of the compound described herein, its isomers, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof to a mammal (preferably a human) in need of such treatment or prevention.
[0326] On the other hand, the present application also provides the use of the compound described in the present application, its isomer or pharmaceutically acceptable salt or pharmaceutical composition thereof in the treatment or prevention of CDK2-mediated diseases.
[0327] On the other hand, the present application also provides the compound described in the present application, its isomer, or its pharmaceutically acceptable salt, or its pharmaceutical composition for treating or preventing CDK2-mediated diseases.
[0328] On the other hand, in some embodiments of the present application, the CDK2-mediated disease is selected from tumors or cancers.
[0329] In the present application, the "isomer" includes but is not limited to stereoisomers or tautomers.
[0330] Technical Effects
[0331] The compounds described herein are novel CDK2 inhibitors with potent inhibitory effects on CDK2-induced signaling, including good inhibitory activity against both CDK2 CycA2 and CDK2 CycE1 kinases. These compounds exhibit favorable properties in at least one or more of in vitro and in vivo inhibitory activity, safety (e.g., low toxicity), and CDK2 selectivity. The compounds described herein exhibit favorable pharmacokinetic properties and are a promising candidate for development into novel CDK2 inhibitors.
[0332] Related definitions
[0333] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be construed as indefinite or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.
[0334] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0335] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present application, which are prepared by reacting the compounds with specific substituents discovered herein with relatively non-toxic acids or bases. When the compounds of the present application contain relatively acidic functional groups, base addition salts can be obtained by contacting the compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. When the compounds of the present application contain relatively basic functional groups, acid addition salts can be obtained by contacting the compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Certain specific compounds of the present application contain both basic and acidic functional groups and can be converted into either base or acid addition salts.
[0336] The pharmaceutically acceptable salts of the present application can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, the preparation method of such salts is: in water or an organic solvent or a mixture of the two, the compounds in the form of free acid or base are reacted with a stoichiometric amount of a suitable base or acid to prepare.
[0337] The compounds of the present invention may exist in specific stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All of these isomers and their mixtures are within the scope of the present invention.
[0338] Unless otherwise specified, use a solid wedge key and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed bond Indicates the relative configuration of a stereocenter.
[0339] The compounds and intermediates of the present application can also exist in different tautomeric forms, and all such forms are included in the scope of the present application. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. The specific example of a proton tautomer is the imidazole moiety, in which a proton can migrate between two ring nitrogens. Valence tautomers include interconversions by reorganization of some bonding electrons.
[0340] The compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C). For example, deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and extended drug biological half-life. All isotopic variations of the compounds of this application, whether radioactive or not, are included within the scope of this application.
[0341] The terms "optional" or "optionally" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0342] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., =O), it means that two hydrogen atoms are replaced. Oxygen substitution does not occur on aromatic groups. The term "optionally substituted" means that it may be substituted or unsubstituted, and unless otherwise specified, the type and number of substituents can be any on the basis of chemical achievable.
[0343] The term "one or more substitutions" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which may include deuterium and hydrogen variants, and the number of substituents includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, based on chemical achievability.
[0344] The "substituents" described herein include, but are not limited to, the terms "alkyl", "alkoxy", "cycloalkyl", "heterocycloalkyl", "heteroaryl", "alkyl ring", "heteroalkyl ring", "heteroaryl ring", etc., and corresponding non-limiting or exemplary groups, wherein some non-limiting examples of the "substituents" include protium, deuterium, tritium, -OH, -SH, halogen, -NH2, nitro, nitroso, -CN, azide, sulfoxide, sulfone, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, etc. radical, alkyl, halo-alkyl, cycloalkyl, halo-cycloalkyl, alkenyl, halo-alkenyl, cycloalkenyl, halo-cycloalkenyl, alkynyl, halo-alkynyl, cycloalkynyl, halo-cycloalkynyl, heteroalkyl, halo-heteroalkyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, aralkyl, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroaralkyl, heteroarylalkoxy, heteroarylalkylthio, heterocyclyl, heterocyclyloxy, heterocyclylthio, heterocyclylalkyl, heterocyclyl Alkoxy, heterocyclylalkylthio, acyl, acyloxy, carbamate group, amide group, urea group, epoxy group and ester group, etc., which are optionally substituted by one or more substituents selected from the following: oxo, hydroxyl, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C (O) O-alkyl, -OC (O) -alkyl, -C (O) NH2, -C (O) NH -alkyl, -C(O)N(alkyl)2, -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O)2-alkyl, -S(O)2NH2, -S(O)2NH-alkyl, -S(O)2N(alkyl)2, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkyl, heterocyclyloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, aryl, arylalkyl or aryloxy.
[0345] In some embodiments herein, the “substituent” is selected from deuterium, tritium, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azide, sulfoxide, sulfone, sulfonamide, carboxyl, aldehyde, imine, C 1-12 Alkyl, halo-C 1-12 Alkyl, 3-12 membered cycloalkyl, halogenated 3-12 membered cycloalkyl, C 2-12 Alkenyl, halo-C 2-12 Alkenyl, 3-12 membered cycloalkenyl, halogenated 3-12 membered cycloalkenyl, C 2-12 Alkynyl, halo-C 2-12 Alkynyl, 8-12 membered cycloalkynyl, halogenated 8-12 membered cycloalkynyl, C 1-12 Heteroalkyl, halo-C 1-12 Heteroalkyl, C1-12 Alkoxy, C 1-12 Alkylthio, 6-10 membered aryl, 6-10 membered aryloxy, 6-10 membered arylthio, 6-10 membered arylC 1-12 Alkylene, 6-10 membered aryl C 1-12 Alkoxy, 6-10 membered aryl C 1-12 alkylthio, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, 5-10 membered heteroarylthio, 5-10 membered heteroarylalkylene, 5-10 membered heteroarylalkoxy, 5-10 membered heteroarylalkylthio, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, 3-12 membered heterocyclylthio, 3-12 membered heterocyclylC 1-12 Alkylene, 3-12 membered heterocyclic group C 1-12 Alkoxy, 3-12 membered heterocyclic group C 1-12 Alkylthio, C 1-12 Acyl, C 1-12 Acyloxy, carbamate group, C 1-12 Amide group, urea group, epoxy group, C 2-12 Ester group and oxo, said substituent being optionally substituted by one or more substituents selected from the group consisting of oxo, hydroxy, amino, nitro, halogen, cyano, C 1-12 Alkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, C 1-12 Alkylamino, di-C 1-12 Alkylamino, halogenated C 1-12 Alkylamino, halogenated di-C 1-12 Alkylamino, carboxyl, -C(O)OC 1-12 Alkyl, -OC(O)-C 1-12 Alkyl, -C(O)NH2, -C(O)NH-C 1-12 Alkyl, -C(O)N(C 1-12 Alkyl)2, -NHC(O)-C 1-12 Alkyl, -C(O)-C 1-12 Alkyl, -S(O)-C 1-12 Alkyl, -S(O)2-C 1-12 Alkyl, -S(O)2NH2, -S(O)2NH-C 1-12 Alkyl, -S(O)2N(C 1-12 alkyl) 2, 3-12 membered cycloalkyl, 3-12 membered cycloalkyl C 1-12 Alkylene, 3-12 membered cycloalkyloxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group C 1-12 Alkylene, 3-12 membered heterocyclyloxy, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkylC1-12 Alkylene, 3-12 membered heterocycloalkyloxy, 5-10 membered heteroaryl, 5-10 membered heteroarylC 1-12 Alkylene, 5-10 membered heteroaryloxy, 6-10 membered aryl, 6-10 membered arylC 1-12 an alkylene group or a 6- to 10-membered aryloxy group.
[0346] In this article, C m-n , means that the moiety has an integer number of carbon atoms in a given range. For example, "C 1-6 " means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. For example, C 1-3 It means that the group may have 1 carbon atom, 2 carbon atoms, or 3 carbon atoms.
[0347] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permissible only if such combinations result in stable compounds.
[0348] When one of the variables is selected from a single bond, it means that the two groups it connects are directly connected. For example, when L in ALZ represents a single bond, it means that the structure is actually AZ.
[0349] When the linking group is listed without specifying its linking direction, its linking direction is arbitrary, for example, The connecting group L is -MW-, in which case -MW- can connect ring A and ring B in the same direction as the reading order from left to right to form You can also connect ring A and ring B in the opposite direction of reading from left to right to form Combinations of linkers, substituents, and / or variations thereof are permissible only if such combinations result in stable compounds.
[0350] Unless otherwise specified, when a group has one or more connectable sites, any one or more sites of the group can be connected to other groups through chemical bonds. When the chemical bond connection mode is non-positional and there are H atoms at the connectable sites, when the chemical bond is connected, the number of H atoms at the site will decrease accordingly with the number of connected chemical bonds, and become a group with a corresponding valence. The chemical bond connecting the site to other groups can be a straight solid bond. Straight dotted key or wavy lines For example, the straight solid bond in -OCH3 indicates that it is connected to other groups through the oxygen atom in the group; The straight dashed bond in the group indicates that the two ends of the nitrogen atom in the group are connected to other groups; The wavy line in the phenyl group indicates that it is connected to other groups through the carbon atoms at positions 1 and 2 in the phenyl group; Indicates that any linkable site on the piperidinyl group can be connected to other groups through a chemical bond, including at least In these four connection methods, even if an H atom is drawn on -N-, Still includes For groups connected in this way, when one chemical bond is connected, the H at that site will be reduced by one and become a corresponding monovalent piperidine group.
[0351] Unless otherwise specified, the term “C 1-3 "Alkyl" is used to represent a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms. 1-3 Alkyl groups include C 1-2 and C 2-3 Alkyl, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or polyvalent (such as methine). 1-3 Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
[0352] Unless otherwise specified, the term “C 1-3 "Alkoxy" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via an oxygen atom. The C 1-3 Alkoxy groups include C 1-2 、C 2-3 , C3 and C2 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
[0353] The term "halogen," by itself or as part of another substituent, means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
[0354] Unless otherwise specified, C n-n+m or C n -C n+m Any specific case including n to n+m carbons, such as C 1-12 Including C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 、C 11 , and C 12 , also includes any range from n to n+m, such as C 1-12Including C 1-3 、C 1-6 、C 1-9 、C 3-6 、C 3-9 、C 3-12 、C 6-9 、C 6-12 , and C 9-12 Similarly, n-membered to n+m-membered means that the number of atoms in the ring is n to n+m, for example, a 3-12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, and a 12-membered ring, and also includes any range from n to n+m, for example, a 3-12-membered ring includes a 3-6-membered ring, a 3-9-membered ring, a 5-6-membered ring, a 5-7-membered ring, a 6-7-membered ring, a 6-8-membered ring, and a 6-10-membered ring, etc.
[0355] Unless otherwise specified, the term “C 3-6 "Cycloalkyl" means a saturated cyclic hydrocarbon group consisting of 3 to 6 carbon atoms, which is a monocyclic or bicyclic ring system. 3-6 Cycloalkyl groups include C 3-5 、C 4-5 and C 5-6 Cycloalkyl, etc.; it may be monovalent, divalent or polyvalent. 3-6 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
[0356] Unless otherwise specified, the term "3-6 membered heterocycloalkyl" by itself or in combination with other terms means a saturated cyclic group consisting of 3 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). p, p is 1 or 2). It is a monocyclic ring system. In addition, with respect to the "3-6 membered heterocycloalkyl", a heteroatom may occupy the position where the heterocycloalkyl is connected to the rest of the molecule. The 3-6 membered heterocycloalkyl includes 3-membered, 4-membered, 5-membered and 6-membered heterocycloalkyls. Examples of 3-6 membered heterocycloalkyls include, but are not limited to, oxirane, thiirane, aziridine, Azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophene (including tetrahydrothiophene-2-yl and tetrahydrothiophene-3-yl, etc.), tetrahydrothiophene 1,1,-dioxide-3-yl, tetrahydrothiophene 1,1,-dioxide-2-yl, tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl or homopiperidinyl, etc.
[0357] Unless otherwise specified, the term "5-6 membered heteroaryl" refers to a cyclic group consisting of 5 to 6 ring atoms with a conjugated π electron system, 1, 2 or 3 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., C=O, NO and S(O) p , p is 1 or 2)). 5-6 membered heteroaryl can be connected to the rest of the molecule through a heteroatom or a carbon atom. The 5-6 membered heteroaryl includes 5-membered and 6-membered heteroaryl. Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl, etc.), pyrazinyl, pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.), etc.
[0358] Unless otherwise specified, the term “C 3-10"Alkyl ring" means a saturated hydrocarbon ring consisting of 3 to 10 carbon atoms, including monocyclic and bicyclic systems, wherein the bicyclic system includes spiro, fused and bridged rings. 3-10 Alkane rings include C 3-6 、C 3-5 、C 4-8 、C 4-6 、C 4-5 、C 5-8 or C 5-6 Alkane ring; it can be monovalent, divalent or polyvalent. 3-10 Examples of the alkane ring include, but are not limited to, a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a norbornane ring, a [2.2.2]bicyclooctane ring and the like.
[0359] Unless otherwise specified, the term "5-10 membered heteroalkyl ring" means a saturated cyclic group consisting of 5 to 10 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized and the carbon, nitrogen and sulfur heteroatoms are optionally oxidized (i.e., C=O, NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spirocyclic, fused and bridged rings. In addition, with respect to the "5-10 membered heteroalkane ring", a heteroatom may occupy the position at which the heteroalkane ring connects to the rest of the molecule. The 5-10 membered heteroalkane ring includes a 5-6 membered heteroalkane ring, etc. Examples of the 5-10 membered heteroalkyl ring include, but are not limited to, an azetidine ring, an oxetane ring, a thietane ring, a pyrrolidine ring, a pyrazolidine ring, an imidazolidine ring, a tetrahydrothiophene ring (including a tetrahydrothiophene-2-ring and a tetrahydrothiophene-3-ring, etc.), a tetrahydrofuran ring (including a tetrahydrofuran-2-ring, etc.), a tetrahydropyran ring, a piperidine ring (including a 1-piperidine ring, a 2-piperidine ring and a 3-piperidine ring, etc.), a piperazine ring (including a 1-piperazine ring and a 2-piperazine ring, etc.), a morpholine ring (including a 3-morpholine ring and a 4-morpholine ring, etc.), a dioxane ring, a dithiane ring, an isoxazolidine ring, an isothiazolidine ring, a 1,2-oxazine ring, a 1,2-thiazine ring, a hexahydropyridazine ring, a homopiperazine ring, a homopiperidine ring or a dioxepane ring, etc. It should be understood that the term "5-10 membered heteroalkyl ring" includes the case where the ring heteroatoms are oxidized, for example when a substituent is represented by a substituent selected from When it contains at least The specific structure.
[0360] Unless otherwise specified, the term "phenyl ring and C 5-6 Alkane ring" or "benzene ring and 5-6 membered heteroalkane ring", respectively means benzene ring and C 5-6 alkane ring, or a fused bicyclic ring formed by a 5-6 membered heteroalkane ring, for example: wait.
[0361] Unless otherwise specified, the term "5-6 membered heteroaromatic ring and C 5-6 alkane ring" or "5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring", respectively means a 5-6 membered heteroaromatic ring and a C 5-6 alkane ring, or a fused bicyclic ring formed by a 5-6 membered heteroalkane ring, for example: wait.
[0362] Unless otherwise specified, the term "5-10 membered heteroaromatic ring" means a cyclic group consisting of 5 to 10 ring atoms having a conjugated π electron system, wherein 1, 2, 3 or 4 of the ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., C=O, NO and S(O) p , p is 1 or 2). It can be a monocyclic, fused bicyclic or fused tricyclic ring system, wherein each ring is aromatic. The 5-10 membered heteroaromatic ring can be connected to the rest of the molecule via a heteroatom or carbon atom. The 5-10 membered heteroaromatic ring includes 5-8 membered, 5-7 membered, 5-6 membered, 5 membered and 6 membered heteroaromatic rings, etc. Examples of the 5-10 membered heteroaromatic ring include, but are not limited to, a pyrrole ring (including an N-pyrrole ring, a 2-pyrrole ring and a 3-pyrrole ring), a pyrazole ring (including a 2-pyrazole ring and a 3-pyrazole ring), an imidazole ring (including an N-imidazole ring, a 2-imidazole ring, a 4-imidazole ring and a 5-imidazole ring), an oxazole ring (including a 2-oxazole ring, a 4-oxazole ring and a 5-oxazole ring), a triazole ring (1H-1,2,3-triazole ring, a 2H-1,2,3-triazole ring, a 1H-1,2,4-triazole ring and a 4H-1,2,4-triazole ring), a tetrazole ring, an isoxazole ring (3-isoxazole ring, a 4-isoxazole ring and a 5-isoxazole ring), a thiazole ring (including a 2-thiazole ring, a 4-thiazole ring) azole ring and 5-thiazole ring, etc.), furan ring (including 2-furan ring and 3-furan ring, etc.), thiophene ring (including 2-thiophene ring and 3-thiophene ring, etc.), pyridine ring (including 2-pyridine ring, 3-pyridine ring and 4-pyridine ring, etc.), pyrazine ring, pyrimidine ring (including 2-pyrimidine ring and 4-pyrimidine ring, etc.), benzothiazole ring (including 5-benzothiazole ring, etc.), purine ring, benzimidazole ring (including 2-benzimidazole ring, etc.), benzoxazole ring, indole ring (including 5-indole ring, etc.), isoquinoline ring (including 1-isoquinoline ring and 5-isoquinoline ring, etc.), quinoxaline ring (including 2-quinoxaline ring and 5-quinoxaline ring, etc.), quinoline ring (including 3-quinoline ring and 6-quinoline ring, etc.), etc.
[0363] Unless otherwise specified, the term "parallel" refers to a non-aromatic, saturated or partially unsaturated ring system formed by two or more cyclic structures sharing two adjacent atoms, including para-carbocyclic and para-heterocyclic rings, wherein the ring atoms of the para-heterocyclic ring contain one or more heteroatoms independently selected from oxygen, nitrogen and sulfur.
[0364] The term "treatment" means administering the compound or formulation described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:
[0365] (i) inhibiting a disease or disease state, i.e., arresting its development;
[0366] (ii) ameliorating the disease or condition, i.e., causing regression of the disease or condition.
[0367] The term "prevention" means administering a compound or formulation described herein to prevent a disease or one or more symptoms associated with the disease, and includes preventing the occurrence of a disease or disease state in a mammal, particularly when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state.
[0368] The term "therapeutically or prophylactically effective amount" means an amount of a compound of the present invention that (i) treats a particular disease, condition, or disorder, or (ii) alleviates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the effects of a particular disease, condition, or disorder described herein. The amount of a compound of the present invention that constitutes a "therapeutically or prophylactically effective amount" varies depending on the compound, the disease state and its severity, the route of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art based on their knowledge and this disclosure.
[0369] The therapeutic or prophylactic dose of the compounds of the present invention may depend, for example, on the specific therapeutic or prophylactic use, the manner in which the compound is administered, the patient's health and condition, and the discretion of the prescribing physician. The proportion or concentration of the compounds of the present invention in a pharmaceutical composition may not be fixed and depends on a variety of factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the compounds of the present invention may be provided in a physiologically buffered aqueous solution containing about 0.1 to 10% w / v of the compound for parenteral administration. Some typical dosage ranges are from about 0.001 mg / kg to about 1000 mg / kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of the disease or condition, the general health of the particular patient, the relative biological efficacy of the selected compound, the excipient formulation, and its route of administration. The effective dose can be obtained by extrapolation from dose-response curves derived from in vitro or animal model test systems.
[0370] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be understood as having an open and non-exclusive meaning, ie, "including but not limited to".
[0371] A "pharmaceutical composition" refers to a composition containing one or more compounds described herein, their isomers, or pharmaceutically acceptable salts thereof, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0372] The pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients.
[0373] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art.
[0374] The compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.
[0375] The chemical reactions described in the specific embodiments of the present application are carried out in a suitable solvent that is compatible with the chemical transformations described herein and the reagents and materials required. To obtain the compounds described herein, it may sometimes be necessary for those skilled in the art to modify or select synthetic steps or reaction schemes based on existing embodiments.
[0376] The raw materials or intermediates used in the embodiments of the present application can be obtained commercially or prepared by methods of the prior art.
[0377] An important consideration in synthetic route planning in this field is the selection of a suitable protecting group for a reactive functional group (such as the amino group in this application). For example, reference may be made to Greene's Protective Groups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley & Sons, Inc.
[0378] In some embodiments, some of the compounds of the present application can be prepared by those skilled in the art of organic synthesis by referring to the following routes:
[0379] Route 1:
[0380] in,
[0381] R 1 , L 2 and Ring A is as defined above;
[0382] Y is selected from halogen (eg bromine).
[0383] Route 2:
[0384] in,
[0385] R 1 and Ring A is as defined above;
[0386] Y is selected from halogen (eg bromine).
[0387] For the sake of clarity, the present application is further illustrated with examples, but the examples do not limit the scope of the present application. All reagents used in the present application are commercially available and can be used without further purification. DETAILED DESCRIPTION
[0388] The present invention is described in detail below by way of examples, but this is not intended to limit the present invention in any way. The present invention has been described in detail herein, and specific embodiments thereof have been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.
[0389] Example 1: Preparation of Compound 1
[0390] 6-Bromopyridin-3-amine (0.50 g), diisopropylethylamine (0.49 g), and methanesulfonic anhydride (1.01 g) were stirred in dichloromethane (5 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and intermediate 1A (0.43 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 329.0 [M+H] + .
[0391] Intermediate 1A (200 mg), Intermediate K (256 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (25 mg), and potassium phosphate (203 mg) were reacted in dioxane (10 mL) under nitrogen protection in a microwave oven at 120°C. After completion of the reaction, the product was filtered and concentrated to afford Intermediate 1B (365 mg). MS (ESI): m / z 557.3 [M+H] + .
[0392] Intermediate 1B (365 mg) and potassium carbonate (100 mg) were stirred in 1,4-dioxane (5 mL) and water (1 mL) at 100°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and Intermediate 1C (95 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 479.3 [M+H] + ..
[0393] Intermediate 1C (95 mg) was stirred in formic acid (5 mL) at 70°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to an alkaline pH by adding aqueous sodium bicarbonate. Solids precipitated and were filtered. The filter cake was slurried with methanol to obtain Example 1, Compound 1 (47 mg). MS (ESI): m / z 423.2 [M+H] + .
[0394] 1 H NMR(500MHz,DMSO-d6)δ11.80(s,1H),9.21(s,1H),9.14(s,1H),7.98(d,J=2.7Hz,1H),7 .42(dd,J=8.9,2.7Hz,1H),7.27(s,1H),6.94(d,J=7.8Hz,1H),6.08(s,1H),5.11–4.93( m,1H),3.61-3.54(m,1H),3.07-3.00(m,1H),2.90(s,3H),2.48-2.43(m,1H),2.04-1.97 (m,1H),1.94–1.85(m,1H),1.76-1.68(m,2H),1.64-1.57(m,1H),1.03(d,J=6.7Hz,6H).
[0395] Example 2: Preparation of Compound 2
[0396] Refer to the preparation method of the compound in Example 1, except that 6-bromopyridin-3-amine was replaced with 6-bromo-N-methylpyridin-3-amine to obtain a crude compound 2.
[0397] The crude compound 2 was purified by medium-low pressure preparative liquid chromatography (silica gel column, dichloromethane / methanol (30 / 1)) to obtain compound 2 (13 mg). MS (ESI): m / z 437.2 [M+H] + .
[0398] 1H NMR (500MHz, DMSO-d6) δ11.85(s,1H),9.28(s,1H),8.12(d,J=2.7Hz,1H),7.59(dd,J= 9.0,2.8Hz,1H),7.28(s,1H),6.95(d,J=7.8Hz,1H),6.12(s,1H),4.99(s,1H),3.61-3. 54(m,1H),3.19(s,3H),3.07-3.00(m,1H),2.95(s,3H),2.48-2.45(m,1H),2.05–1.97( m,1H),1.95–1.84(m,1H),1.76-1.67(m,2H),1.64-1.56(m,1H),1.03(d,J=6.2Hz,6H).
[0399] Example 3: Preparation of Compound 3
[0400] Refer to the preparation method of the compound in Example 1, except that 6-bromopyridin-3-amine was replaced with 4-bromo-3-fluoroaniline to obtain a crude compound 3.
[0401] The crude compound 3 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 3 (10 mg). MS (ESI): m / z 440.2 [M+H] + .
[0402] 1 H NMR(500MHz,DMSO-d6)δ11.73(s,1H),9.37(s,1H),8.00(brs,1H),7.96(s,1H) ,6.99(d,J=13.0,,1H),6.94-6.90(m,2H),5.71(s,1H),4.99(s,1H),3.67–3.49 (m,1H),3.06-2.99(m,1H),2.91(s,3H),2.48-2.42(m,1H),2.03-1.96(m,1H),1 .93-1.85(m,1H),1.76-1.65(m,2H),1.62-1.54(m,1H),1.03(d,J=5.35Hz,6H).
[0403] Example 4: Preparation of Compound 4
[0404] 6-Bromo-N-methylpyridin-3-amine (500 mg), triethylamine (580 mg), and acetic anhydride (468 mg) were stirred in dichloromethane (5 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and intermediate 4A (396 mg) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 229.0 [M+H] + .
[0405] Refer to the preparation method of the compound in Example 2, replace intermediate 2A with intermediate 4A to obtain crude compound 4.
[0406] The crude compound 4 was purified by medium-low pressure preparative liquid chromatography (silica gel column, dichloromethane / methanol (30 / 1)) to obtain compound 4 (28 mg). MS (ESI): m / z 401.2 [M+H] + .
[0407] 1 H NMR (500MHz, DMSO-d6) δ11.85(s,1H),9.29(s,1H),8.06(d,J=2.6Hz,1H),7.52(dd,J=9.1,2. 7Hz,1H),7.29(d,J=7.9Hz,1H),6.95(d,J=7.8Hz,1H),6.15(s,1H),5.13–4.92(m,1H),3.58( h,J=6.7Hz,1H),3.09(s,3H),3.08-3.03(m,1H),2.49-2.44(m,1H),2.06-1.98(m,1H),1.94- 1.88(m,1H),1.76(s,3H),1.75-1.67(m,2H),1.64-1.56(m,1H),1.03(dd,J=6.7,2.6Hz,6H).
[0408] Example 5: Preparation of Compound 5
[0409] Methanesulfonamide (20.00 g) and tert-butyldimethylsilyl chloride (41.20 g) were dissolved in chloroform (350 mL) at 0°C under nitrogen, and triethylamine (42.60 g) was added. The mixture was stirred at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and water and ethyl acetate were added to the residue. The mixture was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Intermediate 5A (43.00 g), which was used directly in the next step without further purification.
[0410] Under nitrogen, triphenylphosphine (18.19 g) and hexachloroethane (16.42 g) were stirred in chloroform (90 ml) at 73°C for 6 h. The temperature was cooled to room temperature, triethylamine (10.50 g) was added, and the mixture was stirred at room temperature for 15 min. The temperature was cooled to 0°C, and a solution of Intermediate 5A (12.10 g) in chloroform (10 ml) was added, and the mixture was stirred at 0°C for 0.5 h. A solution of 6-bromopyridin-3-amine (2.00 g) and triethylamine (11.70 g) in tetrahydrofuran (10 ml) was added, and the mixture was stirred at 0°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and water and dichloromethane were added to the residue. The mixture was separated, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to afford Intermediate 5B (1.60 g).
[0411] Referring to the preparation method of Intermediate 1B in Example 1, Intermediate 1A was replaced with Intermediate 5B to obtain Intermediate 5C (0.07 g). MS (ESI): m / z 592.4 [M+H] + .
[0412] Intermediate 5C (0.07 g) and a solution of hydrochloric acid in 1,4-dioxane (0.6 mL, 4 mol / L) were stirred in dichloromethane (10 mL) at room temperature. After the reaction was complete, saturated aqueous sodium bicarbonate was added to adjust the pH to 9-10. The mixture was separated, dried over anhydrous magnesium sulfate, filtered, and concentrated to afford Intermediate 5D (0.05 g), which was used directly in the next step without further purification.
[0413] Intermediate 5D (0.05 g) was stirred in formic acid (20 mL) at 70°C. After completion of the reaction, the solvent was evaporated under reduced pressure, and compound 5 (6 mg) was isolated by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (25 / 75), with 1 / 1000 ammonia in the eluent). MS (ESI): m / z 373.2 [M+H] + .
[0414] 1H NMR(500MHz,DMSO)δ11.77(s,1H),10.03(9.85)(s,1H),8.99(8.56)(s,1H),8.32(8.48 )(s,1H),8.21(7.98)(s,1H),7.74-7.72(7.43-7.42)(m,1H),7.29(s,1H),6.94(s,1H) ,6.03(s,1H),4.99(s,1H),3.62-3.51(m,1H),3.09-2.98(m,1H),2.48-2.40(m,1H),2. 05-1.95(m,1H),1.94-1.84(m,1H),1.79-1.66(m,2H),1.65-1.55(m,1H),1.03(d,6H).
[0415] Example 6: Preparation of Compound 6
[0416] 6-Bromopyridin-3-amine (500 mg), triethylamine (731 mg), and acetic anhydride (590 mg) were stirred in dichloromethane (5 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and compound 6A (0.528 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 214.85 [M+H] + .
[0417] Refer to the preparation method of compound 2 in Example 2, replacing intermediate 2A with intermediate 6A to obtain crude compound 6.
[0418] The crude compound 6 was slurried with methanol to obtain compound 6 (46 mg). MS (ESI): m / z 387.2144 [M+H] + .
[0419] 1H NMR(500MHz,DMSO-d6)δ11.74(s,1H),9.76(s,1H),8.93(s,1H),8.27(s,1H),7.70(d ,J=8.20Hz,1H),7.26(s,1H),6.95(d,J=7.10Hz,1H),6.03(s,1H),5.13-4.90(m,1H), 3.56-3.60(m,1H),3.01-3.04(m,1H),2.44-2.47(m,1H),2.01(s,3H),1.99-1.96(m, 1H), 1.92-1.84 (m, 1H), 1.76-1.68 (m, 2H), 1.64-1.56 (m, 1H), 1.03 (d, J = 6.40Hz, 6H).
[0420] Example 7: Preparation of Compound 7
[0421] 4-Bromoaniline (1.00 g), diisopropylethylamine (3.00 g), and methanesulfonic anhydride (4.10 g) were stirred in dichloromethane (15 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and intermediate 7A (0.66 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 325.0 [MH] - .
[0422] Intermediate 7A (200 mg), Intermediate K (125 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (95 mg), potassium phosphate (283 mg), and celite (480 mg) were reacted in toluene / tert-butyl alcohol (10 mL, 5:1 (v / v)) under nitrogen in an oil bath at 120°C. After completion of the reaction, the product was filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 7B (208 mg). MS (ESI): m / z 556.3 [M+H] + .
[0423] Intermediate 7B (208 mg) and potassium carbonate (100 mg) were stirred in 1,4-dioxane (5 mL) and water (5 mL) at 100°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and intermediate 7C (130 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 478.3 [M+H] + .
[0424] Refer to the preparation method of compound 1 in Example 1, replace intermediate 1C with intermediate 7C to obtain crude compound 7.
[0425] The crude compound 7 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 7 (40 mg). MS (ESI): m / z 442.2 [M+H] + .
[0426] 1 H NMR (500MHz, DMSO-d6) δ11.67(s,1H),9.10(s,1H),8.27(s,1H),7.28(d,J=8.30H z,2H),7.11-6.99(m,2H),6.95(d,J=7.8Hz,1H),5.60(s,1H),4.99(m,1H),3.59-2 .55(m,1H),3.05-2.98(m,1H),2.85(s,3H),2.47-2.42(m,1H),2.02-1.98(m,1H) ,1.95-1.83(m,1H),1.74-1.67(m,2H),1.63-1.56(m,1H),1.03(d,J=6.60Hz,6H).
[0427] Example 8: Preparation of Compound 8
[0428] 3-Amino-6-bromopyridine (500 mg), pyridine (700 mg), and cyclopropanesulfonyl chloride (800 mg) were stirred in dichloromethane (20 mL) at 50°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and intermediate 8A (758 mg) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 276.9 [M+H] + .
[0429] 1 H NMR (500MHz, DMSO-d6): δ10.17(s,1H),8.25-8.24(m,1H),7.62-7.61(m,2H),2.77-2.72(m,1H),1.00-0.92(m,4H).
[0430] Intermediate 8A (216 mg), Intermediate K (120 mg), 2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (65 mg), (2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-aminoethylphenyl)]palladium(II) chloride (100 mg), and potassium phosphate (330 mg) were reacted in 1,4-dioxane (50 mL) under nitrogen in an oil bath at 110°C. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue, 8B, was used directly in the next reaction without further purification.
[0431] Refer to the preparation method of compound 1 in Example 1, replace intermediate 1C with intermediate 8B to obtain crude compound 8.
[0432] The crude compound 8 was initially purified by column chromatography (developing solvent: dichloromethane / methanol) and then purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (40 / 60), eluent containing 1 / 1000 ammonia water) to obtain compound 8 (10 mg). MS (ESI): m / z 449.1965 [M+H] + .
[0433] 1 H NMR (500MHz, DMSO-d6): δ11.81(s,1H),9.13(brs,1H),9.13(s,1H),7.99(s,1H),7.43 (d,J=7.60Hz,1H),7.26(s,1H),6.94(d,J=7.05Hz,1H),6.08(s,1H),4.99(s,1H),3.6 1-3.52(m,1H),3.10-2.98(m,1H),2.48-2.41(m,1H),2.06-1.95(m,1H),1.94-1.85(m ,1H),1.80-1.66(m,2H),1.64-1.55(m,1H),1.03(d,J=6.25Hz,6H),0.96-1.80(m,5H).
[0434] Example 9: Preparation of Compound 9
[0435] Refer to the preparation method of compound 1 in Example 1, replacing intermediate 1A with 2-bromo-5-methoxypyridine to obtain crude compound 9.
[0436] The crude compound 9 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 9 (18 mg). MS (ESI): m / z 360.2031 [M+H] + .
[0437] 1 H NMR (500MHz, DMSO-d6) δ11.68(s,1H),8.76(s,1H),7.84(s,1H),7.27(d,J=12 .5Hz,2H),6.95(d,J=7.0Hz,1H),6.03(s,1H),4.99(s,1H),3.73(s,3H),3.58 (dd,J=13.3,6.4Hz,1H),3.02(s,1H),2.47-2.44(m,1H),2.02-1.97(m,1H),1 .93-1.85(m,1H),1.74-1.67(m,2H),1.62-1.56(m,1H),1.03(d,J=6.4Hz,6H).
[0438] Example 10: Preparation of Compound 10
[0439] At 0°C, under nitrogen, 4-bromo-3-fluorobenzyl alcohol (2.0 g), triethylamine (2.0 g), and methanesulfonic anhydride (2.7 g) were stirred in dichloromethane (20 mL) at 0°C. After the reaction was complete, dimethylamine (1.3 g) was added and stirring continued. After the reaction was complete, the solvent was evaporated under reduced pressure, and the reaction solution was isolated by column chromatography (developing solvent: dichloromethane / methanol) to obtain Intermediate 10A (1.9 g).
[0440] Referring to the preparation method of compound 1 in Example 1, intermediate 1A was replaced with intermediate 10A to obtain crude compound 10.
[0441] The crude compound 10 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (25 / 75), with 1 / 1000 ammonia in the eluent) to obtain compound 10 (60 mg). MS (ESI): m / z 404.2458 [M+H] + .
[0442] 1H NMR(500MHz,DMSO-d6)δ11.73(s,1H),7.96-7.91(m,2H),6.99(dd,J=12.8,1.2 Hz,1H),6.95-6.91(m,2H),5.73(s,1H),4.99(s,1H),3.60-3.54(m,1H),3.27( s,2H),3.06-3.01(m,1H),2.49-2.41(m,1H),2.11(s,6H),2.04-1.97(m,1H),1 .94-1.85(m,1H),1.74-1.64(m,2H),1.61-1.56(m,1H),1.03(d,J=6.3Hz,6H).
[0443] Example 11: Preparation of Compound 11
[0444] Referring to the preparation method of compound 1 in Example 1, 6-bromopyridin-3-amine was replaced with 6-chloro-2-(trifluoromethyl)pyridin-3-amine to obtain a crude compound 11.
[0445] The crude compound 11 was purified by column chromatography (developing solvent: dichloromethane / methanol (96 / 4)) to obtain compound 11 (40 mg). MS (ESI): m / z 491.1687 [M+H] + .
[0446] 1 H NMR (500MHz, DMSO-d6) δ11.97(s,1H),9.75(s,1H),9.26(s,1H),7.70(d,J=8.9Hz,1H),7.48(d,J=9.1Hz,1H),6.92(d,J=7.8Hz,1H),6.22(s,1H) ,5.00(s,1H),3.60-3.53(m,1H),3.11-3.04(m,1H),3.02(s,3H),2.48-2 .44(m,1H),2.05-1.88(m,2H),1.76-1.56(m,3H),1.03(d,J=5.7Hz,6H).
[0447] Example 12: Preparation of Compound 12
[0448] 6-Bromopyridin-3-amine (1000 mg), sodium tert-butoxide (1666 mg), and 1-bromo-2-methoxyethane (1606 mg) were stirred in acetonitrile (10 mL) at 80°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and the intermediate 12A (486 mg) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 231.0 [M+H] + .
[0449] Intermediate 12A (486 mg), N,N-dimethylaminopyridine (52 mg), and di-tert-butyl carbonate (660 mg) were stirred in dichloromethane (5 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and Intermediate 12B (0.36 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 331.0 [M+H] + .
[0450] Intermediate K1 (200 mg), Intermediate 12B (240 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (120 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (160 mg), cesium carbonate (2400 mg), and celite (800 mg) were added to toluene / tert-butyl alcohol (35 mL, 5:1 (v / v)). The reaction was stirred at 120°C. After completion of the reaction, the mixture was filtered, and the solvent was evaporated from the filtrate under reduced pressure. Intermediate 12C (224 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 559.58 [M+H] + .
[0451] Intermediate 12C (224 mg) was stirred in formic acid (10 ml) at 70°C. After completion of the reaction, the product was concentrated, and the pH of the residue was adjusted to alkaline with saturated aqueous sodium bicarbonate solution. The product was extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered. The solvent was evaporated from the filtrate under reduced pressure, and the product was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 12 (105 mg). MS (ESI): m / z 434.2403 [M+H] + .
[0452] 1H NMR(500MHz,DMSO-d6)δ11.85(s,1H),9.27(s,1H),8.22(s,1H),8.04-8.03(m,1H),7.57-7.55 (m,1H),7.29(s,1H),6.95(d,J=7.4Hz,1H),6.12(s,1H),5.00-4.99(m,1H),3.81-3.76(m,2H) ,3.61-3.54(m,1H),3.41-3.39(m,2H),3.19(s,3H),3.08-3.00(m,1H),2.48-2.44(m,1H),2.0 3-1.99(m,1H),1.93-1.85(m,1H),1.76-1.68(m,2H),1.63-1.57(m,1H),1.03(d,J=6.5Hz,6H).
[0453] Example 13: Preparation of Compound 13
[0454] Refer to the preparation method of compound 12 in Example 12, replace intermediate 12B with 2-bromopyridine, and replace intermediate K1 with intermediate K to obtain crude compound 13.
[0455] The crude compound 13 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (28 / 72), with 1 / 1000 ammonia in the eluent) to obtain compound 13 (50 mg). MS (ESI): m / z 330.1927 [M+H] + .
[0456] 1 H NMR (500MHz, DMSO-d6): δ11.79(s,1H),9.04(s,1H),8.09(d,J=3.95Hz,1H),7.51(t,J =7.50Hz,1H),7.24(s,1H),6.95(d,J=7.25Hz,1H),6.66(t,J=5.40Hz,1H),6.10(s,1H ),5.00(s,1H),3.60-3.56(m,1H),3.05-3.02(m,1H),2.47-2.43(m,1H),2.01-1.98(m ,1H),1.93-1.85(m,1H),1.76-1.66(m,2H),1.64-1.58(m,1H),1.03(d,J=6.30Hz,6H).
[0457] Example 14: Preparation of Compound 14
[0458] 6-Bromo-N-methylpyridin-3-amine (500 mg), 4-chlorobutyryl chloride (530 mg), and N,N-diisopropylethylamine (1121 mg) were added to dichloromethane (10 mL). The reaction was stirred at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and the intermediate 14A (800 mg) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 276.9 [M+H] + .
[0459] Intermediate 14A (800 mg) and potassium tert-butoxide (485 mg) were stirred in acetonitrile (10 mL) at 80°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and Intermediate 14B (572 mg) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 241.0 [M+H] + .
[0460] Refer to the preparation method of compound 12 in Example 12, replace intermediate 12B with intermediate 14B, and replace intermediate K1 with intermediate K to obtain crude compound 14.
[0461] The crude compound 14 was purified by column chromatography (developing solvent: dichloromethane / methanol = 5 / 1) to obtain compound 14 (30 mg). MS (ESI): m / z 413.2303 [M+H] + .
[0462] 1 H NMR(500MHz,DMSO-d6)δ11.79(s,1H),9.08(s,1H),8.30(d,J=2.7Hz,1H),7.86-7.85(m,1H), 7.30(s,1H),6.95(d,J=7.7Hz,1H),6.06(s,1H),4.99(m,1H),3.78(t,J=7.0Hz,2H),3.61-3.5 4(m,1H),3.08-2.97(m,1H),2.47(d,J=7.2Hz,1H),2.46-2.43(m,2H),2.09-2.03(m,2H),2.02 -1.98(m,1H),1.93-1.85(m,1H),1.75-1.68(m,2H),1.63-1.56(m,1H),1.03(d,J=6.4Hz,6H).
[0463] Example 15: Preparation of Compound 15
[0464] Referring to the preparation method of compound 1 in Example 1, 6-bromopyridin-3-amine was replaced with 2-amino-5-bromopyridine to obtain crude compound 15.
[0465] The crude compound 15 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (22 / 78), eluent containing 1 / 1000 ammonia water) to obtain compound 15 (13 mg). MS (ESI): m / z 423.1810 [M+H] + .
[0466] 1 H NMR (500MHz, DMSO-d6) δ8.05 (d, J = 2.9Hz, 1H), 7.83 (s, 1H), 7.49-7.37 (m, 1H), 6. 96(d,J=7.8Hz,1H),6.53(d,J=8.8Hz,1H),5.50(s,1H),4.98-4.97(m,1H),3.59- 3.55(m,1H),3.02-2.96(m,1H),2.83(s,3H),2.46-2.40(m,1H),2.02-1.96(m,1H ),1.92-1.83(m,1H),1.75-1.66(m,2H),1.59-1.55(m,1H),1.03(d,J=6.5Hz,6H).
[0467] Example 16: Preparation of Compound 16
[0468] Methylamine hydrochloride (1000 mg), sodium hydroxide (285 mg), and 4-bromo-3-fluorobenzenesulfonyl chloride (1000 mg) were stirred in acetonitrile (20 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and the intermediate 16A (800 mg) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 268.04 [MH] - .
[0469] Referring to the preparation method of compound 1 in Example 1, intermediate 1A was replaced by intermediate 16A, and intermediate K was replaced by intermediate K1 to obtain crude compound 16.
[0470] The crude compound 16 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 16 (60 mg). MS (ESI): m / z 440.5 [M+H] + .
[0471] 1H NMR(500MHz,DMSO-d6)δ12.00(s,1H),8.70(s,1H),8.20(m,1H),7.46-7.44(m,2H) ,7.23-7.20(m,1H),6.95(d,J=7.8Hz,1H),5.83(s,1H),5.00(m,1H),3.59-3.55(m ,1H),3.09-3.03(m,1H),2.48-2.44(s,1H),2.39(d,J=4.1Hz,3H),2.04-2.00(m,1 H), 1.96-1.86 (m, 1H), 1.76-1.67 (m, 2H), 1.64-1.56 (m, 1H), 1.03 (d, J = 6.6Hz, 6H).
[0472] Example 17: Preparation of Compound 17
[0473] 2-Bromo-4-aminopyridine (500 mg), methanesulfonic anhydride (503 mg), and N,N-diisopropylethylamine (747 mg) were stirred in dichloromethane (30 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and the intermediate 17A (200 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 251.02 [M+H] + .
[0474] Refer to the preparation method of compound 12 in Example 12, replace intermediate 12B with intermediate 17A to obtain crude compound 17.
[0475] The crude compound 17 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (40 / 60), with 1 / 1000 ammonia in the eluent) to obtain compound 17 (30 mg). MS (ESI): m / z 423.1813 [M+H] + .
[0476] 1H NMR (500MHz, DMSO-d6): δ8.78(s,1H),7.66(d,J=8.85Hz,1H),6.95(d,J=7.40Hz, 1H),6.58(s,1H),6.24(dd,J=1.50,5.80Hz,1H),5.81(s,1H),4.99(s,1H),3.61-3 .54(m,1H),3.00-2.95(m,1H),2.73(s,3H),2.45-2.40(m,1H),1.99-1.95(m,1H) ,1.91-1.85(m,1H),1.71-1.68(m,2H),1.64-1.59(m,1H),1.03(d,J=6.50Hz,6H).
[0477] Example 18: Preparation of Compound 18
[0478] At 0°C, under nitrogen, sodium hydride (1.3 g) and 6-bromo-3-pyridinemethanol (2.0 g) were dissolved in N,N-dimethylformamide (20 mL) and stirred at 0°C for half an hour. Iodomethane (2.3 g) was added and the mixture was stirred at 0°C. After the reaction was complete, water was added to quench the mixture, and the mixture was extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated from the filtrate under reduced pressure. Intermediate 18A (1.6 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 202.0 [M+H] + .
[0479] Referring to the preparation method of compound 1 in Example 1, intermediate 1A was replaced by intermediate 18A, and intermediate K was replaced by intermediate K1 to obtain crude compound 18.
[0480] The crude compound 18 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (35 / 65), with 1 / 1000 ammonia in the eluent) to obtain compound 18 (19 mg). MS (ESI): m / z 374.2188 [M+H] + .
[0481] 1H NMR(500MHz,DMSO-d6)δ11.79(s,1H),9.09(s,1H),8.04(s,1H),7.49(d,J=8.1Hz,1H), 7.26(d,J=7.3Hz,1H),6.95(d,J=6.9Hz,1H),6.10(s,1H),5.00(s,1H),4.26(s,2H),3.5 8(dd,J=13.3,6.7Hz,1H),3.23(s,3H),3.05-3.04(m,1H),2.47-2.45(m,1H),2.08-1.99 (m,1H),1.93-1.85(m,1H),1.72-1.68(m,2H),1.63-1.57(m,1H),1.03(d,J=6.4Hz,6H).
[0482] Example 19: Preparation of Compound 19
[0483] Refer to the preparation method of compound 17 in Example 17, replacing 2-bromo-4-aminopyridine with 5-amino-2-bromopyrimidine to obtain crude compound 19.
[0484] The crude compound 19 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (40 / 60), with 1 / 1000 ammonia in the eluent) to obtain compound 19 (32 mg). MS (ESI): m / z 424.1760 [M+H] + .
[0485] 1 H NMR (500MHz, DMSO-d6): δ9.37(s,1H),8.17(s,2H),6.95(d,J=7.45Hz,1H),6.20(s,1H),4.99(s,1H),3.61-3.53(m,1H),3.04-3.00(m,1 H),2.79(s,3H),2.48-2.42(m,1H),2.02-1.97(m,1H),1.92-1.84(m,1H),1.75-1.69(m,2H),1.65-1.60(m,1H),1.03(d,J=6.50Hz,6H).
[0486] Example 20: Preparation of Compound 20
[0487] Compound 12 (80 mg) from Example 12 was stirred in dilute hydrochloric acid (1 M, 5 mL) at 50°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to alkaline pH with saturated aqueous sodium bicarbonate. The residue was extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered. The solvent was evaporated under reduced pressure from the filtrate, and the product was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia aqueous solution in the eluent) to obtain Compound 20 (25 mg). MS (ESI): m / z 403.2455 [M+H] + .
[0488] 1 H NMR(500MHz,DMSO-d6)δ11.60(s,1H),8.43(s,1H),7.57(d,J=2.9Hz,1H),7.11(s,1H) ,6.98-6.94(m,2H),5.90(s,1H),5.11-4.84(m,2H),3.59-3.56(m,1H),3.48(t,J=5.6 Hz,2H),3.28(s,3H),3.13(m,2H),3.04-2.95(m,1H),2.46-2.39(m,1H),2.00-1.96(m ,1H),1.94-1.83(m,1H),1.73-1.67(m,2H),1.63-1.56(s,1H),1.03(d,J=6.6Hz,6H).
[0489] Example 21: Preparation of Compound 21
[0490] Intermediate K1 (200 mg), 6-chloro-2,3-dihydrofuro[2,3-b]pyridine (120 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (120 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (160 mg), cesium carbonate (2400 mg), and celite (800 mg) were stirred in toluene / tert-butyl alcohol (35 mL, 5:1 (v / v)) at 120°C under nitrogen. After completion of the reaction, the mixture was filtered, and the solvent was evaporated under reduced pressure. Intermediate 21A (108 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 428.51 [M+H] + .
[0491] Intermediate 21A (108 mg) was stirred in formic acid (5 ml) at 70°C. After the reaction was complete, the solvent was evaporated under reduced pressure. The pH of the residue was adjusted to alkaline with saturated aqueous sodium bicarbonate. The solid precipitated and was filtered. The filter cake was slurried with methanol to obtain compound 21 (49 mg). MS (ESI): m / z 372.2036 [M+H] + .
[0492] 1 H NMR (500MHz, DMSO-d6) δ11.74(s,1H),8.89(s,1H),7.37(d,J=8.0Hz,1H),6.94(d ,J=7.9Hz,1H),6.79(d,J=7.9Hz,1H),6.01(s,1H),5.00(s,1H),4.49(t,J=8.4Hz ,2H),3.58-3.57(m,1H),3.08-3.02(m,3H),2.48-2.40(m,1H),2.07-1.95(m,1H) ,1.92-1.84(m,1H),1.77-1.65(m,2H),1.63-1.54(m,1H),1.03(d,J=6.6Hz,6H).
[0493] Example 22: Preparation of Compound 22
[0494] 1-N-Methylsulfonyl-4-piperidone (264 mg), Intermediate K1 (200 mg), and acetic acid (42.8 mg) were stirred in 1,2-dichloroethane (15 mL) under nitrogen and allowed to react at room temperature. After the reaction was complete, sodium triacetoxyborohydride (550 mg) was added and the reaction was stirred at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and Intermediate 22A (300 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 470.6 [M+H] + .
[0495] Intermediate 22A (200 mg) was stirred in formic acid (10 mL) at 110°C. After the reaction was complete, the solvent was evaporated under reduced pressure. The pH of the residue was adjusted to alkaline by adding triethylamine. The solvent was then evaporated under reduced pressure. The crude compound 22 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia aqueous solution in the eluent) to yield compound 22 (37 mg). MS (ESI): m / z 414.5 [M+H] + .
[0496] 1H NMR(500MHz,DMSO-d6)δ11.17(s,1H),6.94(d,J=7.8Hz,1H),5.25(s,1H),5.04- 4.84(m,2H),3.60-3.54(m,1H),3.48-3.44(m,2H),3.26(s,1H),2.98-2.89(m,1 H),2.89-2.77(m,5H),2.41-2.35(m,1H),2.03-1.91(m,3H),1.88-1.84(m,1H), 1.71-1.62(m,2H),1.57-1.52(m,1H),1.46-1.39(m,2H),1.03(d,J=6.5Hz,6H).
[0497] Example 23: Preparation of Compound 23
[0498] 4-Bromo-2-fluoroaniline (3.00 g), N,N-diisopropylethylamine (10.20 g), and methanesulfonic anhydride (8.25 g) were stirred in dichloromethane (85 mL) at room temperature under nitrogen. After completion of the reaction, the solvent was evaporated under reduced pressure. Dichloromethane and saturated aqueous ammonium chloride were added to the residue. The organic phase was separated, dried, and filtered. The solvent was evaporated from the filtrate under reduced pressure to obtain Intermediate 23A (3.80 g).
[0499] Intermediate K (0.60 g), Intermediate 23A (1.00 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.46 g), dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine (0.28 g), tripotassium phosphate (1.40 g), and celite (2.4 g) were stirred in toluene / tert-butyl alcohol (30 mL, 5:1 (v / v)) at 120°C under nitrogen. After completion of the reaction, the mixture was filtered, and the solvent was evaporated from the filtrate under reduced pressure. Intermediate 23B (1.00 g) was isolated by column chromatography (developing solvent: dichloromethane / methanol) to give Intermediate 23B.
[0500] Intermediate 23B (0.12 g) was stirred in formic acid (20 mL) at 70° C. After the reaction was complete, the solvent was evaporated under reduced pressure to leave Intermediate 23C, which was directly used in the next reaction without further purification.
[0501] Intermediate 23C and sodium carbonate (0.74 g) were stirred in methanol (25 mL) and water (5 mL) at 70°C. After the reaction was complete, the solvent was evaporated under reduced pressure. Dichloromethane and water were added to the residue, and the organic phase was separated. The solvent was evaporated under reduced pressure and purified by column chromatography (developing solvent: dichloromethane / methanol (40 / 1)) to obtain compound 23 (0.30 g). HRMS (ESI, [M+H] + )m / z:440.1841.
[0502] 1 H NMR(500MHz,DMSO-d6)δ11.80(s,1H),9.06(s,1H),8.67(s,1H),7.43(d,J=12.4H z,1H),7.11(t,J=8.9Hz,1H),6.96-6.95(m,2H),5.62(s,1H),4.99(s,1H),3.62- 3.54(m,1H),3.09-3.00(m,1H),2.91(s,3H),2.49-2.43(m,1H),2.03-1.99(m,1H ),1.94-1.85(m,1H),1.74-1.66(m,2H),1.62-1.56(m,1H),1.03(d,J=6.3Hz,6H).
[0503] Example 24: Preparation of Compound 24
[0504] Referring to the preparation method of compound 1 in Example 1, 2-bromo-4-aminopyridine was replaced with 2-fluoro-6-bromo-3-aminopyridine to obtain crude compound 24.
[0505] The crude compound 24 was purified by column chromatography (developing solvent: dichloromethane / methanol (96 / 4)) to obtain compound 24 (106 mg). MS (ESI): m / z 441.1722 [M+H] + .
[0506] 1H NMR(500MHz,DMSO-d6)δ11.95(s,1H),9.52(s,1H),9.19(s,1H),7.58(dd,J=10.3,8.5 Hz,1H),7.21-7.08(m,1H),6.94(d,J=7.8Hz,1H),6.06(s,1H),5.04-4.96(m,1H),3.6 1-3.54(m,1H),3.08-3.03(m,1H),2.95(s,3H),2.48-2.44(m,1H),2.05-1.99(m,1H), 1.94-1.85(m,1H),1.76-1.67(m,2H),1.64-1.54(m,1H),1.03(dd,J=6.6,2.4Hz,6H).
[0507] Example 25: Preparation of Compound 25
[0508] Refer to the preparation method of compound 16A in Example 16, replacing methylamine hydrochloride with ammonia water to obtain compound 25A.
[0509] Refer to the preparation method of compound 16 in Example 16, replace intermediate 16A with intermediate 25A, and replace intermediate K1 with intermediate K to obtain crude compound 25.
[0510] The crude compound 25 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 25 (50 mg). MS (ESI): m / z 426.5 [M+H] + .
[0511] 1 H NMR(500MHz,DMSO-d6)δ11.96(s,1H),8.62(s,1H),8.19(t,J=8.5Hz,1H),7.50 (d,J=9.9Hz,2H),7.17(s,2H),6.94(d,J=7.8Hz,1H),5.82(s,1H),5.00(s,1H) ,3.68-3.48(m,1H),3.09-3.02(m,1H),2.48-2.44(m,1H),2.04-2.00(m,1H),1 .95-1.89(m,1H),1.75-1.67(m,2H),1.62-1.56(m,1H),1.03(d,J=6.5Hz,6H).
[0512] Example 26: Preparation of Compound 26
[0513] Intermediate K (450 mg), 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide (241 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (230 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (139 mg), and potassium phosphate (960 mg) were added to N,N-dimethylformamide (20 ml). The mixture was stirred at 110°C. After completion of the reaction, the mixture was filtered, and the solvent was evaporated from the filtrate under reduced pressure. Intermediate 26A (655 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 475.33 [M+H] + .
[0514] Intermediate 26A (108 mg) was stirred in formic acid (10 ml) at 70°C. After the reaction was complete, the solvent was evaporated under reduced pressure. The residue was adjusted to a basic pH with saturated sodium bicarbonate solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered. The solvent was evaporated under reduced pressure from the filtrate. The product was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to afford compound 26 (140 mg). MS (ESI): m / z 419.1753 [M+H] + .
[0515] 1H NMR(500MHz,DMSO-d6)δ11.73(s,1H),8.48(s,1H),7.41(s,1H),7.22(d,J=8.4Hz,1 H),7.14(d,J=8.4Hz,1H),6.95(d,J=7.9Hz,1H),5.63(s,1H),4.99(m,1H),4.41(s,2 H),4.32(s,2H),3.60-3.56(m,1H),3.08-3.00(m,1H),2.48-2.42(m,1H),2.03-1.98 (m,1H),1.93-1.85(m,1H),1.73-1.68(m,2H),1.62-1.56(m,1H),1.04-1.02(m,6H).
[0516] Example 27: Preparation of Compound 27
[0517] Referring to the preparation method of compound 1A in Example 1, 6-bromopyridin-3-amine was replaced with 2-amino-5-bromotrifluorotoluene to obtain compound 27A.
[0518] Referring to the preparation method of compound 1 in Example 1, compound 1A was replaced with compound 27A to obtain crude compound 27.
[0519] The crude compound 27 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 27 (60 mg). MS (ESI): m / z 490.3 [M+H] + .
[0520] 1 H NMR(500MHz,DMSO-d6)δ11.87(s,1H),9.04(s,1H),8.80(s,1H),7.90(s,1H),7.46-7. 45(m,1H),7.34(d,J=8.7Hz,1H),6.95(d,J=7.9Hz,1H),5.62(s,1H),5.01-4.97(m,1H ),3.61-3.54(m,1H),3.05-2.98(m,1H),2.99(s,3H),2.48-2.40(m,1H),2.04-1.98(m ,1H),1.95-1.84(m,1H),1.75-1.67(m,2H),1.62-1.59(m,1H),1.03(d,J=6.1Hz,6H).
[0521] Example 28: Preparation of Compound 28
[0522] Referring to the preparation method of compound 14A in Example 14, 4-chlorobutyryl chloride was replaced with 3-chloropropanesulfonyl chloride to obtain compound 28A.
[0523] Refer to the preparation method of compound 14B in Example 14, replace intermediate 14A with compound 28A to obtain compound 28B.
[0524] Refer to the preparation method of compound 14 in Example 14, replace intermediate 14B with compound 28B to obtain crude compound 28.
[0525] The crude compound 28 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (25 / 75), with 1 / 1000 ammonia in the eluent) to obtain compound 28 (25 mg). MS (ESI): m / z 449.1964 [M+H] + .
[0526] 1H NMR(500MHz,DMSO-d6)δ11.81(s,1H),9.17(s,1H),8.02(d,J=2.1Hz,1H),7.55-7.47(m,1H), 7.33(s,1H),6.93(d,J=6.8Hz,1H),6.08(s,1H),5.00(s,1H),3.66(t,J=6.6Hz,2H),3.62-3.5 4(m,1H),3.43(t,J=7.6Hz,2H),3.07-3.00(m,1H),2.48-2.42(m,1H),2.41-2.35(m,2H),2.03 -1.99(m,1H),1.93-1.84(m,1H),1.76-1.68(m,2H),1.63-1.56(s,1H),1.03(d,J=6.4Hz,6H).
[0527] Example 29: Preparation of Compound 29
[0528] 2-Bromo-5-nitropyridine (5.00 g), hydrazine hydrate (1.48 g), and rhodium on carbon (485 mg) were stirred in tetrahydrofuran (150 ml) at room temperature. After the reaction was complete, the mixture was filtered and the solvent was evaporated under reduced pressure to obtain Intermediate 29A (4.20 g). MS (ESI): m / z 189.0 [M+H] + .
[0529] Intermediate 29A (4.20 g), sodium bicarbonate (2.10 g), and benzyl chloroformate (4.17 g) were stirred in 1,4-dioxane (200 ml) at room temperature. After completion, the reaction was filtered, and the filtrate was evaporated under reduced pressure to remove the solvent. Intermediate 29B (3.63 g) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 323.16 [M+H] + .
[0530] Intermediate 29B (3.63 g) and 3,3-dimethyl-1-(trifluoromethyl)-1,2-benzoiodooxolane (4.17 g) were stirred in dichloromethane (100 ml) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure to obtain Intermediate 29C (4.00 g). MS (ESI): m / z 391.25 [M+H] + .
[0531] Intermediate 29C (4.00 g) was stirred in nitromethane (50 ml) at 120°C. After the reaction was complete, the solvent was evaporated under reduced pressure and the reaction solution was separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to obtain Intermediate 29D (930 mg). MS (ESI): m / z 391.25 [M+H]+ .
[0532] Intermediate K (200 mg), Intermediate 29D (300 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (120 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (160 mg), cesium carbonate (2400 mg), and celite (800 mg) were stirred in toluene / tert-butyl alcohol (35 mL, 5:1 (v / v)) at 120°C under nitrogen. After completion of the reaction, the mixture was filtered, and the solvent was evaporated from the filtrate under reduced pressure. Intermediate 29E (120 mg) was isolated by column chromatography (developing solvent: dichloromethane / methanol). MS (ESI): m / z 619.49 [M+H] + .
[0533] Intermediate 29E (120 mg) and palladium on carbon (30 mg, 50% (w / w)) were dissolved in tetrahydrofuran (5 ml) and stirred at room temperature under a hydrogen atmosphere. After completion of the reaction, the mixture was filtered and the solvent was evaporated under reduced pressure to afford Intermediate 29F (70 mg). MS (ESI): m / z 485.31 [M+H] + .
[0534] Intermediate 29F (70 mg), methanesulfonic anhydride (83 mg), and N,N-diisopropylethylamine (42 mg) were stirred in dichloromethane (5 ml) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure to obtain compound 29G (90 mg). MS (ESI): m / z 641.31 [M+H] + .
[0535] Intermediate 29G (90 mg) was stirred in formic acid (5 ml) at 90°C. After the reaction was complete, the solvent was evaporated under reduced pressure. The residue was adjusted to alkaline pH with saturated aqueous sodium bicarbonate solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain Intermediate 29H (70 mg). MS (ESI): m / z 585.18 [M+H] + .
[0536] Intermediate 29H (70 mg) and sodium carbonate (70 mg) were stirred in methanol (5 ml) and water (1 ml) at 70°C. After the reaction was complete, the methanol was evaporated under reduced pressure, and the residue was extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered. The solvent was evaporated from the filtrate under reduced pressure, and the product was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 29 (20 mg). MS (ESI): m / z 507.1638 [M+H] + .
[0537] 1 H NMR(500MHz,DMSO-d6)δ11.92(s,1H),9.62(s,1H),9.26(s,1H),7.58(d,J=8.6Hz ,1H),6.97(d,J=8.6Hz,1H),6.90(d,J=7.9Hz,1H),6.31(s,1H),4.99(s,1H),3.62 -3.55(m,1H),3.07-3.01(m,1H),2.92(s,3H),2.48-2.44(m,1H),2.05-1.99(m,1H ),1.96-1.85(m,1H),1.75-1.65(m,2H),1.61-1.55(m,1H),1.03(d,J=6.7Hz,6H).
[0538] Example 30: Preparation of Compound 30
[0539] Referring to the preparation method of compound 1A in Example 1, 2-bromo-4-aminopyridine was replaced with 2-chloro-3-amino-6-bromopyridine to obtain compound 30A.
[0540] Referring to the preparation method of compound 1 in Example 1, intermediate 1A was replaced with intermediate 30A to obtain crude compound 30.
[0541] The crude compound 30 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (18 / 82), with 1 / 1000 ammonia in the eluent) to obtain compound 30 (30 mg). MS (ESI): m / z 457.1422 [M+H] + .
[0542] 1 H NMR(500MHz,DMSO-d6)δ11.94(s,1H),9.59(s,1H),9.26(s,1H),7.57(d,J=8.6 Hz,1H),7.30(s,1H),6.93(d,J=8.8Hz,1H),6.04(s,1H),5.00(s,1H),3.62-3.5 3(m,1H),3.12-3.02(m,1H),2.99(s,3H),2.48-2.44(m,1H),2.05-1.99(m,1H), 1.94-1.85(m,1H),1.76-1.67(m,2H),1.64-1.54(m,1H),1.03(d,J=4.8Hz,6H).
[0543] Example 31: Preparation of Compound 31
[0544] Referring to the preparation method of compound 29D in Example 29, intermediate 29C was reacted in nitromethane and then purified by column chromatography to obtain intermediate 31A.
[0545] Referring to the preparation method of compound 29 in Example 29, intermediate 29D was replaced with intermediate 31A to obtain crude compound 31.
[0546] The crude compound 31 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 31 (13 mg). MS (ESI): m / z 507.1638 [M+H] + .
[0547] 1 H NMR(500MHz,DMSO-d6)δ11.99(s,1H),9.60(s,1H),9.28(s,1H),8.12(s,1H) ,7.64(s,1H),6.93(d,J=7.2Hz,1H),5.99(s,1H),4.99(s,1H),3.64-3.54(m, 1H),3.06-3.01(m,1H),2.98(s,3H),2.49-2.43(m,1H),2.07-1.97(m,1H),1. 96-1.84(m,1H),1.75-1.67(m,2H),1.62-1.56(m,1H),1.03(d,J=6.3Hz,6H).
[0548] Example 32: Preparation of Compound 32
[0549] Referring to the preparation method of compound 23A in Example 23, 4-bromo-2-fluoroaniline was replaced with 4-bromo-2,5-difluoroaniline to obtain compound 32A.
[0550] Referring to the preparation method of compound 23 in Example 23, intermediate 23A was replaced with compound 32A to obtain crude compound 32.
[0551] The crude compound 32 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (24 / 76), eluent containing 1 / 1000 ammonia water) to obtain compound 32 (25 mg). MS (ESI): m / z 458.1670 [M+H] + .
[0552] 1H NMR(500MHz,DMSO-d6)δ11.87(s,1H),9.29(s,1H),8.47(s,1H),8.13-8.09(m,1 H),7.14-7.10(m,1H),6.93(d,J=7.1Hz,1H),5.77(s,1H),5.00(s,1H),3.61-3. 55(m,1H),3.08-3.01(m,1H),2.96(s,3H),2.47-2.43(m,1H),2.05-1.99(m,1H) ,1.94-1.87(m,1H),1.75-1.65(m,2H),1.61-1.55(m,1H),1.03(d,J=6.3Hz,6H).
[0553] Example 33: Preparation of Compound 33
[0554] Referring to the preparation method of compound 16A in Example 16, methylamine hydrochloride was replaced with ammonia water, and 4-bromo-3-fluorobenzenesulfonyl chloride was replaced with 4-bromo-2-fluorobenzenesulfonyl chloride to prepare compound 33A.
[0555] Refer to the preparation method of compound 16 in Example 16, replace intermediate K1 with intermediate K to obtain crude compound 33.
[0556] The crude compound 33 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 33 (40 mg). MS (ESI): m / z 426.3 [M+H] + .
[0557] 1 H NMR (500MHz, DMSO-d6) δ11.96(s,1H),9.15(s,1H),7.54(t,J=8.7Hz,1H),7.43(dd,J=13. 9,2.1Hz,1H),7.27(s,2H),7.03(dd,J=8.8,2.1Hz,1H),6.94(d,J=7.8Hz,1H),5.69(d,J=2 .2Hz,1H),5.00(s,1H),3.66-3.54(m,1H),3.10-3.02(m,1H),2.48-2.44(m,1H),2.07-1. 97(m,1H),1.95-1.83(m,1H),1.75-1.66(m,2H),1.63-1.56(s,1H),1.03(d,J=6.8Hz,6H).
[0558] Example 34: Preparation of Compound 34
[0559] Referring to the preparation method of compound 16A in Example 16, methylamine hydrochloride was replaced with ammonia water, and 4-bromo-3-fluorobenzenesulfonyl chloride was replaced with 4-bromo-2-fluorobenzenesulfonyl chloride to prepare compound 34A.
[0560] Refer to the preparation method of compound 16 in Example 16, replace intermediate K1 with intermediate K2 to obtain crude compound 34.
[0561] The crude compound 34 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 34 (25 mg). MS (ESI): m / z 426.3 [M+H] + .
[0562] 1 H NMR (500MHz, DMSO-d6) δ11.96 (s, 1H), 8.61 (s, 1H), 8.18 (t, J = 8.4Hz, 1H), 7. 57–7.45(m,2H),7.16(s,2H),6.93(d,J=7.9Hz,1H),5.82(s,1H),5.00(s,1H) ,3.65-3.50(m,1H),3.16-2.97(m,1H),2.50-2.42(m,1H),2.08-1.97(m,1H), 1.96-1.85(m,1H),1.79-1.61(m,2H),1.63-1.54(m,1H),1.03(d,J=6.9,6H).
[0563] Example 35: Preparation of Compound 35
[0564] Referring to the preparation method of compound 14 in Example 14, 6-bromo-N-methylpyridin-3-amine was replaced with 4-bromo-2-fluoroaniline to obtain crude compound 35.
[0565] The crude compound 35 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 35 (30 mg). MS (ESI): m / z 430.2246 [M+H] + .
[0566] 1H NMR (500MHz, DMSO-d6) δ11.79(s,1H),8.66(s,1H),7.41(d,J=13.9Hz,1H),7.13(t,J=8.8H z,1H),7.03–6.88(m,2H),5.62(s,1H),4.99(s,1H),3.65(t,J=7.0Hz,2H),3.60-3.56(m,1H ),3.07-3.00(m,1H),2.49–2.426(m,1H),2.38(t,J=8.0Hz,2H),2.11–2.06(m,2H),2.04–1 .97(m,1H),1.94–1.84(m,1H),1.74-1.68(m,2H),1.62-1.56(m,1H),1.03(d,J=6.5Hz,6H).
[0567] Example 36: Preparation of Compound 36
[0568] 1-(6-Bromopyridin-3-yl)ethan-1-one (3.00 g) and liquid bromine (0.90 mL) were dissolved in hydrobromic acid (45 mL) and stirred at 70°C under nitrogen. After the reaction was complete, diethyl ether was added, stirred for 30 minutes, filtered, and the filter cake dried to obtain Intermediate 36A (4.00 g). MS (ESI): m / z 277.88 [M+H] + .
[0569] Intermediate 36A (3.00 g) was dissolved in formamide (20 mL) and microwave-treated at 150°C. After completion, the reaction was poured into water, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 36B (0.45 g). MS (ESI): m / z 225.0 [M+H] + .
[0570] Refer to the preparation method of compound 12 in Example 12, replacing intermediate 12B with intermediate 36B to obtain crude compound 36.
[0571] The crude compound 36 was purified by methanol slurry to obtain compound 36 (28 mg). MS (ESI): m / z 397.1988 [M+H] + .
[0572] 1H NMR(500MHz,DMSO-d6)δ11.84(s,1H),9.27(s,1H),8.55(s,1H),8.48(s,1H),8.43 (s,1H),7.89(d,J=8.2Hz,1H),7.35(s,1H),6.94(d,J=6.8Hz,1H),6.12(s,1H),5.0 0(s,1H),3.60-3.56(m,1H),3.08-3.02(m,1H),2.53-2.50(m,1H),2.05-1.98(m,1 H), 1.94-1.86 (m, 1H), 1.78-1.68 (m, 2H), 1.66-1.57 (m, 1H), 1.03 (d, J = 5.9Hz, 6H).
[0573] Example 37: Preparation of Compound 37
[0574] Referring to the preparation method of compound 23 in Example 23, 4-bromo-2-fluoroaniline was replaced with 4-bromo-2,3-difluoroaniline to obtain crude compound 37.
[0575] The crude compound 37 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (28 / 72), with 1 / 1000 ammonia in the eluent) to obtain compound 37 (156 mg). MS (ESI): m / z 458.1674 [M+H] + .
[0576] 1 H NMR(500MHz,DMSO-d6)δ11.84(s,1H),9.31(s,1H),8.31(s,1H),7.80-7.76(m,1 H),7.02-6.98(m,1H),6.93(d,J=7.1Hz,1H),5.75(s,1H),5.00(s,1H),3.60-3. 56(m,1H),3.08-3.02(m,1H),2.96(s,3H),2.47-2.43(m,1H),2.05-1.99(m,1H) ,1.94-1.86(m,1H),1.75-1.65(m,2H),1.61-1.55(m,1H),1.03(d,J=6.4Hz,6H).
[0577] Example 38: Preparation of Compound 38
[0578] 2-Bromo-5-fluoropyridine (2.00 g), 1H-imidazole (0.90 g), and potassium carbonate (3.10 g) were stirred in N,N-dimethylformamide (20 mL) at 100°C. After completion of the reaction, the product was poured into water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and separated by column chromatography (developing solvent: dichloromethane / methanol) to obtain Intermediate 38A (0.50 g).
[0579] Refer to the preparation method of compound 12 in Example 12, replacing intermediate 12B with intermediate 38A to obtain crude compound 38.
[0580] The crude compound 38 was purified by acetonitrile slurrying to obtain compound 38 (100 mg). MS (ESI): m / z 396.2147 [M+H] + .
[0581] 1 H NMR(500MHz,DMSO-d6)δ11.86(s,1H),9.42(s,1H),8.38(d,J=2.6Hz,1H),8.09(s,1H),7.81 (dd,J=9.0,2.8Hz,1H),7.61(s,1H),7.36(d,J=8.9Hz,1H),7.09(s,1H),6.94(d,J=7.2Hz,1H ),6.13(s,1H),5.01(s,1H),3.62-3.55(m,1H),3.09–3.02(m,1H),2.49–2.45(m,1H),2.06- 2.00(m,1H),1.94-1.86(m,1H),1.79-1.67(m,2H),1.64-1.58(m,1H),1.03(d,J=6.4Hz,6H).
[0582] Example 39: Preparation of Compound 39
[0583] Referring to the preparation method of compound 26 in Example 26, 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide was replaced with 4-bromo-1,2-methylenedioxybenzene to obtain crude compound 39.
[0584] The crude compound 39 was purified by medium-low pressure preparative liquid chromatography (C18 column, nitrile / water (30 / 70), eluent containing 1 / 1000 ammonia water) to obtain compound 39 (28 mg). MS (ESI): m / z 373.1869 [M+H] + .
[0585] 1H NMR(500MHz,DMSO-d6)δ11.60(s,1H),8.09(s,1H),7.09(s,1H),6.93(d,J= 7.2Hz,1H),6.72–6.69(m,2H),5.87(s,2H),5.54(s,1H),4.99(s,1H),3.61 -3.54(m,1H),3.04-2.98(m,1H),2.47-2.41(m,1H),2.03-1.97(m,1H),1.9 3–1.85(m,1H),1.75-1.65(m,2H),1.61-1.55(m,1H),1.03(d,J=6.4Hz,6H).
[0586] Example 40: Preparation of Compound 40
[0587] Referring to the preparation method of compound 23 in Example 23, 4-bromo-2-fluoroaniline was replaced with 4-bromo-2-chloroaniline to obtain crude compound 40.
[0588] The crude compound 40 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 40 (70 mg). MS (ESI): m / z 456.1470 [M+H] + .
[0589] 1 H NMR(500MHz,DMSO-d6)δ11.80(s,1H),9.08(s,1H),8.64(s,1H),7.68(s,1H),7.19(d ,J=8.7Hz,1H),7.13(d,J=8.1Hz,1H),6.94(d,J=8.2Hz,1H),5.61(s,1H),4.99(s,1H) ,3.61-3.54(m,1H),3.07-3.00(m,1H),2.93(s,3H),2.48-2.42(m,1H),2.04-1.99(m ,1H),1.94-1.86(m,1H),1.75-1.67(m,2H),1.62-1.56(m,1H),1.03(d,J=6.4Hz,6H).
[0590] Example 41: Preparation of Compound 41
[0591] Referring to the preparation method of compound 26 in Example 26, 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide was replaced with 4-bromophenyldimethylphosphine oxide to obtain crude compound 41.
[0592] The crude compound 41 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 41 (120 mg). MS (ESI): m / z 405.2055 [M+H] + .
[0593] 1 H NMR(500MHz,DMSO-d6)δ11.83(s,1H),8.68(s,1H),7.53-7.49(m,2H),7.39-7.37(m,2H),6.94(d, J=7.9Hz,1H),5.67(s,1H),5.04-4.95(m,1H),3.61-3.55(m,1H),3.08-3.01(m,1H),2.47-2.43(m,1H),2.04-1.99 (m,1H),1.96-1.86(m,1H),1.76-1.69(m,2H),1.63-1.54(m,1H),1.58(s,3H),1.55(s,3H),1.03(d,J=6.7Hz,6H).
[0594] Example 42: Preparation of Compound 42
[0595] 4-Bromoindolin-2-one (4.60 g), sodium carbonate (18.39 g), and di-tert-butyl dicarbonate (9.47 g) were stirred in tetrahydrofuran (150 mL) at 65°C. After the reaction was complete, the reaction solution was filtered, concentrated, and separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to obtain intermediate 42A (3.25 g). MS (ESI): m / z: 412.21 [M+H] + .
[0596] Refer to the preparation method of compound 1 in Example 11, replace intermediate 1A with intermediate 42A to obtain crude compound 42.
[0597] The crude compound 42 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 42 (10 mg). MS (ESI): m / z 384.20 [M+H] + .
[0598] 1H NMR(500MHz,DMSO-d6)δ11.51(s,1H),10.04(s,1H),7.97(s,1H),7.26(s,1H),7.10-7.08(m,1H),6. 94(d,J=7.9Hz,1H),6.62(d,J=8.3Hz,1H),5.55(s,1H),4.99(s,1H),3.60-3.55(m,1H),3.39(s,2H),
[0599] 3.05-2.98(m,1H),2.47-2.41(m,1H),2.03-1.97(m,1H),1.95-1.84(m,1H),1.76-1.65(m,2H),1.61-1.55(m,
[0600] 1H), 1.03-1.02 (m, 6H).
[0601] Example 43: Preparation of Compound 43
[0602] 2-Nitrobenzyl bromide (10.00 g), anhydrous sodium sulfite (7.58 g), and tetrabutylammonium iodide (171 mg) were stirred in water (80 mL) at 90° C. After the reaction was complete, the solvent was evaporated under reduced pressure to obtain intermediate 43A (10.00 g).
[0603] Intermediate 43A (10.00 g) and palladium carbon (5% palladium content, 50% water content (w / w), 1.90 g) were dissolved in methanol (50 mL) and the atmosphere was replaced with hydrogen. The mixture was stirred at room temperature. After completion of the reaction, the mixture was filtered and concentrated to afford Intermediate 43B (5.00 g).
[0604] Intermediate 43B (5.00 g) was stirred in phosphorus oxychloride (100 mL) under nitrogen at 115°C. After completion of the reaction, the solvent was evaporated under reduced pressure, and the pH was adjusted to alkaline with aqueous sodium hydroxide (1 M), extracted with ethyl acetate, and the pH of the organic phase was adjusted to acidic with dilute hydrochloric acid (2 N). The mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 43C (670 mg). MS (ESI): m / z 168.1 [MH] - .
[0605] Intermediate 43C (0.63 g) and bromine (0.46 g) were stirred in acetic acid (8 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure and the intermediate 43D (0.75 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 246.0 [MH] - .
[0606] Intermediate 43D (0.75 g), potassium carbonate (0.83 g), and benzyl bromide (0.54 g) were stirred in DMF (10 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure and the intermediate 43E (800 mg) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 335.95 [MH] - .
[0607] Intermediate K (425 mg), Intermediate 43E (680 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (217 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (131 mg), and potassium phosphate (877 mg) were stirred in N,N-dimethylformamide (20 mL) at 110°C under nitrogen. After completion of the reaction, the mixture was filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 43F (223 mg). MS (ESI): m / z 566.41 [M+H] + .
[0608] Intermediate 43F (223 mg) and palladium on carbon (5% palladium content, 50% water content (w / w), 83 mg) were dissolved in methanol (20 mL). After hydrogen substitution, the mixture was stirred at room temperature. After completion of the reaction, the mixture was filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 43G (127 mg). MS (ESI): m / z 476.32 [M+H] + .
[0609] Intermediate 43G (127 mg) was reacted in ethanol (1 mL) and dilute hydrochloric acid (1N, 20 mL) under microwave conditions at 100°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to a basic pH with saturated aqueous sodium bicarbonate. The mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered. The solvent was evaporated from the filtrate under reduced pressure, and the product was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to afford compound 43 (9 mg). MS (ESI): m / z 420.1701 [M+H] + .
[0610] 1H NMR(500MHz,DMSO-d6)δ11.61(s,1H),9.74(s,1H),8.18(s,1H),7.37(s,1H),7.15(d,J=8 .6Hz,1H),6.94(d,J=7.7Hz,1H),6.71(d,J=8.6Hz,1H),5.57(s,1H),4.99(s,1H),4.43(s, 2H),3.61-3.55(m,1H),3.03(q,J=8.7Hz,1H),2.44(dt,J=14.3,7.4Hz,1H),2.04-1.97(m, 1H),1.94-1.85(m,1H),1.76-1.67(m,2H),1.63-1.55(m,1H),1.03(dd,J=6.7,2.3Hz,6H).
[0611] Example 44: Preparation of Compound 44
[0612] Refer to the preparation method of compound 1B in Example 1, except that 6-bromopyridin-3-amine was replaced with 3-amino-2-methoxy-6-bromopyridine to obtain crude intermediate 44B.
[0613] Refer to the preparation method of compound 1 in Example 1, replacing intermediate 1C with intermediate 44B to obtain crude compound 44.
[0614] The crude compound 44 was purified by column chromatography (developing solvent: dichloromethane / methanol (90 / 10)) to obtain compound 44 (39 mg). MS (ESI): m / z 531.27 [M+H] + .
[0615] 1 H NMR(500MHz,DMSO-d6)δ12.17(s,1H),9.12(s,1H),9.00(s,1H),7.78(s,1H),6.91( d,J=7.8Hz,1H),6.54(s,1H),5.00(d,J=8.6Hz,1H),4.01(s,3H),3.64-3.48(m,1H) ,3.26(s,3H),3.11(q,J=8.7Hz,1H),2.97(s,3H),2.49-2.42(m,1H),2.09-1.99(m, 1H),1.98-1.85(m,1H),1.79-1.67(m,2H),1.64-1.60(m,1H),1.02(d,J=6.2Hz,6H).
[0616] Example 45: Preparation of Compound 45
[0617] Refer to the preparation method of compound 1 in Example 1, replacing intermediate 1A with intermediate 44A to obtain crude compound 45.
[0618] The crude compound 45 was purified by column chromatography (developing solvent: dichloromethane / methanol (90 / 10)) to obtain compound 45 (55 mg). MS (ESI): m / z 453.29 [M+H] + .
[0619] 1 H NMR (500MHz, DMSO-d6) δ11.84(s,1H),9.18(s,1H),8.72(s,1H),7.33(d,J=8.3Hz,1H),6. 92(d,J=7.9Hz,1H),6.79-6.62(m,1H),6.23(s,1H),5.00(d,J=7.8Hz,1H),3.90(s,3H),3 .58(dt,J=13.8,7.0Hz,1H),3.08-3.02(m,1H),2.88(s,3H),2.48-2.40(m,1H),2.05-1.9 6(m,1H),1.95-1.84(m,1H),1.80-1.66(m,2H),1.64-1.60(m,1H),1.02(d,J=6.6Hz,6H).
[0620] Example 46: Preparation of Compound 46
[0621] p-Bromobenzamide (1.00 g), 4-dimethylaminopyridine (0.06 g), N,N-diisopropylethylamine (2.58 g), and di-tert-butyl dicarbonate (3.27 g) were stirred in dichloromethane (50 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure and the intermediate 46A (0.37 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z: 422.1 [M+Na] + .
[0622] 1 H NMR (500MHz, DMSO-d6) δ7.81-7.83(m,2H),7.71-7.68(m,2H),1.36(s,18H).
[0623] Refer to the preparation method of compound 23 in Example 23, replace 23A with 46A, and replace formic acid with ethanol / 1N dilute hydrochloric acid (1 / 5) to obtain crude compound 46.
[0624] The crude compound 46 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 46 (13 mg). MS (ESI): m / z 372.2035 [M+H] + .
[0625] 1 H NMR(500MHz,DMSO-d6)δ11.51(s,1H),10.04(s,1H),7.97(s,1H),7.26(s,1H),7.10 -7.08(m,1H),6.94(d,J=7.9Hz,1H),6.62(d,J=8.3Hz,1H),5.55(s,1H),4.99(s,1H ),3.60-3.55(m,1H),3.39(s,2H),3.05-2.98(m,1H),2.47-2.41(m,1H),2.03-1.97 (m,1H),1.95-1.84(m,1H),1.76-1.65(m,2H),1.61-1.55(m,1H),1.03-1.02(m,6H).
[0626] Example 47: Preparation of Compound 47
[0627] Refer to the preparation method of compound 7 in Example 7, replacing 4-bromoaniline with 4-bromo-2-trifluoromethoxyaniline to obtain intermediate 47C (146 mg). MS (ESI): m / z 562.14 [M+H] + .
[0628] Intermediate 47C (145 mg) was reacted in ethanol (2 mL) and dilute hydrochloric acid (1 N, 20 mL) under microwave conditions at 100°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to a basic pH with saturated aqueous sodium bicarbonate. The residue was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to afford compound 47 (30 mg). MS (ESI): m / z 506.1693 [M+H] + .
[0629] 1H NMR(500MHz,DMSO-d6)δ11.86(s,1H),9.12(s,1H),8.75(s,1H),7.70(s,1H) ,7.22(d,J=8.8Hz,1H),7.14-7.12(m,1H),6.93(d,J=7.8Hz,1H),5.60(d,J= 2.2Hz,1H),4.99(s,1H),3.60-3.55(m,1H),3.09-2.98(m,1H),2.93(s,3H), 2.49-2.42(m,1H),2.03-1.98(m,1H),1.92-1.87(m,1H),1.77-1.66(m,2H), 1.63-1.55(m,1H),1.03(d,J=6.5Hz,6H).
[0630] Example 48: Preparation of Compound 48
[0631] Benzyl (1-(tert-butyl)-3-((1S,3R)-3-(4-nitrophenoxy)carbonyl)oxy)cyclopentyl)-1H-pyrazol-5-yl)carbamate (0.50 g), N,N-diisopropylethylamine (0.50 g), and 1-methylcyclopropane-1-amine hydrochloride (0.15 g) were stirred in tetrahydrofuran (20 mL) at 60°C. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was added with ethyl acetate, washed with aqueous sodium hydroxide (1N) and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give Intermediate 48A (0.40 g). MS (ESI): m / z 455.35 [M+H] + .
[0632] Intermediate 48A (0.40 g) and palladium on carbon (5% palladium content, 50% water content (w / w), 0.30 g) were stirred in tetrahydrofuran (5 mL) and ethyl acetate (5 mL) at room temperature under a hydrogen atmosphere. After completion, the reaction was filtered and concentrated to afford Intermediate 48B (0.25 g). MS (ESI): m / z 321.30 [M+H] + .
[0633] Intermediate 48B (0.23 g), 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide (0.27 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.11 g), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (0.10 g), and potassium phosphate (0.46 g) were added to N,N-dimethylformamide (10 mL). The reaction was stirred at 110°C under nitrogen. After completion of the reaction, the mixture was filtered, concentrated, and isolated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 48C (0.20 g). MS (ESI): m / z 487.29 [M+H] + .
[0634] Intermediate 48C (0.20 g) was stirred in ethanol (2 mL) and dilute hydrochloric acid (1 N, 20 mL) at 100°C in a microwave oven. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to a basic pH with saturated aqueous sodium bicarbonate. The residue was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (20 / 80), with 1 / 1000 ammonia in the eluent) to afford compound 48 (15 mg). MS (ESI): m / z 431.1745 [M+H] + .
[0635] 1 H NMR (500MHz, DMSO) δ11.69(s,1H),8.46(s,1H),7.36(d,J=22.0Hz,2H),7.20(d,J=8.1Hz,1H),7.13(d,J=8.4Hz,1H),5.62(s,1H),4.98( s,1H),4.40(s,2H),4.32(s,2H),3.03(s,1H),2.48-2.41(m,1H),2.05-1.84(m,2H),1.75-1.52(m,3H),1.23(s,3H),0.63-0.44(m,4H).
[0636] Example 49: Preparation of Compound 49
[0637] Refer to the preparation method of Intermediate 26A in Example 26, replace Intermediate K with Intermediate K2 to obtain Intermediate 49A (120 mg). MS (ESI): m / z 475.50 [M+H] + .
[0638] Refer to the preparation method of compound 47 in Example 47, replace intermediate 47C with intermediate 49A to obtain compound 49 (40 mg). MS (ESI): m / z 419.1756 [M+H] + .
[0639] 1 H NMR(500MHz,DMSO-d6)δ11.73(s,1H),8.46(s,1H),7.41(s,1H),7.22-7.21(m,1 H),7.14-7.13(m,1H),6.94(d,J=7.05Hz,1H),5.63(s,1H),4.99(s,1H),4.40(s ,2H),4.32(s,2H),3.60-3.56(m,1H),3.05-3.02(m,1H),2.48-2.42(m,1H),2.0 3-1.99(m,1H),1.92-1.88(m,1H),1.75-1.68(m,2H),1.62-1.56(m,1H),1.03(d, J = 6.35 Hz, 6H).
[0640] Example 50: Preparation of Compound 50
[0641] Refer to the preparation method of Compound 47 in Example 47, replacing 4-bromo-2-trifluoromethoxyaniline with 4-bromo-2-trifluoromethylaniline, and replacing Intermediate K with Intermediate K2 to obtain crude Compound 50.
[0642] The crude compound 50 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 50 (20 mg). MS (ESI): m / z 490.1742 [M+H] + .
[0643] 1H NMR(500MHz,DMSO-d6)δ11.86(s,1H),9.04(s,1H),8.77(s,1H),7.89(s,1H),7.46-7. 45(m,1H),7.34(d,J=8.7Hz,1H),6.92(d,J=7.9Hz,1H),5.62(s,1H),5.01-4.97(m,1H ),3.58-3.56(m,1H),3.05-2.98(m,1H),2.98(s,3H),2.48-2.40(m,1H),2.04-1.98(m ,1H),1.95-1.84(m,1H),1.75-1.67(m,2H),1.62-1.59(m,1H),1.03(d,J=6.1Hz,6H).
[0644] Example 51: Preparation of Compound 51
[0645] 5-Bromoindoline (1.00 g), triethylamine (1.02 g), and methanesulfonic anhydride (1.05 g) were stirred in dichloromethane (30 mL) at room temperature overnight. After the reaction was complete, the solvent was evaporated under reduced pressure and the reaction solution was separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to obtain Intermediate 51A (1.05 g).
[0646] 1 H NMR (500MHz, DMSO-d6) δ7.47 (s, 1H), 7.38-7.36 (m, 1H), 7.18 (d, J = 8.55Hz, 1H), 3.94 (t, J = 8.40Hz, 2H), 3.12 (t, J = 8.45Hz, 2H), 3.01 (s, 3H).
[0647] Refer to the preparation method of compound 47 in Example 47, replace intermediate 47A with intermediate 51A to obtain compound 51 (72 mg). MS (ESI): m / z 448.2015 [M+H] + .
[0648] 1H NMR(500MHz,DMSO-d6)δ11.62(s,1H),8.21(s,1H),7.34(s,1H),7.11-7.06(m,2H ),6.95(d,J=7.35Hz,1H),5.58(s,1H),4.99(s,1H),3.86(t,J=8.35Hz,1H),3.60- 3.54(m,1H),3.06-3.00(s,3H),2.86(s,3H),2.47-2.42(m,1H),2.03-1.98(m,1H) ,1.93-1.85(m,1H),1.75-1.67(m,2H),1.62-1.55(m,1H),1.03(d,J=6.40Hz,6H).
[0649] Example 52: Preparation of Compound 52
[0650] Refer to the preparation method of compound 16 in Example 16, replace methylamine hydrochloride with ammonia water, and replace intermediate K1 with intermediate K to obtain intermediate 52B (210 mg). MS (ESI): m / z 499.48 [M+H] + .
[0651] Refer to the preparation method of compound 47 in Example 47, replace intermediate 47C with intermediate 52B to obtain compound 52 (60 mg). MS (ESI): m / z 443.42 [M+H] + .
[0652] 1 H NMR(500MHz,DMSO-d6)δ12.10(s,1H),10.10(s,1H),8.04(d,J=8.7Hz,1H),7. 43(s,2H),7.34(s,1H),6.94(d,J=7.7Hz,1H),6.08(s,1H),5.08-4.93(m,1H), 3.65-3.52(m,1H),3.14-2.98(m,1H),2.49-2.42(m,1H),2.09-1.98(m,1H),1 .97-1.85(m,1H),1.79-1.66(m,2H),1.65-1.54(m,1H),1.03(d,J=6.8Hz,6H).
[0653] Example 53: Preparation of Compound 53
[0654] Refer to the preparation method of compound 48 in Example 48, replacing 1-methylcyclopropane-1-amine hydrochloride with methylamine hydrochloride to obtain crude compound 53.
[0655] The crude compound 53 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 53 (55 mg). MS (ESI): m / z 391.46 [M+H] + .
[0656] 1 H NMR(500MHz,DMSO-d6)δ11.73(s,1H),8.48(s,1H),7.41(s,1H),7.22-7.21(m,1H), 7.13(d,J=8.4Hz,1H),6.92(d,J=5.3Hz,1H),5.62(d,J=2.2Hz,1H),5.08-4.88(m,1 H),4.40(s,2H),4.32(s,2H),3.07-3.00(m,1H),2.55(d,J=4.6Hz,3H),2.47-2.41( m,1H),2.06-1.96(m,1H),1.95-1.85(m,1H),1.79-1.64(m,2H),1.65-1.52(m,1H).
[0657] Example 54: Preparation of Compound 54
[0658] Refer to the preparation method of Compound 26 in Example 26, replacing 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide with 1-bromo-4-methylsulfonylbenzene to obtain a crude compound 54.
[0659] The crude compound 54 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with the eluent containing 1 / 1000 ammonia water) to obtain compound 54 (20 mg). MS (ESI, [M+H] + )m / z:407.1748.
[0660] 1 H NMR(500MHz,DMSO-d6)δ9.13(s,1H),7.73-7.64(m,2H),7.50-7.39(m,2H),6.94(d,J=7.2Hz,1H),5.75(s,1H),5.13-4.9 7(m,1H),4.11(s,3H),3.63-3.53(m,1H),2.46(m,1H),2.02(m,1H),1.91(m,1H),1.72(m,2H),1.61(m,1H),1.03(m,6H).
[0661] Example 55: Preparation of Compound 55
[0662] Refer to the preparation method of Compound 47 in Example 47, replacing 4-bromo-2-trifluoromethoxyaniline with 4-bromo-2-methoxyaniline to obtain crude Compound 55.
[0663] The crude compound 55 was purified by column chromatography (developing solvent: dichloromethane / methanol (90 / 10)) to obtain compound 55 (44 mg). MS (ESI): m / z 452.28 [M+H] + .
[0664] 1 H NMR(500MHz,DMSO-d6)δ11.75(s,1H),8.72-8.44(m,1H),8.38(s,1H),7.19(s,1H),6.97( d,J=8.6Hz,1H),6.94(d,J=7.9Hz,1H),6.77(d,J=8.6Hz,1H),5.62(s,1H),4.99(s,1H),3. 76(s,3H),3.64-3.51(m,1H),3.04-2.99(m,1H),2.82(s,3H),2.50-2.39(m,1H),2.06-1. 95(m,1H),1.95-1.81(m,1H),1.76-1.69(m,2H),1.62-1.57(m,1H),1.03(d,J=6.3Hz,6H).
[0665] Example 56: Preparation of Compound 56
[0666] 4-Bromo-2-methylbenzene-1-sulfonyl chloride (5.0 g) and aqueous ammonia (115.0 g) were dissolved in dioxane (70 mL) and stirred in an ice bath. After the reaction was complete, the solvent was evaporated under reduced pressure to obtain Intermediate 56A (4.6 g).
[0667] Intermediate 56A (4.60 g), sodium hydroxide (3.34 g), and potassium permanganate (14.7 g) were stirred in water (50 ml) at 40° C. After the reaction was complete, the reaction was quenched with saturated aqueous sodium sulfite solution, filtered, and the filtrate was adjusted to pH 2 and concentrated to give Intermediate 56B (2.58 g).
[0668] Intermediate 56B (2.58 g) was dissolved in polyphosphoric acid (50 ml) and stirred at 140°C. After the reaction was complete, the mixture was returned to room temperature and quenched with ice water. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to obtain Intermediate 56C (2.00 g). MS (ESI): m / z 260.0 [MH] - .
[0669] Intermediate 56C (2.00 g) and sodium borohydride (2.89 g) were dissolved in tetrahydrofuran (50 ml). Boron trifluoride etherate (12.00 g) was added at -10°C and the mixture was stirred at 80°C. After the reaction was complete, the mixture was quenched with water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to obtain Intermediate 56D (1.72 g). MS (ESI): m / z 246.0 [MH] - .
[0670] Refer to the preparation method of compound 47 in Example 47, replace intermediate 47A with intermediate 56D to obtain intermediate 56E (200 mg). MS (ESI): m / z 476.16 [M+H] + .
[0671] Refer to the preparation method of Compound 47 in Example 47, replacing Intermediate 47C with Intermediate 56E to obtain crude Compound 56.
[0672] The crude compound 56 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (33 / 67), with 1 / 1000 ammonia in the eluent) to obtain compound 56 (40 mg). MS (ESI): m / z 420.1693 [M+H] + .
[0673] 1 H NMR(500MHz,DMSO-d6)δ11.90(s,1H),8.99(s,1H),7.58-7.38(m,3H),7.30(d ,J=8.6Hz,1H),6.94(d,J=7.8Hz,1H),5.71(s,1H),4.99(q,J=7.2,6.1Hz,1H), 4.29(s,2H),3.58(h,J=7.0Hz,1H),3.07(q,J=8.7Hz,1H),2.48-2.42(m,1H), 2.02(m,1H),1.90(m,,1H),1.73(m,2H),1.66-1.55(m,1H),1.06-1.01(m,6H).
[0674] Example 57: Preparation of Compound 57
[0675] Refer to the preparation method of compound 14 in Example 14, replacing the intermediate 6-bromo-N-methylpyridin-3-amine with 3-amino-6-bromo-2-chloropyridine to obtain crude compound 57.
[0676] The crude compound 57 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (32 / 68), with 1 / 1000 ammonia in the eluent) to obtain compound 57 (9 mg). MS (ESI): m / z 447.1904 [M+H] + .
[0677] 1 H NMR (500MHz, DMSO-d6): δ11.89(s,1H),9.64(s,1H),9.44(s,1H),7.67(d,J=8.7Hz ,1H),7.28(d,J=8.7Hz,1H),6.93(d,J=7.7Hz,1H),6.03(s,1H),5.08-4.91(m,1H) ,3.58(h,J=6.8Hz,1H),3.05(p,J=8.7,8.3Hz,1H),2.46(q,J=7.2Hz,1H),2.02(m, 1H),1.89(m,2H),1.78-1.55(m,3H),1.03(d,J=6.8Hz,6H),0.78(d,J=6.1Hz,4H).
[0678] Example 58: Preparation of Compound 58
[0679] Refer to the preparation method of compound 16 in Example 16, except that methylamine hydrochloride is replaced by 2-benzyl-1-ethylamine, 4-bromo-3-fluorobenzenesulfonyl chloride is replaced by 4-bromo-2-fluorobenzenesulfonyl chloride, and intermediate K1 is replaced by K to obtain a crude intermediate 58C.
[0680] The crude intermediate 58C was separated by column chromatography (developing solvent: dichloromethane / methanol) to obtain product 58C (150 mg). MS (ESI): m / z 560.29 [M+H] + .
[0681] Under hydrogen, palladium on carbon (5% palladium content, 50% water content (w / w), 70 mg) and intermediate 58C (150 mg) were stirred in methanol (10 mL) at room temperature. After completion, the reaction was filtered, concentrated, and purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), eluent containing 1 / 1000 ammonia water) to obtain compound 58 (23 mg). MS (ESI): m / z 470.29 [M+H]+ .
[0682] 1 H NMR(500MHz,DMSO-d6)δ11.98(s,1H),8.67(s,1H),8.17(s,1H),7.59-7.38(m,2H),7.35(s,1H),6.93 (d,J=7.8Hz,1H),5.83(s,1H),5.00(s,1H),4.66(s,1H),3.58(q,J=8.5,7.7Hz,1H),3.36(t,J=6.4Hz, 2H),3.13-2.99(m,1H),2.76(t,J=6.3Hz,2H),2.50-2.40(m,1H),2.10-1.98(m,1H ),1.96-1.83(m,1H),1.79-1.65(m,2H),1.65-1.55(m,1H),1.03(d,J=6.6Hz,6H).
[0683] Example 59: Preparation of Compound 59
[0684] Reference Example 26 Preparation of Compound 26, wherein 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide was replaced with ((4-bromophenyl)imino)dimethyl-λ 6 -cyclic sulfone to obtain crude compound 59.
[0685] The crude compound 59 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (34 / 66), with 1 / 1000 ammonia in the eluent) to obtain compound 59 (8 mg). MS (ESI, [M+H] + )m / z:420.2058.
[0686] 1 H NMR(500MHz,DMSO-d6)δ11.56(s,1H),7.92(s,1H),7.14-7.13(m,2H),6.95- 6.94(m,1H),6.77-6.75(s,2H),5.56(s,1H),4.99(m,1H),3.61-3.53(m,1H) ,3.11(s,6H),3.04-2.97(m,1H),2.47-2.41(s,1H),2.02-1.96(m,1H),1.91 -1.85(m,1H),1.76-1.65(m,2H),1.61-1.55(m,1H),1.03(d,J=6.85Hz,6H).
[0687] Example 60: Preparation of Compound 60
[0688] Refer to the preparation method of Compound 22 in Example 22, replacing 1-N-methylsulfonyl-4-piperidone with tert-butyl 4-oxopiperidine-1-carboxylate to obtain Intermediate 60A (203 mg). MS (ESI): m / z 492.39 [M+H] + .
[0689] Intermediate 60A (200 mg) and a 4M dioxane hydrochloride solution (5 mL) were stirred in dichloromethane (20 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure to obtain Intermediate 60B (150 mg). MS (ESI): m / z 392.38 [M+H] + .
[0690] Intermediate 60B (32 mg), Intermediate 60C (22 mg), and N,N-diisopropylethylamine (53 mg) were stirred in dichloromethane (10 mL) at room temperature. The solvent was evaporated under reduced pressure to obtain Intermediate 60D (40 mg). MS (ESI): m / z 536.37 [M+H] + .
[0691] Refer to the preparation method of compound 47 in Example 47, replacing intermediate 47C with intermediate 60D to obtain crude compound 60.
[0692] The crude compound 60 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (32 / 68), with 1 / 1000 ammonia in the eluent) to obtain compound 60 (8 mg). MS (ESI, [M+H] + )m / z:480.2387.
[0693] 1 H NMR(500MHz,DMSO-d6)δ11.12(s,1H),8.31(s,1H),7.76(s,1H),6.91(d,J =7.6Hz,1H),5.22(s,1H),4.94(m,2H),3.91(s,3H),3.60-3.53(m,1H),3.3 8-3.35(m,2H),3.15-3.069(m,1H),2.93-2.86(m,1H),2.45-2.41(m,2H),2 .39-2.33(m,1H),1.98-1.80(m,4H),1.72-1.44(m,5H),1.03-1.01(m,6H).
[0694] Example 61: Preparation of Compound 61
[0695] 4-Bromothioanisole (1.0 g), diethyl iodophenyl ester (1.7 g), and cyanamide (0.4 g) were stirred in dichloromethane (30 mL) at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure, and intermediate 61A (1.1 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 243.03 [M+H] + .
[0696] Potassium permanganate (1.6 g) was added to a solution of 61A (1.1 g) in acetone (30 mL) and the mixture was stirred at room temperature. After the reaction was complete, the mixture was filtered, concentrated, and separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to obtain intermediate 61B (1.2 g). MS (ESI): m / z 258.91 [M+H] + .
[0697] Trifluoroacetic anhydride (3.3 mL) was added to a solution of 61B (1.2 g) in dichloromethane (50 mL). The mixture was stirred at room temperature. After the reaction was complete, the solvent was evaporated under reduced pressure and the intermediate 61C (1.5 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 329.99 [MH] - .
[0698] Intermediate 61C (241 mg), Intermediate K (150 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (114 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (70 mg), and potassium phosphate (475 mg) were stirred in dioxane (40 ml) at 100°C under nitrogen. After completion of the reaction, the product was filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 61D (200 mg). MS (ESI): m / z 462.32 [M+H] + .
[0699] Intermediate 61D (200 mg) was stirred in 1.0 M aqueous hydrochloric acid (10 ml) at 100°C. After completion of the reaction, the pH was adjusted to alkaline with saturated aqueous sodium bicarbonate solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure to remove the solvent, and purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), eluent containing 1 / 1000 ammonia water) to obtain compound 61 (100 mg). MS (ESI): m / z 406.25 [M+H] + .
[0700] 1H NMR (500MHz, DMSO-d6) δ11.90(s,1H),8.92(s,1H),7.74–7.63(m,2H),7.42(d,J=7. 8Hz,2H),6.94(d,J=7.8Hz,1H),5.70(s,1H),5.00(s,1H),3.81(s,1H),3.65–3.50( m,1H),3.12–3.01(m,1H),2.97(d,J=1.1Hz,3H),2.48–2.43(m,1H),2.05–1.99(m,1 H),1.96–1.84(m,1H),1.75–1.69(m,2H),1.64–1.60(m,1H),1.03(d,J=6.8Hz,6H).
[0701] Example 62: Preparation of Compound 62
[0702] Refer to the preparation method of Compound 61 in Example 61, replacing 4-bromothioanisole with 1-bromo-4-(cyclopropylthio)benzene to obtain crude Compound 62.
[0703] The crude compound 62 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 62 (40 mg). MS (ESI): m / z 432.24 [M+H] + .
[0704] 1 H NMR(500MHz,DMSO-d6)δ11.89(s,1H),8.91(s,1H),7.64(d,J=8.6Hz,2H),7.41(d,J=8.5Hz,2H),6 .94(d,J=7.8Hz,1H),5.70(s,1H),5.00(s,1H),3.76(s,1H),3.60–3.56(m,1H),3.36–3.33(m,1H) ,3.13–2.99(m,1H),2.59–2.50(m,1H),2.48–2.41(m,1H),2.08–1.97(m,1H),1.95–1.83(m,1H),1 .79–1.66(m,2H),1.64–1.56(m,1H),1.03(d,J=6.4Hz,6H),0.94–0.88(m,1H),0.88–0.77(m,2H).
[0705] Examples 63 and 64: Preparation of Compounds 63 and 64
[0706] Benzyl (1-(tert-butyl)-3-((1S,3R)-3-hydroxycyclopentyl)-1H-pyrazol-5-yl)carbamate (2.00 g), triethylamine (1.70 g), and bis(2,5-dioxopyrrolidin-1-yl) carbonate (4.30 g) were stirred in acetonitrile (20 mL) at 40°C. After completion of the reaction, the solvent was evaporated under reduced pressure and the intermediate 63A (1.73 g) was isolated by column chromatography (developing solvent: petroleum ether / ethyl acetate). MS (ESI): m / z 499.32 [M+H] + .
[0707] N,N-Diisopropylethylamine (1.02 g), 1,1,1-trifluoropropan-2-amine (0.36 g), and Intermediate 63A (1.00 g) were stirred in dichloromethane (20 mL) at 35°C. After the reaction was complete, the product was washed sequentially with saturated aqueous sodium bicarbonate solution and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford Intermediate 63B (0.80 g). MS (ESI): m / z 497.34 [M+H] + .
[0708] Intermediate 63B (0.80 g) and palladium on carbon (5% palladium content, 50% water content (w / w), 0.34 g) were stirred in tetrahydrofuran (8 mL) and ethyl acetate (8 mL) at room temperature under a hydrogen atmosphere. After completion, the reaction was filtered and concentrated to afford Intermediate 63C (0.45 g). MS (ESI): m / z 363.27 [M+H] + .
[0709] Intermediate 63C (0.25 g), 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide (0.26 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.11 g), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (0.10 g), and potassium phosphate (0.44 g) were added to N,N-dimethylformamide (10 mL). The reaction was stirred at 110°C under nitrogen. After completion of the reaction, the mixture was filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 63D (0.23 g). MS (ESI): m / z 529.28 [M+H] + .
[0710] Intermediate 63D (0.23 g) was stirred in ethanol (2 mL) and dilute hydrochloric acid (1 N, 20 mL) at 100°C in a microwave oven. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to a basic pH with saturated aqueous sodium bicarbonate. The residue was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 63E (70 mg). MS (ESI): m / z 473.14 [M+H] + .
[0711] Intermediate 63E (70 mg) was chiral prepared by SFC (CHIRALART Amylose-SA column (30*250 mm, 5 μm), mobile phase: ethanol / n-hexane (0-60%)) to give compound 63 (35 mg). MS (ESI): m / z 473.1491 [M+H] + .
[0712] 1 H NMR(500MHz,DMSO-d6)δ11.75(s,1H),8.47(s,1H),7.82(d,J=8.95Hz,1H),7.4 0(m,1H),7.22-7.20(m,1H),7.14-7.13(m,1H),5.64(s,1H),5.18-4.94(m,1H), 4.40(s,2H),4.32(s,2H),4.30-4.23(m,1H),3.08-3.02(m,1H),2.05-2.00(m,1 H),1.97-1.90(m,1H),1.77-1.69(m,2H),1.68-1.54(m,1H),1.23-1.22(m,3H).
[0713] Compound 64 (35 mg). MS (ESI): m / z 473.1485 [M+H] + .
[0714] 1H NMR(500MHz,DMSO-d6)δ11.75(s,1H),8.47(s,1H),7.82(d,J=8.95Hz,1H),7.4 0(m,1H),7.22-7.20(m,1H),7.14-7.13(m,1H),5.64(s,1H),5.18-4.94(m,1H), 4.40(s,2H),4.32(s,2H),4.30-4.23(m,1H),3.08-3.02(m,1H),2.05-2.00(m,1 H),1.97-1.90(m,1H),1.77-1.69(m,2H),1.68-1.54(m,1H),1.23-1.22(m,3H).
[0715] Example 65: Preparation of Compound 65
[0716] Referring to the preparation method of compound 33 in Example 33, 4-bromo-2-fluorobenzenesulfonyl chloride was replaced with 4-bromobenzenesulfonyl chloride to prepare compound 65 (35 mg). MS (ESI): m / z 408.1709 [M+H] + .
[0717] 1 H NMR(500MHz,DMSO-d6)δ11.86(s,1H),8.85(s,1H),7.61-7.59(m,2H),7.39(d, J=8.40Hz,2H),7.00(s,2H),6.95-6.93(m,1H),5.68(s,1H),5.09-4.92(m,1H) ,3.61-3.55(m,1H),3.09-3.02(m,1H),2.49-2.42(m,1H),2.04-2.00(m,1H),1 .94-1.86(m,1H),1.75-1.69(m,2H),1.63-1.57(m,1H),1.03(d,J=6.40Hz,6H).
[0718] Example 66: Preparation of Compound 66
[0719] Referring to the preparation method of compound 33 in Example 33, 4-bromo-2-fluorobenzenesulfonyl chloride was replaced with 4-bromo-2-trifluoromethylbenzenesulfonyl chloride to prepare compound 66 (35 mg). MS (ESI): m / z 476.1585 [M+H] + .
[0720] 1H NMR(500MHz,DMSO-d6)δ12.03(s,1H),9.28(s,1H),8.00(s,1H),7.93(d,J=8.90H z,1H),7.58-7.57(m,1H),7.30(s,2H),6.93(d,J=7.15Hz,1H),5.69(s,1H),4.99( s,1H),3.60-3.56(m,1H),3.08-3.03(m,1H),2.49-2.42(m,1H),2.05-2.00(m,1H) ,1.94-1.88(m,1H),1.75-1.69(m,2H),1.64-1.54(m,1H),1.03(d,J=6.45Hz,6H).
[0721] Example 67: Preparation of Compound 67
[0722] Refer to the preparation method of compound 48 in Example 48, replacing 1-methylcyclopropane-1-amine hydrochloride with cyclopropylamine to obtain crude compound 67.
[0723] The crude compound 67 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain compound 67 (20 mg). MS (ESI): m / z 417.1596 [M+H] + .
[0724] 1 H NMR(500MHz,DMSO-d6)δ11.72(s,1H),8.46(s,1H),7.40(s,1H),7.21(d,J= 9.8Hz,2H),7.13(d,J=8.4Hz,1H),5.63(s,1H),5.00(s,1H),4.40(s,2H),4. 32(s,2H),3.05(m,1H),2.45(m,2H),2.03-1.98(m,1H),1.94-1.86(m,1H), 1.78-1.67(m,2H),1.63-1.56(s,1H),0.55-0.53(m,2H),0.39-0.35(m,2H).
[0725] Example 68: Preparation of Compound 68
[0726] Refer to the preparation method of compound 1 in Example 1, replacing 1A with 6-chloro-N-cyclopropylpyridine-3-sulfonamide to obtain the crude product of compound 68 in Example 68.
[0727] The crude compound 68 was purified by column chromatography (developing solvent: dichloromethane / methanol (90 / 10)) to obtain compound 68 (70 mg). MS (ESI): m / z 449.1967 [M+H] + .
[0728] 1 H NMR (500MHz, DMSO-d6) δ12.02(s,1H),9.85(s,1H),8.46(d,J=2.5Hz,1H),7.83(dd,J=8.9,2.5 Hz,1H),7.70(s,1H),7.34(s,1H),6.93(d,J=7.8Hz,1H),6.18(s,1H),5.00 (s,1H),3.60-3.54(m,1H),3.17-2.98(m,1H),2.49-2.44(m,1H),2.15-2.12 (m,1H),2.05-2.00(m,1H),1.95-1.83(m,1H),1.80-1.67(m,2H),1.64-1.5 8(m,1H),1.03(dd,J=6.9,2.8Hz,6H),0.57–0.42(m,2H),0.38–0.35(m,2H).
[0729] Example 69: Preparation of Compound 69
[0730] Referring to the preparation method of compound 33 in Example 33, 4-bromo-2-fluorobenzenesulfonyl chloride was replaced with 2-chloropyridine-5-sulfonyl chloride, and aqueous ammonia was replaced with dimethylamine to prepare compound 69 (10 mg). MS (ESI): m / z 437.1966 [M+H] + .
[0731] 1 H NMR(500MHz,DMSO-d6)δ12.05(s,1H),9.93(s,1H),8.41(d,J=1.30Hz,1H),7.82(dd ,J=2.15,8.90Hz,1H),7.35(s,1H),6.93(d,J=6.85Hz,1H),6.22(s,1H),5.11-4.90 (m,1H),3.61-3.54(m,1H),3.14-3.02(m,1H),2.60(s,6H),2.49-2.35(m,1H),2.06 -2.00(m,1H),1.94-1.86(m,1H),1.78-1.67(m,2H),1.65-1.58(m,1H),1.03(m,6H).
[0732] Example 70: Preparation of Compound 70
[0733] Refer to the preparation method of Compound 61 in Example 61, and replace 4-bromothioanisole with 4-bromo-2-fluoro-1-methylthiobenzene to obtain the crude product of Compound 70 in Example 70.
[0734] The crude compound 70 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain Example 70 compound 70 (80 mg). MS (ESI): m / z 424.23 [M+H] + .
[0735] 1 H NMR(500MHz,DMSO-d6)δ11.98(s,1H),9.20(s,1H),7.61(t,J=8.7Hz,1H),7.44(d,J =13.7Hz,1H),7.07(d,J=8.8Hz,1H),6.94(d,J=7.8Hz,1H),5.70(s,1H),4.99(s,1H ),4.27(s,1H),3.68-3.49(m,1H),3.10-3.04(m,4H),2.49-2.41(m,1H),2.09-1.97 (m,1H),1.96-1.85(m,1H),1.75-1.68(m,2H),1.63-1.59(m,1H),1.15-0.94(m,6H).
[0736] Example 71: Preparation of Compound 71
[0737] N-Bromosuccinimide (2.46 g) and 2-(difluoromethoxy)aniline (2.00 g) were dissolved in dichloromethane (20 mL) and stirred in an ice bath. After completion of the reaction, the product was concentrated to give Intermediate 71A (1.90 g).
[0738] Intermediate 71A (1.80 g), N,N-diisopropylethylamine (2.93 g), and methanesulfonic anhydride (3.95 g) were stirred in dichloromethane (20 mL) at room temperature. After completion of the reaction, the product was concentrated and separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to afford Intermediate 71B (2.0 g). MS (ESI): m / z 315.97 [MH] - .
[0739] Intermediate 71B (0.46 g), Intermediate K (0.3 g), methanesulfonic acid [9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene][2'-amino-1,1'-biphenyl] palladium(II) dichloromethane adduct (0.18 g), and cesium carbonate (0.95 g) were stirred in dioxane (20 mL) at 110°C under nitrogen. After completion, the reaction was filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to obtain Intermediate 71C (350 mg). MS (ESI): m / z 544.46 [M+H] + .
[0740] Intermediate 71C (0.35 g) and saturated aqueous sodium carbonate solution (10 mL) were added to dioxane (20 mL). The mixture was stirred at 50°C. After the reaction was complete, the mixture was extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Intermediate 71D (300 mg).
[0741] Intermediate 71D (300 mg) was stirred in ethanol (1 mL) and dilute hydrochloric acid (1 N, 15 mL) at 100°C in a microwave oven. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to a basic pH with saturated aqueous sodium bicarbonate. The residue was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 71 (100 mg). MS (ESI): m / z 488.1787 [M+H] + .
[0742] 1 H NMR(500MHz,DMSO-d6)δ11.83(s,1H),8.93(s,1H),8.64(s,1H),7.44(s,1H), 7.23-7.02(m,3H),6.95-6.90(m,1H),5.61(s,1H),4.99(s,1H),3.61-3.54(m, 1H),3.06-2.98(m,1H),2.91(s,3H),2.48-2.42(m,1H),2.03-1.98(m,1H),1. 93-1.86(m,1H),1.76-1.65(m,2H),1.62-1.55(m,1H),1.03(d,J=7.10Hz,6H).
[0743] Example 72: Preparation of Compound 72
[0744] Refer to the preparation method of compound 1 in Example 1, replace 1A with 4-bromobenzonitrile to obtain compound 72 (60 mg). MS (ESI): m / z 354.1923 [M+H] + .
[0745] 1 H NMR(500MHz,DMSO-d6)δ11.96(s,1H),9.07(s,1H),7.57-7.55(m,2H),7.42 -7.40(m,2H),7.70(s,1H),6.94-6.93(m,1H),5.71(s,1H),5.00(s,1H),3. 60-3.56(m,1H),3.08-3.04(m,1H),2.48-2.44(m,1H),2.05-2.00(m,1H),1 .94-1.86(m,1H),1.76-1.67(m,2H),1.64-1.58(m,1H),1.04-1.02(m,6H).
[0746] Example 73: Preparation of Compound 73
[0747] Refer to the preparation method of Compound 61 in Example 61, replacing 4-bromothioanisole with 1-bromo-3-chloro-4-(methylthio)benzene to obtain a crude product of Compound 73.
[0748] The crude compound 73 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain Example 73 compound 73 (50 mg). MS (ESI): m / z 440.15 [M+H] + .
[0749] 1 H NMR(500MHz,DMSO-d6)δ11.98(s,1H),9.15(s,1H),7.85(d,J=8.8Hz,1H),7.71(s,1H),7 .31-7.22(m,1H),6.94(d,J=7.8Hz,1H),5.68(s,1H),5.00(s,1H),4.20(s,1H),3.62-3. 55(m,1H),3.13(d,J=1.2Hz,3H),3.10-3.03(m,1H),2.49-2.40(m,1H),2.05-1.97(m,1H ),1.96-1.83(m,1H),1.79-1.65(m,2H),1.63-1.57(m,1H),1.03(dd,J=6.6,2.2Hz,6H).
[0750] Example 74: Preparation of Compound 74
[0751] 5-Bromo-2-nitrobenzaldehyde (3.00 g) and diethylaminosulfur trifluoride (3.15 g) were dissolved in dichloromethane (20 mL) and stirred in an ice bath. After completion of the reaction, the mixture was concentrated to give Intermediate 74A (3.00 g).
[0752] Intermediate 74A (3.00 g), zinc powder (3.89 g), and ammonium chloride (3.82 g) were added to methanol (30 mL). The mixture was stirred at room temperature. After completion of the reaction, the mixture was filtered, concentrated, and separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to afford Intermediate 74B (1.37 g).
[0753] Intermediate 74B (1.37 g), N,N-diisopropylethylamine (2.39 g), and methanesulfonic anhydride (3.22 g) were added to dichloromethane (20 mL). The mixture was stirred at room temperature. After completion of the reaction, the mixture was concentrated and separated by column chromatography (developing solvent: petroleum ether / ethyl acetate) to afford Intermediate 74C (0.90 g).
[0754] Intermediate 74C (0.36 g), Intermediate K (0.20 g), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.10 g), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (0.06 g), and potassium phosphate (0.34 g) were added to dioxane (20 mL). The reaction was stirred at 100°C under nitrogen. After completion of the reaction, the product was filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 74D (0.30 g).
[0755] Intermediate 74D (0.3 g) and saturated aqueous sodium carbonate solution (10 mL) were stirred in dioxane (20 mL) at 50°C. After the reaction was complete, the mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 74E (230 mg). MS (ESI): m / z 528.29 [M+H] + .
[0756] Intermediate 74E (100 mg) was stirred in ethanol (1 mL) and dilute hydrochloric acid (1 N, 15 mL) at 100°C in a microwave oven. After the reaction was complete, the solvent was evaporated under reduced pressure, and the residue was adjusted to a basic pH with saturated aqueous sodium bicarbonate. The residue was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography (developing solvent: dichloromethane / methanol) to afford Intermediate 74 (25 mg). MS (ESI): m / z 472.1821 [M+H] + .
[0757] 1H NMR(500MHz,DMSO-d6)δ11.83(s,1H),9.07(s,1H),8.69(s,1H),7.81(s,1H), 7.47-7.34(m,1H),7.26-6.89(m,3H),5.62(s,1H),5.00(s,1H),3.60-3.56(m, 1H),3.08-3.01(m,1H),2.94(s,3H),2.46-2.43(m,1H),2.03-2.00(m,1H),1. 95-1.85(m,1H),1.76-1.68(m,2H),1.63-1.57(m,1H),1.03(d,J=6.25Hz,6H).
[0758] Example 75: Preparation of Compound 75
[0759] Refer to the preparation method of Compound 26 in Example 26, and replace 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide with 6-bromo-2,3-dihydrobenzo[b]thiophene-1,1-dioxide to obtain crude Compound 75.
[0760] The crude compound 75 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to obtain Example 75 compound 75 (60 mg). MS (ESI): m / z 419.23 [M+H] + .
[0761] 1 H NMR(500MHz,DMSO-d6)δ11.82(s,1H),8.82(s,1H),7.93(s,1H),7.38(dd,J=8.5,2.2Hz,1H), 7.29(d,J=8.5Hz,1H),6.95(d,J=7.8Hz,1H),5.61(s,1H),5.10-4.80(m,1H),3.64-3.54(m,1 H),3.52(t,J=6.8Hz,2H),3.20(t,J=6.8Hz,2H),3.12-2.96(m,1H),2.49-2.40(m,1H),2.06- 1.97(m,1H),1.95-1.85(m,1H),1.78-1.64(m,2H),1.65-1.53(m,1H),1.03(d,J=6.5Hz,6H).
[0762] Example 76: Preparation of Compound 76
[0763] Refer to the preparation method of Compound 26 in Example 26, and replace 5-bromo-1,3-dihydrobenzo[c]thiophene-2,2-dioxide with 5-bromo-6-fluoro-1,3-dihydrobenzo[c]thiobenzene 2,2-dioxide to obtain crude Compound 76.
[0764] The crude compound 76 was purified by medium-low pressure preparative liquid chromatography (C18 column, acetonitrile / water (30 / 70), with 1 / 1000 ammonia in the eluent) to give Example 76 compound 76 (110 mg). MS (ESI, [M+H] + )m / z:437.1662.
[0765] 1 H NMR(500MHz,DMSO-d6)δ11.80(s,1H),8.22(s,1H),8.10(d,J=8.10Hz,1H),7.16(d, J=11.70Hz,1H),6.93(d,J=7.80Hz,1H),5.77(s,1H),5.03-4.96(m,1H),4.41(s,2H ),4.36(s,2H),3.60-3.56(m,1H),3.08-3.03(m,1H),2.48-2.43(m,1H),2.05-2.00 (m,1H),1.94-1.86(m,1H),1.76-1.65(m,2H),1.62-1.56(m,1H),1.04-1.03(m,6H).
[0766] Example 77: Preparation of Compound 77
[0767] Refer to the preparation method of compound 48 in Example 48, replacing 1-methylcyclopropane-1-amine hydrochloride with isopropylamine hydrochloride-d7 to obtain intermediate 77B.
[0768] Refer to the preparation method of compound 52 in Example 52, replace intermediate K with intermediate 77B to obtain compound 77 (80 mg). MS (ESI): m / z 450.1821 [M+H] + .
[0769] 1H NMR(500MHz,DMSO-d6)δ12.09(s,1H),10.08(s,1H),8.03(d,J=8.75Hz,1H),7.42(s,2H),7.34(s,1H),6.91(s,1H),6.08(s,1H) ,5.00(m,1H),3.11-3.04(m,1H),2.49-2.42(m,1H),2.05-1.98(m,1H),1.95-1.86(m,1H),1.79-1.66(m,2H),1.65-1.56(m,1H).
[0770] Example 78: Preparation of Compound 78
[0771] Refer to the preparation method of compound 26 in Example 26, replace intermediate K with intermediate 77B to obtain compound 78 (40 mg). MS (ESI): m / z 426.2284 [M+H] + .
[0772] 1 H NMR(500MHz,DMSO-d6)δ11.72(s,1H),8.46(s,1H),7.41(s,1H),7.22(d,J= 7.95Hz,1H),7.14(d,J=8.40Hz,1H),6.92(d,J=7.95Hz,1H),5.63(s,1H),4. 99(m,1H),4.40(s,2H),4.32(s,2H),3.08-3.00(m,1H),2.48-2.42(m,1H), 2.03-1.98(m,1H),1.93-1.86(m,1H),1.73-1.68(m,2H),1.62-1.56(m,1H).
[0773] Example 79: Preparation of Compound 79
[0774] Referring to the preparation method of Compound 13 of Example 13, the intermediate 2-bromopyridine was replaced with 5-bromo-2-cyanopyridine to obtain Compound 79 of Example 79 (70 mg). MS (ESI): m / z 355.1880 [M+H] + .
[0775] 1H NMR(500MHz,DMSO-d6)δ12.15–12.01(m,1H),9.42(s,1H),8.58(d,1H),7.96(dd,1H),7.77(d,1H),6.93(d,1H),5.74(d,1H),5.00(s, 1H),3.58(dd,1H),3.13–3.01(m,1H),2.49–2.41(m,1H),2.07–1.98(m,1H),1.96–1.86(m,1H),1.80–1.67(m,2H),1.09–0.98(m,6H).
[0776] Example 80: Preparation of Compound 80
[0777] 2-Bromo-5-cyanopyridine (178 mg), potassium tert-butoxide (0.146 g), and Intermediate K (0.2 g) were reacted in THF (15 mL) in an oil bath at 80°C. After completion of the reaction, the solvent was evaporated under reduced pressure, and the reaction mixture was separated by column chromatography (developing solvent: dichloromethane / methanol) to obtain Intermediate 80A (100 mg). MS (ESI): m / z 411.29 [M+H] + .
[0778] Referring to the preparation method of Example 79, compound 79, intermediate 79A was replaced with 80A to obtain Example 80 compound 80 (30 mg). MS (ESI): m / z 355.1882 [M+H] + .
[0779] 1H NMR(500MHz,DMSO-d6)δ8.37(d,1H),7.30–7.21(m,1H),6.92(d,1H),6.68(d,1H),6.45(s,1H),5.01(t,1H),3.57(h,1H) ,3.16(p,1H),2.47(dd,1H),2.13–2.02(m,1H),1.94–1.89(m,1H),1.81–1.71(m,2H),1.65(ddd,4.7Hz,1H),1.03(t,6H).
[0780] Experimental Example 1 In vitro kinase inhibitory activity
[0781] 1.1 CDK2 / CycA2 kinase inhibitory activity assay
[0782] CDK2 / CycA2 kinase solution (concentration 0.078ng / ul) was added to the detection wells at 6μL per well. Different compounds dissolved in DMSO were added to the detection wells using a nanoliter pipette to make the final concentration of the compound 1000nM-0.244nM, with 2 replicates, and a control was set up at the same time. The above system was incubated for 30 minutes, ATP (concentration 50μM or 5000μM) and ULight-Myelin Basic Protein Peptide substrate (manufacturer: PerkinElmer, concentration 0.25μM) were mixed at a ratio of 1:1 and added to the detection wells at 4μL per well; after reacting at room temperature for 2 hours, 5μL EDTA was added to terminate the reaction, and then 5μL detection antibody (manufacturer: PerkinElmer, concentration 8nM) was added and incubated at room temperature for 1 hour; detection was performed using a PerkinElmer Envision multi-function microplate reader (excitation 320nm, emission 615nm / 665nm), and IC was calculated using a four-parameter fit. 50 .
[0783] 1.2 CDK2 CycE1 kinase inhibitory activity assay
[0784] CDK2 CycE1 kinase solution (concentration 0.015 ng / μL) was added to the detection wells at 6 μL per well. Different compounds dissolved in DMSO were added to the detection wells using a nanoliter pipette to make the final concentration of the compound 300 nM-0.07 nM, with two replicates, and a control was set up at the same time. The above system was incubated for 30 minutes. ATP (concentration 50 μM or 5000 μM) and ULight-Myelin Basic Protein Peptide substrate (manufacturer: PerkinElmer, concentration 0.25 μM) were mixed at a ratio of 1:1 and added to the detection wells at 4 μL per well. After reacting at room temperature for 2 hours, 5 μL EDTA was added to terminate the reaction, and 5 μL detection antibody (manufacturer: PerkinElmer, concentration 8 nM) was added. The reaction was incubated at room temperature for 1 hour. The detection was performed using a PerkinElmer Envision multi-function microplate reader (excitation 320 nm, emission 615 nm / 665 nm). The IC was calculated using a four-parameter fit. 50 .
[0785] The experimental results are shown in Table 1, where A represents: 0nM<IC 50 ≤10nM; B represents: 10nM<IC 50 ≤50nM; C represents: 50nM<IC 50 ≤100nM; D represents: 100nM<IC 50 ≤1000nM; E represents: 1000nM<IC 50 .
[0786] Table 1: Inhibitory activity of compounds against CDK2 CycA2 and CDK2 CycE1 kinases
Claims
1. A compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof, in, Ring A is selected from C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 alkyl ring or 5-6 membered heteroaryl ring and 5-6 membered heteroalkyl ring are optionally independently substituted by one or more R a replace; L 1 and L 2 Each independently selected from a single bond, -N(R b )-, -N=, -O-, -S-, -(CH2) m -、-(CD2) m -、-(CHD) m -, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=N(R b ))-、-S(=O)(R c )-、-P(=O)(R c )-or-P(=O)(NR b R b )-; R 1 Selected from H, deuterium, C 1-3 Alkyl, C 1-3 Alkoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R d Substitute, the C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl are optionally independently substituted by one or more R e replace; R 2 、R 3 and R 4 Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with one or more R z replace; or R 2 and R 3 and the carbon atoms that are connected together to form C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, R 4 Selected from H, deuterium, halogen, OH, CN, NH2, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl optionally independently substituted by one or more R z replace; Each R a Each independently selected from deuterium, halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with one or more R x replace; Each R b Each independently selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -C(=O)H, -S(=O)2C 1-3 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution; said C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl optionally independently substituted by one or more R y replace; R c Selected from halogen, OH, CN or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with one or more R x replace; Each R d are each independently selected from deuterium, halogen, OH, CN or NH2; Each R e Each independently selected from deuterium, halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with one or more R x replace; Each R x are each independently selected from deuterium, halogen, OH, CN or NH2; Each R y Each independently selected from deuterium, halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally substituted independently with one or more substituents selected from deuterium, halogen, OH, CN or NH2; Each R z are each independently selected from deuterium, halogen, OH, CN or NH2; m is selected from 1, 2 or 3; The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer; Or, each L 1 , L 2 、R 1 、R 2 、R 3 、R 4 、R a 、R b 、R c 、R d 、R e 、R x 、R y or R z Each is independently optionally substituted with one or more substituents.
2. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein the ring A is selected from C 3-6 Alkane ring, 5-6 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-6 Alkane ring, 5-6 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 The alkyl ring or 5-6 membered heteroaryl ring and the 5-6 membered heteroalkyl ring are optionally independently substituted by 1, 2, 3 or 4 R a replace; Alternatively, the ring A is selected from a 6-membered heteroalkane ring containing 1 N atom, a benzene ring, a 5-membered heteroalkane ring containing 1 N atom, a 5-membered heteroaromatic ring containing 1 or 2 N atoms, a 6-membered heteroaromatic ring having only 1 N atom, a 6-membered heteroaromatic ring containing 1 N atom and a 5-membered heteroalkane ring containing 1 N atom, or a 6-membered heteroaromatic ring containing 1 N atom and a 6-membered heteroalkane ring containing 1 N atom, wherein the 6-membered heteroalkane ring containing 1 N atom, the benzene ring, the 5-membered heteroalkane ring containing 1 N atom, the 5-membered heteroaromatic ring containing 1 or 2 N atoms, the 6-membered heteroaromatic ring having only 1 N atom, the 5-membered heteroalkane ring containing 1 N atom and a 6-membered heteroaromatic ring containing 1 N atom, or the 6-membered heteroalkane ring containing 1 N atom and a 6-membered heteroalkane ring containing 1 N atom are optionally independently substituted by 1, 2 or 3 R a replace; Alternatively, the ring A is selected from a piperidine ring, a benzene ring, a benzene ring and a dioxolane ring, a benzene ring and a pyrrolidine ring, a benzene ring and a tetrahydrothiophene ring, a benzene ring and an isothiazolidine ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyridine ring, a pyridine ring and a tetrahydrofuran ring, a pyridine ring and an isothiazolidine ring or a pyridine ring and a thiazinane ring, and the ring A is optionally independently substituted by 1, 2 or 3 R a replace; Alternatively, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a replace; Alternatively, the ring A is selected from The ring A is optionally independently substituted with 1, 2 or 3 R a replace; Alternatively, the ring A is selected from The ring A is optionally independently substituted with 1, 2, 3 or 4 R a replace.
3. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a replace; Alternatively, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a replace; Alternatively, the structural unit Selected from The ring A is optionally independently substituted with 1, 2 or 3 R a replace.
4. The compound of formula (I) according to claim 1, its isomers or pharmaceutically acceptable salts thereof, wherein the "hetero" mentioned in Ring A is independently selected from oxygen, sulfur and nitrogen heteroatoms, wherein the nitrogen atom is optionally quaternized or oxidized to N(O), and the sulfur atom is optionally oxidized to S(O) or S(O)2; Alternatively, the "hetero" mentioned in ring A is each independently selected from oxygen, sulfur and nitrogen heteroatoms, wherein the sulfur heteroatom is optionally oxidized to S(O) or S(O)2.
5. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein L 1 Selected from single bond, -N(R b )-, -N=, -O-, -S(=O)2-, -S-, -(CH2) m - or -C(=O)-; or, the L 1 is selected from a single bond, -NH-, -N=, -N(C(=O)H)-, -N(CH3)-, -S(=O)2-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -C(=O)- or -N(S(=O)2CH3)-; or, said L 1 is selected from a single bond, -NH-, -N=, -N(C(=O)H)-, -N(CH3)-, -S(=O)2-, -CH2-, -C(=O)- or -N(S(=O)2CH3)-; or, said L 1 Selected from -NH-.
6. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein L 2 Selected from single bond, -NH-, -N(C 1-3 alkyl)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=NH)-, -S(=O)(C 1-3 alkyl)-, -P(=O)(C 1-3 alkyl)-, -P(=O)(NH2)- or -P(=O)(NH(C 1-3 Alkyl))-; or, the L 2 is selected from a single bond, -NH-, -N(CH3)-, -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=NH)-, -S(=O)(CH3)-, -P(=O)(CH3)-, -P(=O)(NH2)-, or -P(=O)(NHCH3)-; or, a single bond, -NH-, -N(CH3)-, -CH2-CH2-, -C(=O)-, -S(=O)2-, -S(=O)(=NH)-, -S(=O)(CH3)-, -P(=O)(CH3) or -P(=O)(NHCH3)-; or, L 2 is selected from a single bond or -S(=O)2-.
7. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, 2 -L 1 - is selected from the group consisting of a single bond, -NH-, -N(CH3)-, -C(=O)-, -CH2-, -CH2-CH2-, -S(=O)2-, -CH2-NH-, -NH-CH2-, -CH2-N(CH3)-, -CH2-N(C(=O)H)-, -N(CH3)-CH2-, -N(C(=O)H)-CH2-, -C(=O)-CH2-, -CH2-C(=O)-, -C(=O)-NH-, -NH-C(=O )-, -NH-S(=O)2-, -S(=O)2-NH-, -N(CH3)-S(=O)2-, -N(S(=O)2CH3)-S(=O)2-, -S(=O)2-N(S(=O)2CH3)- , -S(=O)(CH3)=N-, -S(=O)2-N(CH3)-, -N(CH3)-C(=O)-, -C(=O)-N(CH3)-, -NH-S(=O)(=NH)-, -S(=O)(= NH)-NH-, -S(=O)(=NH)-, -P(=O)(CH3)-, -CH2-S(=O)(=NH)-, -S(=O)(=NH)-CH2-, -CH2-P(=O)(CH3)-,- P(=O)(CH3)-CH2-, -NH-P(=O)(CH3)-, -P(=O)(CH3)-NH-, -NH-P(=O)(NHCH3)-, -P(=O)(NHCH3)-NH-, -N H-P(=O)(NH2)-, -P(=O)(NH2)-NH-, -CH2-P(=O)(NHCH3)-, -P(=O)(NHCH3)-CH2-, -N(CH3)-CH2-CH2-, -N(C(=O)H)-CH2-CH2-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)-, -NH-CH2-CH2- or -CH2-CH2-NH-; or, -L 2 -L 1 -selected from a single bond, -NH-, -CH2-, -S(=O)2-, -N(CH3)-CH2-, -NH-C(=O)-, -NH-C(=O)-, -S(=O)2-NH-, -NH-S(=O)2-, -S(=O)(CH3)=N-, -S(=O)2-N(CH3)-, -C(=O)-NH-, -C(=O)-N(CH3)-, -S(=O)(=NH)-NH-, -S(=O) (=NH)-, -P(=O)(CH3)-, -CH2-S(=O)(=NH)-, -P(=O)(CH3)-CH2-, -P(=O)(CH3)-NH-, -P(=O)(NHCH3)-NH-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)-, -CH2-CH2-NH- or -S(=O)2-N(S(=O)2CH3)-; or, a single Bond, -NH-, -CH2-, -S(=O)2-, -N(CH3)-CH2-, -NH-C(=O)-, -N(CH3)-C(=O)-, -S(=O)2-NH-, -NH-S(=O) 2-, -S(=O)(CH3)=N-, -S(=O)2-N(CH3)-, -C(=O)-NH-, -C(=O)-N(CH3)-, -S(=O)(=NH)-NH-, -S(=O) (=NH)-, -P(=O)(CH3)-, -S(=O)(=NH)-CH2-, -P(=O)(CH3)-CH2-, -P(=O)(CH3)-NH-, -P(=O)(NHCH3)-NH-, -CH2-CH2-N(CH3)-, -CH2-CH2-N(C(=O)H)-, -CH2-CH2-NH- or -S(=O)2-N(S(=O)2CH3)-; or, -L 2 -L 1 - is selected from a single bond or -S(=O)2-NH-.
8. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein R 1 is selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, cyclobutyl, cyclopentyl, a 4-6 membered heterocycloalkyl containing 1 or 2 N, O, S atoms, or a 5-6 membered heteroaryl containing 1 or 2 N atoms, wherein the methyl, ethyl or methoxy group is optionally independently replaced by 1, 2 or 3 R d substituted, the 4-6 membered heterocycloalkyl or 5-6 membered heteroaryl is optionally independently substituted by 1, 2 or 3 R e Replace; or, R 1 Selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -NH2, -NH(C 1-3 alkyl), cyclopropyl, cyclobutyl, cyclopentyl, 4-6 membered heterocycloalkyl containing 1 or 2 atoms selected from N, O, S or 5-6 membered heteroaryl containing 1 or 2 N atoms, said C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R d Substituted; the 4-6 membered heterocycloalkyl or 5-6 membered heteroaryl is optionally independently substituted by 1, 2 or 3 R e Substituted; or, the R 1 is selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), cyclopropyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, pyrazolyl, oxazolyl or pyrimidinyl, wherein the methyl, ethyl or methoxy group is optionally substituted independently by 1, 2 or 3 R d Substituted; the cyclopropyl, oxetanyl, pyrazolidinyl, isothiazolidinyl, isoxazolidinyl, imidazolyl, oxazolyl or pyrimidinyl are optionally independently substituted by 1, 2 or 3 R e replace; Alternatively, the R 1 Selected from H, methyl, ethyl, methoxy, -NH2, -NH(CH3), -NH(CH2CH3), The methyl, ethyl or methoxy groups are optionally independently substituted with 1, 2 or 3 R d Replace, the Optionally independently 1, 2 or 3 R e replace; Or, R 1 Selected from H, methyl, -CH2CH2OH, methoxy, -OCF3, -CH2OH, -NH2, -NH(CH3), -NH(CH2CH2OH), Alternatively, the R 1 Selected from H, methyl, -CH2CH2OH, methoxy, -OCF3, -CH2OH, -NH2, -NH(CH3), -NH(CH2CH2OH), Alternatively, the R 1 is selected from H, methyl or methoxy.
9. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein R 2 、R 3 and R 4 are each independently selected from H, deuterium or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R z Replacement; or R 2 、R 3 and R 4 are each independently selected from H, deuterium, methyl, -CD3, difluoromethyl, trifluoromethyl or ethyl; or R 2 、R 3 and R 4 are each independently selected from H, deuterium, methyl, -CD3, or trifluoromethyl; or R 2 Selected from H or deuterium, R 3 and R 4 Each is independently selected from methyl, -CD3 or trifluoromethyl.
10. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein R 2 and R 3 and the carbon atoms that are connected together to form C 3-4 Cycloalkyl or 3-4 membered heterocycloalkyl, R 4 Selected from H or C 1-3 Alkyl, the C 1-3 Alkyl, C 3-4 Cycloalkyl or 3-4 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R z Replacement; or R 2 and R 3 and the carbon atoms to which they are attached together form a cyclopropyl group, R 4 is selected from H or methyl, said methyl or cyclopropyl optionally independently substituted by 1, 2 or 3 R z replace.
11. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein each R a Each independently selected from deuterium, F, Cl, Br, I, CN, ═O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Replace; or, each R a Each is independently selected from F, Cl, CN, =O, methyl or methoxy, said methyl or methoxy being optionally substituted independently by 1, 2 or 3 halogens; or, each R a Each is independently selected from F, Cl, CN, =0, methyl, methoxy, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy.
12. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein each R b Each independently selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution; said C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R y Replace; or each R b Each independently selected from H or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x Replace; or, each R b are each independently selected from H or methyl, said methyl optionally independently replaced by 1, 2 or 3 R x Replace; or, each R b are each independently selected from H or methyl.
13. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein R c Selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x Substituted; or, the R c Selected from methyl.
14. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein each R d are each independently selected from F, Cl, Br, I or OH; or, each R d are each independently selected from F or OH.
15. The compound of formula (I) according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein each R e Each independently selected from F, Cl, Br, I, ═O or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x Replace; or, each R e Each independently selected from F, Cl, Br, I, ═O or C 1-3 alkyl.
16. A compound represented by formula (II), an isomer thereof, or a pharmaceutically acceptable salt thereof, in, Ring A is selected from C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 Alkane ring or 5-6 membered heteroaromatic ring and 5-6 membered heteroalkane ring, the C 3-10 Alkane ring, 5-10 membered heteroalkane ring, benzene ring, naphthalene ring, benzene ring and C 5-6 Alkane ring, benzene ring and 5-6 membered heteroalkane ring, 5-10 membered heteroaromatic ring, 5-6 membered heteroaromatic ring and C 5-6 The alkyl ring or 5-6 membered heteroaryl ring and the 5-6 membered heteroalkyl ring are optionally independently substituted by 1, 2 or 3 R a replace; L 1 and L 2 Each independently selected from a single bond, -N(R b )-、-O-、-S-、-(CH2) m -, -C(=O)-, -S(=O)-, -S(=O)2-, -S(=O)(=N(R b ))-、-P(=O)(R c )-or-P(=O)(NR b R b )-; R 1 Selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R d Substitute, the C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl are optionally independently substituted by 1, 2 or 3 R e replace; Each R a Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x replace; Each R b Each independently selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, -C(=O)H, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x Substitution; said C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl is optionally independently substituted by 1, 2 or 3 R y replace; R c Selected from halogen, OH, CN or C 1-3 Alkyl, the C 1-3 The alkyl group is optionally independently substituted with 1, 2 or 3 R x replace; Each R d Each independently selected from halogen, OH, CN or NH2; Each R e Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally independently substituted with 1, 2 or 3 R x replace; Each R x Each independently selected from halogen, OH, CN or NH2; Each R y Each independently selected from halogen, OH, CN, NH2, =O, C 1-3 Alkyl or C 1-3 Alkoxy, the C 1-3 Alkyl or C 1-3 Alkoxy is optionally substituted independently with 1, 2 or 3 substituents selected from halogen, OH, CN or NH2; m is selected from 1, 2 or 3; The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer.
17. The compound of formula (II) according to claim 16, its isomer or pharmaceutically acceptable salt thereof, which is selected from the compound of formula (II-1), in, Ring A, R 1 , L 1 and L 2 As defined in claim 16; Alternatively, it is selected from the compound represented by formula (II-2), X is selected from CH or N; R 1 、R a , L 1 and L 2 As defined in claim 16; The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer; Alternatively, it is selected from the compound represented by formula (II-2a), in, X is selected from CH or N; R 1 、R a , L 1 and L 2 As defined in claim 16; Alternatively, it is selected from the compound represented by formula (II-3) in, X is selected from CH or N; R 1 and R a As defined in claim 16; The carbon atom marked with "*" is a chiral carbon atom, existing in the form of a single enantiomer (R) or (S) or in the form enriched in one enantiomer; Alternatively, it is selected from the compound represented by formula (II-3a) in, X is selected from CH or N; R 1 and R a As defined in claim 16.
18. A compound of the formula:
19. A compound of the formula:
20. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the compound according to any one of claims 1 to 19, its isomers or pharmaceutically acceptable salts thereof; optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
21. Use of the compound according to any one of claims 1 to 19, its isomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 20 in the preparation of a medicament for treating or preventing a CDK2-mediated disease.
